

Asia Pacific Academy of Ophthalmology (APAO)

Eye Diseases Clinical Trials Summary

Searched by Topics

(<http://www.clinicaltrials.gov>)

Sorted Out by Xiaoxin Li and Yujing Bai

On Behalf of APAO Standing Committee Meetings & Reports

Table of Contents

1_Amblyopia	41_Hyperopia	81_Retinitis
2_Anisometropia	42_Iridocyclitis	82_Retinitis Pigmentosa
3_Aphakia	43_Keratitis	83_Retinoblastoma
4_Astigmatism	44_Keratoconjunctivitis	84_Retinopathy of Prematurity
5_Behcet Syndrome	45_Keratoconjunctivitis Sicca	85_Retinoschisis
6_Blepharitis	46_Keratoconus	86_Scotoma
7_Blepharoptosis	47_Lacrimal Apparatus Diseases	87_Sjogren's Syndrome
8_Blepharospasm	48_Lens Diseases	88_Strabismus
9_Blindness	49_Low Tension Glaucoma	89_Supranuclear Palsy, Progressive
10_Capsule Opacification	50_Macular Degeneration	90_Usher Syndromes
11_Cataract	51_Macular Edema	91_Uveal Diseases
12_Central Serous Chorioretinopathy	52_Mydriasis	92_Uveitis
13_Choroid Diseases	53_Myopia	93_Vision Disorders
14_Choroidal Neovascularization	54_Neuromyelitis Optica	94_Vitreous Detachment
15_Choroideremia	55_Night Blindness	95_Vitreous Hemorrhage
16_Choroiditis	56_Nystagmus, Pathologic	96_Xerophthalmia
17_Conjunctival Diseases	57_Ocular Hypertension	
18_Corneal Diseases	58_Ocular Motility Disorders	
19_Dacryocystitis	59_Ophthalmoplegia	
20_Diabetic Retinopathy	60_Opsoclonus-Myoclonus Syndrome	
21_Diplopia	61_Optic Atrophies	
22_Dry Eye Syndromes	62_Optic Nerve Diseases	
23_Enophthalmos	63_Optic Neuritis	
24_Epiretinal Membrane	64_Optic Neuropathy, Ischemic	
25_Esotropia	65_Orbital Diseases	
26_Exfoliation Syndrome	66_Panuveitis	
27_Exophthalmos	67_Pars Planitis	
28_Exotropia	68_Presbyopia	
29_Eye Abnormalities	69_Pterygium	
30_Eye Diseases, Hereditary	70_Refractive Errors	
31_Eye Infections	71_Retinal Artery Occlusion	
32_Eye Injuries	72_Retinal Degeneration	
33_Eye Neoplasms	73_Retinal Detachment	
34_Eye Pain	74_Retinal Drusen	
35_Eyelid Diseases	75_Retinal Dystrophies	
36_Geographic Atrophy	76_Retinal Hemorrhage	
37_Glaucoma	77_Retinal Neoplasms	
38_Graves Disease	78_Retinal Neovascularization	
39_Hordeolum	79_Retinal Perforations	
40_Hydrophthalmos	80_Retinal Vein Occlusion	

1. Amblyopia

Rank	Status	Study
1	Completed no results published yet	Thickness of Retinal Layers in Amblyopia Condition: Amblyopia Intervention: Other: Optical coherence tomography

2. Anisometropia

Rank	Status	Study
1	Unknown †	Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment Conditions: Myopia; Anisometropia Intervention:

3. Aphakia

Rank	Status	Study
1	Completed no results published yet	Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery Condition: Congenital Cataract Interventions: Device: Intraocular Lens (Acrysof IOL); Device: No IOL
2	Recruiting	Evaluate Capsular Apposition to Intraocular Lens Conditions: Capsule Opacification; Tissue Adhesions; Aphakia - Lens Capsule Present; Opacification of Intraocular Lens Intervention:
3	Active, not recruiting	Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study Conditions: Aphakia; Cataract Interventions: Device: Study IOL; Device: Hoya iSert 751; Device: Negatively aspheric IOL

4. Astigmatism

Rank	Status	Study
1	Completed Has Results Published on website	Product Performance of a Toric Contact Lens Conditions: Myopia; Astigmatism Interventions: Device: SofLens DD Toric; Device: Ciba Vision Focus Dailies Toric Contact Lens
2	Completed no results published yet	Prospective Comparative Study of Refractive Outcome of STAAR and Alcon Toric Intraocular Lenses Condition: Astigmatism Intervention: Procedure: Phacoemulsification with implantation of toric IOL
3	Completed no results published yet	Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles Conditions: Myopia; Hyperopia; Astigmatism Interventions: Device: Ready-made spectacles; Device: Spectacles
4	Completed no results published yet	Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles Conditions: Myopia; Hyperopia; Astigmatism Interventions: Device: Ready-made spectacles; Device: Spectacles
5	Completed no results published yet	Construction of Computerized Intraoperative Keratometer and Experimental Study Conditions: Corneal Astigmatism; Orientation Intervention: Device: computerized intraoperative keratometer
6	Completed no results published yet	Clinical Trial of Contact Lenses in Extended Wear Condition: Astigmatism Interventions: Device: senofilcon A toric contact lenses; Device: balafilcon A toric contact lens
7	Terminated no results published yet	Silicone Hydrogel Contact Lenses on Low Astigmatism in Japan Conditions: Refractive Error; Myopia; Astigmatism Interventions: Device: senofilcon A toric soft contact lens; Device: senofilcon A

		sphere soft contact lens
8	Recruiting	<p>Clinical Evaluation of Toric Intraocular Lens Made by Aurolab</p> <p>Condition: Astigmatism</p> <p>Intervention: Procedure: intra ocular lens</p>
9	Recruiting	<p>Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia</p> <p>Conditions: Astigmatism; Cataract</p> <p>Interventions: Procedure: phacoemulsification; D</p>
10	Recruiting	<p>Randomized, Non-inferiority Trial Comparing SMILE and LASIK</p> <p>Conditions: Myopia; Astigmatism; Hypermetropia</p> <p>Interventions: Procedure: Femtosecond LASIK; Procedure: Small incision lenticule extraction (SMILE)</p>
11	Active, not recruiting	<p>Toric Orthokeratology - Slowing Eye Elongation</p> <p>Conditions: Myopia; Astigmatism</p> <p>Interventions: Device: Toric Orthokeratology lenses; Device: Single-vision spectacles</p>
12	Unknown †	<p>Randomized, Prospective Comparison of the Outcome of Toric Implantable Contact Lens (TICL) and Q-LASIK for the Correction of Myopia With Astigmatism</p> <p>Conditions: Myopia; Astigmatism</p> <p>Interventions: Procedure: the implantation of toric implantable collamer lens; Procedure: customized laser-assisted in situ keratomileusis</p>
13	Unknown †	<p>Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation</p> <p>Conditions: Pterygium; Cataract; Astigmatism</p> <p>Intervention: Procedure: pterygium excision</p>
14	Unknown †	<p><u>Prospective Evaluation of Limbal Relaxing Incision (LRI) in Conjunction With Phacoemulsification Surgery for Astigmatic Correction in Chinese Eyes</u></p> <p>Condition: Corneal Astigmatism</p> <p>Intervention: Procedure: Limbal relaxing incision</p>

15	Unknown †	Compare Anterior Chamber Biometry in Healthy and Post-LASIK Patients Conditions: Myopia; Astigmatism Intervention:
----	-----------	--

5. Behcet Syndrome

Rank	Status	Study
1	Completed no results published yet	<p>Phase III Study in Refractory Behcet's Disease</p> <p style="text-align: center;">Condition: Behcet Disease</p> <p style="text-align: center;">Interventions: Drug: AIN457; Drug: Placebo</p>
2	Terminated	<p>Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis</p> <p style="text-align: center;">Condition: Uveitis</p> <p style="text-align: center;">Interventions: Biological: AIN457; Drug: Placebo</p>
3	Unknown †	<p>Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease</p> <p style="text-align: center;">Conditions: Ocular Behcet's Disease,; Non-Infectious Uveitis; Refractory Uveitis</p> <p style="text-align: center;">Intervention: Drug: flucinolone acetonide</p>

6. Blepharitis

Rank	Status	Study
1	Completed Has Results Published on website	Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; Drug: Refresh eye drops
2	Completed Has Results published in journal	Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Conditions: Conjunctivitis; Keratitis; Blepharitis Interventions: Drug: Loteprednol and tobramycin; Drug: Tobramycin and dexamethasone

7. Blepharoptosis

Rank	Status	Study
1	Completed no results published yet	Efficacy of Aurosling in Frontalis Sling Suspension Surgery Condition: Ptosis, Eyelid Intervention: Procedure: Aurosling

8. Blepharospasm

Rank	Status	Study
1	<p>Completed no results published yet</p>	<p>Movement Disorder Survey in East China Conditions: Primary Dystonia; Hemifacial Spasm Intervention:</p>
2	<p>Completed no results published yet</p>	<p>Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm Condition: Essential Blepharospasm Intervention: Drug: Botulinum Toxin Type A</p>
3	<p>Completed no results published yet</p>	<p>Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Condition: Blepharospasm Intervention: Drug: Korean Botulinum toxin type A (KbtxA) and Botox injection</p>
4	<p>Completed no results published yet</p>	<p>Efficacy of Aurosling in Frontalis Sling Suspension Surgery Condition: Ptosis, Eyelid Intervention: Procedure: Aurosling</p>

9. Blindness

Rank	Status	Study
1	Completed Has Results Published on website	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Condition: Macular Degeneration Interventions: Drug: Ranibizumab; Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
2	Completed Has Results published in journals	Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh Conditions: Vitamin A Deficiency; Maternal Mortality; Infant Mortality Intervention: Dietary Supplement: Vitamin A or Beta-Carotene Supplements
3	Completed no results published yet	Dietary Vitamin A Requirement in Chinese Children and the New Technology of Dietary Assessment Condition: Vitamin A Deficiency Intervention:
4	Completed no results published yet	Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status Condition: Vitamin A Deficiency Interventions: Other: 0 mg retinol activity equivalents; Other: 12 mg of BC; Other: 6 mg of CX; Other: 1.0 mg RAE
5	Completed no results published yet	The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial Condition: Obesity Intervention: Drug: the extract of green tea
6	Completed no results published yet	Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan Condition: Vitamin A Deficiency Interventions: Dietary Supplement: Vitamin A; Dietary Supplement: Placebo
7	Completed no results published	An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Conditions: Vitamin A Deficiency; Iron D

	yet	<p>efficiency; Zinc Deficiency</p> <p>Intervention: Dietary Supplement: fortified extruded rice</p>
8	Completed no results published yet	<p>Efficacy of Vitamin A in Fortified Extruded Rice in School Children</p> <p>Condition: Vitamin A Deficiency</p> <p>Intervention: Dietary Supplement: Triple fortified extruded rice (Fe, Zn and vitamin A)</p>
9	Terminated	<p>Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh</p> <p>Conditions: Infant Mortality; Vitamin A Deficiency</p> <p>Intervention: Drug: vitamin A supplementation (50,000 IU)</p>
10	Recruiting	<p>Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</p> <p>Conditions: Retinal Degeneration,; Retinitis Pigmentosa</p> <p>Intervention: Procedure: surgical implantation of subretinal device</p>
11	Recruiting	<p>PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)</p> <p>Condition: Anterior Ischemic Optic Neuropathy</p> <p>Intervention: Drug: Diagnostic procedures</p>
12	Recruiting	<p>Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function</p> <p>Condition: Vitamin A Deficiency</p> <p>Interventions: Dietary Supplement: retinyl palmitate; Dietary Supplement: Placebo</p>
13	Active, not recruiting	<p>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)</p> <p>Condition: Myopia, Pathological</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: No Drug</p>

10. Capsule Opacification

Rank	Status	Study
1	Completed no results published yet	<p>Posterior Capsule Opacification (PCO) With Single Piece Hydrophobic Versus Hydrophilic Intraocular Lens (IOL)</p> <p style="text-align: right;">Condition: Posterior Capsule Opacification</p> <p style="text-align: right;">Intervention: Procedure: Phacoemulsification</p>
2	Completed no results published yet	<p>Posterior Capsule Opacification (PCO) With AcrySof Single-Piece IOL</p> <p style="text-align: right;">Condition: Posterior Capsule Opacification</p> <p style="text-align: right;">Intervention: Procedure: Phaco</p>
3	Completed no results published yet	<p>Posterior Capsule Opacification Study</p> <p style="text-align: right;">Condition: Cataract</p> <p style="text-align: right;">Interventions: Device: Square edge PMMA IOL ; Device: Round edge PMMA IOL; Device: Acrysof IOL; Device: square Edge PMMA IOL; Device: Square Edge PMMA IOL</p>
4	Completed no results published yet	<p>AquaLase Capsule Wash for Pediatric Eyes</p> <p style="text-align: right;">Conditions: Cataract; Pediatric Cataract</p> <p style="text-align: right;">Intervention:</p>
5	Recruiting	<p><u>Evaluate Capsular Apposition to Intraocular Lens</u></p> <p style="text-align: right;">Conditions: Capsule Opacification; Tissue Adhesions; Aphakia - Lens Capsule Present; Opacification of Intraocular Lens</p> <p style="text-align: right;">Intervention:</p>

11. Cataract

Rank	Status	Study
1	Completed Has Results published in journals	Ologen (OculusGen)-Phacotrabeulectomy Historical Control Study in India Conditions: Glaucoma; Cataract Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
2	Completed Has Results published on website	ReSTOR Natural +3.0D Study In Japan Condition: Cataract Intervention: Device: ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1
3	Completed Has Results published in journals	Guangdong Uptake of Surgery Trial Condition: Cataract Intervention: Behavioral: Video and counseling for cataract patients
4	Completed Has Results published on website	Study of Phacodepth Required for Safe and Effective Chop During Phacoemulsification for Cataract. Condition: Cataract Intervention:
5	Completed no results published yet	Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery Condition: Cataract Intervention: Drug: adrenalin
6	Completed no results published yet	Combined Intracameral Lidocaine for Manual Small Incision Cataract Surgery Under Topical Anesthesia Condition: Cataract Interventions: Procedure: MSICS under topical anesthesia with intracameral lidocaine; Procedure: MSICS under topical anesthesia with intracameral balanced salt solution.
7	Completed no results published yet	Effect of Mobile Communication on Childhood Cataract Follow-up Adherence Condition: Cataract Intervention: Other: Mobile short message servi ce

8	Completed no results published yet	Outcomes of 3 Incision-size-dependent Phacoemulsification Systems Condition: Cataract Intervention:
9	Completed no results published yet	Evaluation of the Rotational Stability of The AcrySof Toric Intraocular Lens in the Capsular Bag in High Myopic Subjects Condition: Cataract Intervention: Procedure: Cataract Surgery
10	Completed no results published yet	Nepafenac Compared to Placebo for Ocular Pain and Inflammation Condition: Cataract Interventions: Drug: Nepafenac; Other: Nepafenac Vehicle
11	Completed no results published yet	Effect of Phacoemulsification on Ocular Blood Flow in Human Conditions: Cataract; Hypertension; Diabetes Intervention:
12	Completed no results published yet	Evaluation of Anatomic and Visual Outcomes of Initially Closed Macular Holes Condition: Macular Holes Intervention:
13	Completed no results published yet	Effect on Wound Healing of Vigamox Versus Cravit Condition: Cataract Extraction Interventions: Drug: Moxifloxacin 0.5% ophthalmic solution (Vigamox); Drug: Levofloxacin 0.5% ophthalmic solution (Cravit)
14	Completed no results published yet	The Effect of a Blue Light Filtering IOL Conditions: to Compare the Effect of Two Types of IOLs; on the Incidence of Cystoid Macular Edema; After Cataract Surgery Intervention: Procedure: intraocular lens implantation
15	Completed no results published yet	A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery Condition: Cataract Interventions: Procedure: Lens Fragmentation by means of a femtosecondlaser; Procedure: Ma

		nual Phacoemulsification
16	Completed no results published yet	Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery Condition: Congenital Cataract Interventions: Device: Intraocular Lens (Acrysof IOL); Device: No IOL
17	Completed no results published yet	AquaLase Capsule Wash for Pediatric Eyes Conditions: Cataract; Pediatric Cataract Intervention:
18	Completed no results published yet	DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery Condition: Mature Cataracts Intervention: Drug: DYME
19	Completed no results published yet	Outcomes of Phacoemulsification With Torsional Ultrasound Condition: Cataract Interventions: Procedure: Torsional ultrasound (INFINITI, Alcon, USA); Procedure: Longitudinal U/S (Infiniti system, Alcon, USA); Procedure: Longitudinal U/S (LEGACY 20000, Alcon, USA)
20	Completed no results published yet	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction Conditions: Retinitis Pigmentosa; Cataract Intervention: Procedure: IOL surgery
21	Completed no results published yet	Aurolab Hydrophobic Foldable Intraocular Lens Study Condition: Cataract Intervention: Device: Intraocular Lens
22	Completed no results published yet	Posterior Capsule Opacification Study Condition: Cataract Interventions: Device: Square edge PMMA IOL; Device: Round edge PMMA IOL; Device: Acrysof IOL; Device: square Edge PMMA IOL; Device: Square Edge PMMA IOL
23	Completed	Outcome Following Phacoemulsification Versus Small Incision

	no results published yet	Cataract Surgery (SICS) Conditions: Visual Outcomes; Quality of Life Interventions: Procedure: phacoemulsification and SICS; Procedure: manual small incision surgery; Procedure: phacoemulsification
24	Completed no results published yet	Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery Condition: Inflammation Interventions: Drug: Enoxaparin; Drug: Balanced Salt Solution
25	Completed no results published yet	CME With Different Fluidic Parameters Condition: Cystoid Macular Edema Following Cataract Surgery Intervention: Procedure: microcoaxial phacoemulsification
26	Completed no results published yet	Intraoperative and Postoperative Outcomes of Three Ophthalmic Viscosurgical Devices During Phacoemulsification Condition: Intraoperative Performance and Postoperative Outcomes Following Cataract Surgery Intervention: Procedure: Microcoaxial Phacoemulsification
27	Completed no results published yet	Posterior Capsule Opacification (PCO) With Single Piece Hydrophobic Versus Hydrophilic Intraocular Lens (IOL) Condition: Posterior Capsule Opacification Intervention: Procedure: Phacoemulsification
28	Completed no results published yet	Posterior Capsule Opacification (PCO) With AcrySof Single-Piece IOL Condition: Posterior Capsule Opacification Intervention: Procedure: Phaco
29	Completed no results published yet	Posterior Assisted Levitation of Dropped Nucleus Condition: Cataract Intervention:
30	Completed no results published yet	Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses

		<p>Condition: Cataract</p> <p>Interventions: Device: Tecnis Z9000 intraocular lens; Device: MA60 intraocular lens</p>
31	Completed no results published yet	<p>Comparative Study of Three IOL Power Calculation Formulae for Asian Eyes Shorter Than 22mm or Longer Than 25mm</p> <p>Condition: Cataract</p> <p>Intervention: Procedure: IOL calculation formula</p>
32	Completed no results published yet	<p>Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction</p> <p>Condition: Cataract</p> <p>Interventions: Device: Crystalens AO; Device: ReSTOR 3.0; Device: AMO Tecnis Multifocal</p>
33	Completed no results published yet	<p>Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification</p> <p>Condition: Cataract</p> <p>Intervention: Procedure: Honan balloon application</p>
34	Terminated	<p>Visual Function After Implantation of AcrySof® Toric Lens</p> <p>Condition: Cataract</p> <p>Intervention: Device: AcrySof Toric Intraocular Lens</p>
35	Terminated	<p>DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery</p> <p>Condition: Mature Cataracts</p> <p>Intervention: Drug: DYME</p>
36	Recruiting	<p>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy</p> <p>Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer</p> <p>Interventions: Biological: Denosumab; Biological: Placebo</p>
37	Recruiting	<p>Clinical Evaluation of a New Cartridge for the Implantation of Foldable Intraocular Lenses</p>

		<p>Condition: Cataract</p> <p>Intervention: Procedure: cartridge</p>
38	Recruiting	<p>Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts</p> <p>Condition: Cataract</p> <p>Intervention:</p>
39	Recruiting	<p>Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial</p> <p>Condition: Cataract</p> <p>Intervention: Procedure: Microcoaxial Phaco emulsification</p>
40	Recruiting	<p>Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia</p> <p>Conditions: Astigmatism; Cataract</p> <p>Interventions: Procedure: phacoemulsification; Device: Pentacam (Oculus,G ermany)examination</p>
41	Recruiting	<p>Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts</p> <p>Condition: Cataract</p> <p>Intervention:</p>
42	Recruiting	<p>Evaluate Capsular Apposition to Intraocular Lens</p> <p>Conditions: Capsule Opacification; Tissue Adhesions; Aphakia - Lens Capsule Present; Opacification of Intraocular Lens</p> <p>Intervention:</p>
43	Recruiting	<p>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy</p> <p>Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer</p> <p>Interventions: Biological: Denosumab; Biological: Placebo</p>
44	Recruiting	<p>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving</p>

		<p>Denosumab for Bone Loss Due to Androgen-Deprivation Therapy</p> <p>Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer</p> <p>Interventions: Biological: Denosumab; Biological: Placebo</p>
45	Recruiting	<p>Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema</p> <p>Conditions: Macular Edema, Cystoid; Vision Disorders; Diabetic Macular Edema; Cystoid Macular Edema Following Cataract Surgery; Cataract</p> <p>Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surgery</p>
47	Recruiting	<p>Effect of Minimising Ultrasound Power to 1% During Cataract Surgery on Corneal Endothelium.</p> <p>Condition: Cataract</p> <p>Interventions: Procedure: one percent ultrasound power in CMICS; Procedure: 40 percent ultrasound power in CMICS</p>
48	Recruiting	<p>Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts</p> <p>Condition: Cataract</p> <p>Intervention:</p>
49	Recruiting	<p>Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre</p> <p>Condition: Primary Disease: Cataract</p> <p>Interventions: Device: Femtosecond Laser (VICTUS™ Femtosecond Laser Platform); Device: Manual (CCC technique with Utrata forceps)</p>
50	Enrolling by invitation	<p>Antioxidants for Prevention of Cataracts Follow-up Study</p> <p>Condition: Effect of Antioxidants on Occurrence of Cataracts</p> <p>Intervention:</p>

51	Enrolling by invitation	<p>The Effect of Cataract Extraction on the Contractility of Ciliary Muscle</p> <p>Conditions: Presbyopia; Cataract</p> <p>Intervention: Other: UBM with pilocarpine in presbyopia</p>
52	Active, not recruiting	<p>LENS - Long-term Eltrombopag Observational Study</p> <p>Conditions: Ocular Safety; Purpura, Thrombocytopenic, Idiopathic</p> <p>Intervention: Drug: Observational Study</p>
53	Active, not recruiting	<p>LENS - Long-term Eltrombopag Observational Study</p> <p>Conditions: Ocular Safety; Purpura, Thrombocytopenic, Idiopathic</p> <p>Intervention: Drug: Observational Study</p>
54	Active, not recruiting	<p>Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome</p> <p>Condition: Cataract With Exfoliation Syndrome</p> <p>Intervention:</p>
55	Active, not recruiting	<p>Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study</p> <p>Conditions: Aphakia; Cataract</p> <p>Interventions: Device: Study IOL; Device: Hoya iSert 751; Device: Negatively aspheric IOL</p>
56	Active, not recruiting	<p>LENS - Long-term Eltrombopag Observational Study</p> <p>Conditions: Ocular Safety; Purpura, Thrombocytopenic, Idiopathic</p> <p>Intervention: Drug: Observational Study</p>
57	Not yet recruiting	<p>Effects of Vitamin C and Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population</p> <p>Condition: Lens Opacity</p> <p>Interventions: Dietary Supplement: Starch; Dietary Supplement: Vitamin C; Dietary Supplement: Lycium Barbarum</p>
58	Unknown †	<p>Surgical Treatment of Concurrent Cataract and Primary Pterygium</p> <p>Conditions: Pterygium; Cataract; Lenses, Intraocular</p> <p>Interventions: Procedure: combined pterygium and cataract operation</p>
59	Unknown †	<p>Effect of Pterygium Excision on Intraocular Lens Power Calculation</p>

		<p>for Subsequent Cataract Operation</p> <p>Conditions: Pterygium; Cataract; Astigmatism</p> <p>Intervention: Procedure: pterygium excision</p>
60	Unknown †	<p>Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification</p> <p>Conditions: Cataract; Phacoemulsification</p> <p>Interventions: Procedure: MSSICS; Procedure: Phacoemulsification</p>
61	Unknown †	<p><u>Dose-Ranging Study of an Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract</u></p> <p>Condition: Nuclear Cataract</p> <p>Interventions: Drug: LiquiTears; Drug: C-KAD Ophthalmic Solution</p>
62	Unknown †	<p><u>Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof</u></p> <p>Condition: Cataract</p> <p>Interventions: Device: AMO Tecnis Z9000; Device: Alcon SA60AT Acrysof</p>
63	Unknown †	<p><u>Combined Phacotube vs Phacotrabeculectomy: A Randomized Controlled Trial</u></p> <p>Conditions: Glaucoma; Cataract</p> <p>Interventions: Procedure: Glaucoma Implant Surgery; Procedure: trabeculectomy; Procedure: phacoemulsification</p>
64	Unknown †	<p><u>Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study</u></p> <p>Conditions: Cataract; Glaucoma</p> <p>Intervention: Device: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery</p>

12. Central Serous Chorioretinopathy

Rank	Status	Study
1	Completed Has Results published on website	Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Intervention:
2	Completed no results published yet	Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Condition: Central Serous Chorioretinopathy Interventions: Drug: Verteporfin PDT, half-dose; Drug: verteporfin PDT, half-fluence
3	Completed no results published yet	Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Condition: Chronic Central Serous Chorioretinopathy Intervention: Procedure: half-dose photodynamic therapy
4	Completed no results published yet	High-dose Antioxidants for Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Intervention: Drug: antioxidants tablets
5	Recruiting	Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Condition: Central Serous Chorioretinopathy Intervention: Procedure: PDT
6	Recruiting	The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Condition: Central Serous Chorioretinopathy Intervention: Procedure: Photodynamic therapy
7	Recruiting	Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Condition: Chronic Central Serous Chorioretinopathy Interventions: Drug: Verteporfin; Drug: ranibizumab
8	Recruiting	Central Serous Chorioretinopathy: Etiology, Course and

		<p>Prognosis</p> <p>Condition: Central Serous Chorioretinopathy</p> <p>Intervention:</p>
--	--	---

13. Choroid Diseases

Rank	Status	Study
1	Completed Has Results published on website	Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) Conditions: Choroidal Neovascularization; Age-Related Maculopathy Interventions: Drug: dexamethasone; Biological: ranibizumab; Other: sham
2	Completed Has Results published in journals	A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Conditions: Intermediate Uveitis; Posterior Uveitis Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection
3	Completed Has Results published on website	Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Condition: Macular Degeneration Intervention: Drug: pegaptanib sodium
4	Completed Has Results published in journals	Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Condition: Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) Intervention: Drug: Ranibizumab
5	Terminated Has Results published on website	A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration Conditions: Choroid Neovascularization; Age-Related Macular Degeneration Interventions: Drug: AGN 211745; Drug: Ranibizumab 500µg
6	Completed no results published yet	Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients Condition: Age Related Macular Degeneration Intervention: Drug: ranibizumab 0.5 mg

7	Completed no results published yet	A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD Condition: Neovascular Age-related Macular Degeneration Intervention: Biological: Intravitreal injection of KH902
8	Completed no results published yet	Population-based Study of Macular Choroidal Neovascularization in a Chinese Population Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen Intervention: Other: Follow-up observation
9	Completed no results published yet	Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). Condition: Age Related Macular Degeneration Interventions: Drug: 0.5 mg ranibizumab; Drug: 3 mg PF-04523655; Drug: 1 mg PF-04523655
10	Completed no results published yet	Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Condition: Pathological Myopia Interventions: Drug: 0.5 mg ranibizumab driven by disease activity; Drug: 0.5 mg ranibizumab driven by stabilization criteria; Drug: verteporfin PDT
11	Completed no results published yet	EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration Intervention: Drug: ranibizumab
12	Completed no results published yet	Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration) Condition: Macular Degeneration Intervention: Drug: pegaptanib sodium
13	Completed	Safety and Efficacy of Oral PTK787 in Patients With Subfoveal

	no results published yet	<p>Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)</p> <p>Condition: Wet Age-Related Macular Degeneration</p> <p>Interventions: Drug: PTK787; Drug: Placebo</p>
14	Completed no results published yet	<p>Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration</p> <p>Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment</p> <p>Intervention: Drug: Ranibizumab</p>
15	Completed no results published yet	<p>Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</p> <p>Conditions: Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration (AMD)</p> <p>Intervention: Drug: ranibizumab</p>
16	Terminated	<p>A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration</p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention: Drug: AG-013,958</p>
17	Active, not recruiting	<p>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)</p> <p>Condition: Myopia, Pathological</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: No Drug</p>
18	Recruiting	<p>A Randomized, Double-masked, Multicenter, Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD</p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein</p>
19	Recruiting	<p>Pilot Study of a Suprachoroidal Retinal Prosthesis</p>

		<p>Conditions: Retinitis Pigmentosa; Choroid eremia</p> <p>Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis</p>
20	Unknown †	<p>Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia</p> <p>Condition: Myopic Choroidal Neovasc ular Membrane</p> <p>Intervention: Drug: Intravitreal Pegaptan ib</p>

14. Choroidal Neovascularization

Rank	Status	Study
1	Completed Has Results published on website	Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration Condition: Age-related Macular Degeneration Intervention: Drug: ranibizumab
2	Terminated Has Results published on website	A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration Conditions: Choroid Neovascularization; Age-Related Macular Degeneration Interventions: Drug: AGN 211745; Drug: Ranibizumab 500µg
3	Completed Has Results published in journals	Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Condition: Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) Intervention: Drug: Ranibizumab
4	Completed Has Results published on website	Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) Conditions: Choroidal Neovascularization; Age-Related Maculopathy Interventions: Drug: dexamethasone; Biological: ranibizumab
5	Completed Has Results published on website	Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Condition: Macular Degeneration Intervention: Drug: pegaptanib sodium
6	Completed Has Results published on website	Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) Conditions: Choroidal Neovascularization; Age-Related Maculopathy Interventions: Drug: dexamethasone; Biological: ranibizumab; Other: sham
7	Completed no results	A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population

	published yet	<p>Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen</p> <p>Intervention: Other: Follow-up observation</p>
8	Completed no results published yet	<p>A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD</p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: Intravitreal injection of KH 902</p>
9	Completed no results published yet	<p>Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients</p> <p>Condition: Age Related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab 0.5 mg</p>
10	Completed no results published yet	<p>Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</p> <p>Condition: Pathological Myopia</p> <p>Interventions: Drug: 0.5 mg ranibizumab driven by disease activity; Drug: 0.5 mg ranibizumab driven by stabilization criteria; Drug: verteporfin PDT</p>
11	Completed no results published yet	<p>Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).</p> <p>Condition: Age Related Macular Degeneration</p> <p>Interventions: Drug: 0.5 mg ranibizumab; Drug: 3 mg PF-04523655; Drug: 1 mg PF-04523655</p>
12	Completed no results published yet	<p>EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</p> <p>Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab</p>
13	Completed no results published yet	<p>Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)</p> <p>Condition: Macular Degeneration</p>

		Intervention: Drug: pegaptanib sodium
14	Completed no results published yet	Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Conditions: Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration (AMD) Intervention: Drug: ranibizumab
15	Completed no results published yet	Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment Intervention: Drug: Ranibizumab
16	Completed no results published yet	Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) Condition: Wet Age-Related Macular Degeneration Interventions: Drug: PTK787; Drug: Placebo
17	Completed no results published yet	An Extension to Study MD7108240 Condition: Macular Degeneration Intervention: Drug: Pazopanib
18	Completed no results published yet	To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD Condition: Macular Degeneration Intervention: Drug: Pazopanib
19	Completed no results published yet	Myopic Macular Haemorrhages Condition: Myopic Macular Haemorrhages Intervention:
20	Terminated	A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration Condition: Age-Related Macular Degeneration Intervention: Drug: AG-013,958

21	Active, not recruiting	<p>A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD</p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: intravitreal injection of K H902</p>
22	Active, not recruiting	<p>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)</p> <p>Condition: Myopia, Pathological</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: No Drug</p>
23	Recruiting	<p>A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD</p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein</p>
24	Unknown †	<p>Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia</p> <p>Condition: Myopic Choroidal Neovascular Membrane</p> <p>Intervention: Drug: Intravitreal Pegaptanib</p>

15. Choroideremia

Rank	Status	Study
1	Recruiting	<p data-bbox="507 302 1181 336">Pilot Study of a Suprachoroidal Retinal Prosthesis</p> <p data-bbox="670 347 1348 380">Conditions: Retinitis Pigmentosa; Choroideremia</p> <p data-bbox="654 403 1220 481">Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis</p>

16. Choroiditis

Rank	Status	Study
1	Completed Has Results published in journal	A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Conditions: Intermediate Uveitis; Posterior Uveitis Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection

17. Conjunctival Diseases

Rank	Status	Study
1	Completed Has Results published in journals	Acupuncture for Dry Eye Syndrome Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupuncture; Device: Non-acupuncture point shallow penetration acupuncture
2	Completed Has Results published on website	The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Condition: Chlamydial Conjunctivitis Intervention: Drug: Azithromycin
3	Completed Has Results published on website	A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Condition: Bacterial Conjunctivitis Interventions: Drug: Gatifloxacin 0.5% eye drops; Drug: placebo eye drops
4	Completed Has Results published on website	Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC) Condition: Seasonal Allergic Conjunctivitis Interventions: Drug: Loteprednol etabonate 0.2%; Drug: Olopatadine 0.1%
5	Completed Has Results published on website	Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; Drug: Refresh eye drops
6	Completed Has Results published in journals	Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Conditions: Conjunctivitis; Keratitis; Blepharitis Interventions: Drug: Loteprednol and tobramycin; Drug: Tobramycin and dexamethasone
7	Completed Has Results published on website	Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypromellose; Drug: Post-LASIK 0.3% hypromellose
8	Completed	Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in

	Has Results published on website	Patients With Primary Pterygium Condition: Pterygium Interventions: Drug: cyclosporine ophthalmic emuls on 0.05%; Drug: Vehicle
9	Completed No results published yet	Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Condition: Seasonal Allergic Conjunctivitis Intervention: Drug: Ketotifen
10	Completed No results published yet	Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital Conditions: Glaucoma; Pterygium Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
11	Completed No results published yet	Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital Conditions: Glaucomas; Pterygium Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
12	Completed No results published yet	Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital Conditions: Glaucoma; Pterygium Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
13	Completed No results published yet	Polyglactin Sutures Versus Nylon Sutures for Suturing of Conjunctival Autograft in Pterygium Surgery: a Randomised Controlled Trial Condition: Pterygium Interventions: Procedure: Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery; Procedure: Nylon sutures for suturing of conjunctival autograft in pterygium surgery
14	Completed No results published yet	A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Dr

		ug: CP-690,550 Eye drops-vehicle; Drug: Sodium Hyaluronate
15	Completed No results published yet	Acupuncture for Dry Eye Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus
16	Completed No results published yet	Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eyedrops
17	Completed No results published yet	Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
18	Completed No results published yet	A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Condition: Dry Eye Syndrome Interventions: Drug: DA-6034; Drug: Placebo
19	Completed No results published yet	Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: Umbilical cord serum eyedrops; Drug: Autologous serum eyedrops
20	Completed No results published yet	CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome Condition: Dry Eye Syndrome Intervention:
21	Completed No results published yet	Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes Condition: Dry Eye Syndromes Interventions: Drug: Placebo; Drug: KLS-0611
22	Completed No results published	A Study of KCT-0809 in Patients With Dry Eye Syndromes Condition: Dry Eye Syndromes

	yet	Interventions: Drug: KCT-0809; Drug: Placebo
23	Completed No results published yet	Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Conditions: Keratoconjunctivitis; Conjunctivitis Intervention: Drug: FK506
24	Completed No results published yet	Late Phase 2 Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
25	Completed No results published yet	Long Term Administration Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759 Ophthalmic suspension
26	Completed No results published yet	Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Conditions: Keratoconjunctivitis; Conjunctivitis Interventions: Drug: FK506; Drug: placebo
27	Completed No results published yet	Confirmatory Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension; Drug: Hyalein Mini Ophthalmic solution
28	Completed No results published yet	Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis Condition: Allergic Conjunctivitis Interventions: Drug: DE-114 ophthalmic solution; Drug: Placebo ophthalmic solution; Drug: Olopatadine Hydrochloride 0.1% Ophthalmic Solution
29	Completed No results published yet	A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis Condition: Allergic Conjunctivitis Intervention: Drug: DE-114 ophthalmic solution
30	Terminated	Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan

		<p>Condition: Allergic Conjunctivitis</p> <p>Intervention: Drug: beta-1,3-glucan</p>
31	<p>Completed</p> <p>No results published yet</p>	<p>Dose-Response Study of OPC-12759 Ophthalmic Suspension</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759</p>
32	<p>Completed</p> <p>No results published yet</p>	<p>An Open-label, Long-term Study, With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis</p> <p>Condition: Allergic Conjunctivitis</p> <p>Intervention: Drug: AL-4943A (olopatidine 0.2%)</p>
33	<p>Completed</p> <p>No results published yet</p>	<p>Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: 3% DE-089 ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution</p>
34	<p>Completed</p> <p>No results published yet</p>	<p>Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients</p> <p>Condition: Allergic Conjunctivitis</p> <p>Intervention: Drug: Olopatadine hydrochloride ophthalmic solution 0.1%</p>
35	<p>Completed</p> <p>No results published yet</p>	<p>Safety Study of OPC-12759 Ophthalmic Solution</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: OPC-12759 Ophthalmic solution; Drug: OPC-12759 Ophthalmic suspension</p>
36	<p>Completed</p> <p>No results published yet</p>	<p>Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)</p> <p>Conditions: Allergic Rhinoconjunctivitis; Chronic Urticaria</p> <p>Intervention: Drug: Bilastine</p>
37	<p>Completed</p> <p>No results published yet</p>	<p>The Effect of Punctal Plugs on Tear Volume and Osmolality</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: Temporary Collagen Inserts</p>
38	<p>Completed</p>	<p>Safety and Efficacy Study of New Eye Drop Formulations With</p>

	No results published yet	<p>Refresh Tears® in Patients With Dry Eye Disease</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) - 1; Drug: Formulation 2: EDNP - 2; carboxymethylcellulose sodium based artificial tear</p>
39	Completed No results published yet	<p>Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis</p> <p>Condition: Atopic Conjunctivitis</p> <p>Interventions: Drug: Cyclosporine Vehicle; Drug: Cyclosporine 0.010%; Drug: Open-labeled Cyclosporine 0.010%</p>
40	Completed No results published yet	<p>Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis</p> <p>Conditions: Rhinitis, Allergic, Seasonal; Conjunctivitis</p> <p>Interventions: Drug: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution; Drug: olopatadine hydrochloride ophthalmic solution</p>
41	Completed No results published yet	<p>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</p> <p>Condition: Dry Eye</p> <p>Interventions: Other: Systane; Other: Refresh Tears</p>
42	Completed No results published yet	<p>A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis</p> <p>Condition: Allergic Conjunctivitis</p> <p>Intervention: Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%</p>
43	Completed No results published yet	<p>Rotational Narrow Strip Versus Full Conjunctival Graft in Pterygium Excision</p> <p>Condition: Pterygium</p> <p>Interventions: Procedure: Rotational Narrow Strip Conjunctival</p>

		Graft; Procedure: Full Conjunctival Graft
44	Completed No results published yet	Moisture Chamber Glasses for Dry Eye in Asian Population Condition: Dry Eye Intervention: Device: 7eye(Panoptx) TM moisture chamber glasses
45	Completed No results published yet	Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery Conditions: Pterygium; Ocular Surface Cicatrizing Diseases Intervention: Device: Tisseel fibrin adhesive
46	Completed No results published yet	Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Conditions: Pterygium; Ocular Surface Disease; Stevens Johnson Syndrome; Chemical Injury Intervention: Procedure: Cultivated conjunctival transplantation
47	Completed No results published yet	Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye Condition: Xerophthalmia Intervention: Drug: Autologous serum eye drops
48	Completed No results published yet	Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium Condition: Pterygium of the Conjunctiva and Cornea Interventions: Drug: Fluorometholone; Drug: Bevacizumab
49	Completed No results published yet	Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Condition: Viral Conjunctivitis Intervention: Drug: 2% povidone-iodine
50	Completed No results published yet	Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Condition: Dry Eye Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution
51	Completed No results published	To Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation Condition: Pterygium

	yet	Intervention: Procedure: Amniotic membrane transplantation using fibrin glue
52	Completed No results published yet	Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
53	Completed No results published yet	Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC) Condition: Keratoconjunctivitis, Vernal Interventions: Drug: tacrolimus; Drug: cyclosporins
54	Enrolling by invitation	TearLab Core Validation Study Condition: Dry Eye Disease Intervention:
55	Active, not recruiting	A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Placebo
56	Recruiting	Topical Bevacizumab for Preventing Recurrent Pterygium Conditions: Pterygium; Bevacizumab; VEGF; Interventions: Drug: bevacizumab eye drop 0.05%; ine 0.9%
57	Recruiting	Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome Condition: Dry Eye Syndrome Interventions: Drug: DA-6034 3%; Drug: DA-6034 5%; Drug: DA-6034 Placebo
58	Recruiting	Confirmatory Study of OPC-12759 Ophthalmic Solution Condition: Dry Eye Interventions: Drug: OPC-12759; Drug: Placebo
59	Recruiting	Intralesional Bevacizumab Injection on Primary Pterygium Conditions: Pterygium; Inflammation Interventions: Drug: Intralesional injection of bevacizumab; Drug: Topical antihistamine and vasoconstrictor
60	Recruiting	The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis

		<p>Condition: Dry Eye</p> <p>Intervention:</p>
61	Recruiting	<p>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Intervention: Device: Punctal Plug</p>
62	Recruiting	<p>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution ; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
63	Recruiting	<p>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution ; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
64	Recruiting	<p>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: EyeGiene</p>
65	Recruiting	<p>Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease</p> <p>Condition: Moderate to Severe Dry Eye Disease</p> <p>Interventions: Drug: nonsteroid anti-inflammatory drops plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute</p>
66	Recruiting	<p>Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium</p> <p>Condition: Pterygium</p> <p>Intervention:</p>
67	Recruiting	<p>A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
68	Recruiting	<p>Hydroxychloroquine Treatment of Dry Eyes in Patients With</p>

		<p>Primary Sjögren's Syndrome</p> <p>Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye</p> <p>Interventions: Drug: Hydroxychloroquine; Drug: Placebo</p>
69	Recruiting	<p>Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders</p> <p>Conditions: Pterygium; Dry Eye; Tumor</p> <p>Intervention:</p>
70	Recruiting	<p>A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%</p> <p>Conditions: Conjunctivitis, Seasonal Allergic; Conjunctivitis, Giant Papillary; Inflammation</p> <p>Intervention: Drug: Loteprednol Etabonate</p>
71	Unknown †	<p>Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation</p> <p>Conditions: Pterygium; Cataract; Astigmatism</p> <p>Intervention: Procedure: pterygium excision</p>
72	Unknown †	<p>The Pathogenesis of Superior Limbic Keratoconjunctivitis</p> <p>Condition: Superior Limbic Keratoconjunctivitis</p> <p>Intervention:</p>
73	Unknown †	<p>Surgical Treatment of Concurrent Cataract and Primary Pterygium</p> <p>Conditions: Pterygium; Cataract; Lenses, Intraocular</p> <p>Interventions: Procedure: combined pterygium and cataract operation; Procedure: pterygium excision followed by cataract operation</p>
74	Unknown †	<p><u>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin eye drop</p>
75	Unknown †	<p><u>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye</u></p>

		<p>Condition: Stevens-Johnson Syndrome</p> <p>Intervention:</p>
76	Unknown †	<p>Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital</p> <p>Conditions: Glaucomas; Pterygium</p> <p>Intervention: Device: ologen™ Collagen matrix implantation in glaucoma filtering surgery</p>
77	Unknown †	<p>Comparison of Glue With Sutures for Pterygium Surgery</p> <p>Condition: Pterygium</p> <p>Intervention: Procedure: Pterygium excision and conjunctival autograft</p>
78	Unknown †	<p>The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients</p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
79	Not yet recruiting	<p>FST-100 in the Treatment of Acute Adenoviral Conjunctivitis</p> <p>Condition: Acute Adenoviral Conjunctivitis</p> <p>Interventions: Drug: FST-100; Drug: FST-100 (Component #1); Drug: FST-100 Vehicle</p>
80	Not yet recruiting	<p>A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease</p> <p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops</p>
81	Withdrawn	<p>The Application of Fibrin Glue in Ocular Surface Diseases</p> <p>Conditions: Pterygium; Corneal Ulcer</p> <p>Intervention: Drug: tissue fibrin glue application (Tisseel)</p>

18. Corneal Diseases

Rank	Status	Study
1	Completed Has Results Published in journals	Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Conditions: Conjunctivitis; Keratitis; Blepharitis Interventions: Drug: Loteprednol and tobramycin; Drug: Tobramycin and dexamethasone
2	Completed Has Results Published in journals	Acupuncture for Dry Eye Syndrome Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupuncture; Device: Non-acupuncture point shallow penetration acupuncture
3	Completed Has Results Published on website	Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypromellose; Drug: Post-LASIK 0.3% hypromellose
4	Completed No results published yet	A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Drug: CP-690,550 Eye drops-vehicle; Drug: Sodium Hyaluronate
5	Completed No results published yet	Acupuncture for Dry Eye Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus
6	Completed No results published yet	Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eyedrops
7	Completed No results published yet	Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
8	Completed No results	A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers

	published yet	<p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034; Drug: Placebo</p>
9	Completed No results published yet	<p>Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome</p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: Umbilical cord serum eyedrops; Drug: Autologous serum eyedrops</p>
10	Completed No results published yet	<p>CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome</p> <p>Condition: Dry Eye Syndrome</p> <p>Intervention:</p>
11	Completed No results published yet	<p>Effect on Wound Healing of Vigamox Versus Cravit</p> <p>Condition: Cataract Extraction</p> <p>Interventions: Drug: Moxifloxacin 0.5% ophthalmic solution (Vigamox); Drug: Levofloxacin 0.5% ophthalmic solution (Cravit)</p>
12	Completed No results published yet	<p>Using in Vivo Confocal Microscope to Evaluate the Corneal Wound Healing After Various Ocular Surgeries</p> <p>Condition: Corneal Diseases</p> <p>Intervention:</p>
13	Completed No results published yet	<p>Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: Placebo; Drug: KLS-0611</p>
14	Completed No results published yet	<p>A Study of KCT-0809 in Patients With Dry Eye Syndromes</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
15	Completed No results published yet	<p>Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</p> <p>Conditions: Keratoconjunctivitis; Conjunctivitis</p> <p>Intervention: Drug: FK506</p>
16	Completed No results published yet	<p>Late Phase 2 Study of OPC-12759 Ophthalmic Suspension</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759</p>
17	Completed No results published yet	<p>Long Term Administration Study of OPC-12759 Ophthalmic Suspension</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759 Ophthalmic suspension</p>

18	Completed No results published yet	Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis Conditions: Keratoconjunctivitis; Conjunctivitis Interventions: Drug: FK506; Drug: placebo
19	Completed No results published yet	Confirmatory Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension;
20	Completed No results published yet	Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye Condition: Dry Eye Interventions: Drug: DE-089 ophthalmic solution; Drug: Placebo ophthalmic solution
21	Completed No results published yet	Dose-Response Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
22	Completed No results published yet	Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye Condition: Dry Eye Interventions: Drug: 3% DE-089 ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution
23	Completed No results published yet	Safety Study of OPC-12759 Ophthalmic Solution Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic solution; Drug: OPC-12759 Ophthalmic suspension
24	Active, not recruiting	Steroids for Corneal Ulcers Trial Conditions: Corneal Ulcer; Eye Infections, Bacterial Interventions: Drug: Antibiotics; Drug: Topical corticosteroid; Drug: Placebo
25	Completed No results published yet	Mycotic Ulcer Treatment Trial I Conditions: Corneal Ulcer; Eye Infections, Fungal Interventions: Drug: Natamycin; Drug: Voriconazole

26	<p>Completed No results published yet</p>	<p>Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer</p> <p>Condition: Fungal Keratitis</p> <p>Interventions: Drug: Natamycin 5%; Drug: Voriconazole; Procedure: Corneal de-epithelialization</p>
27	<p>Completed No results published yet</p>	<p>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</p> <p>Condition: Dry Eye</p> <p>Interventions: Other: Systane; Other: Refresh Tears</p>
28	<p>Completed No results published yet</p>	<p>Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis</p> <p>Condition: Atopic Conjunctivitis</p> <p>Interventions: Drug: Cyclosporine Vehicle; Drug: Cyclosporine 0.010%; Drug: Open-labeled Cyclosporine 0.010%</p>
29	<p>Completed No results published yet</p>	<p>Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers</p> <p>Conditions: Acute Bacterial Corneal Ulcers; Bacterial Keratitis</p> <p>Interventions: Drug: Gatifloxacin 0.3% ophthalmic solution; Drug: Ciprofloxacin 0.3% ophthalmic solution</p>
30	<p>Completed No results published yet</p>	<p>Moisture Chamber Glasses for Dry Eye in Asian Population</p> <p>Condition: Dry Eye</p> <p>Intervention: Device: 7eye(Panoptx)TM moisture chamber glasses</p>
31	<p>Completed No results published yet</p>	<p>A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients</p> <p>Condition: Keratoconus</p> <p>Intervention:</p>
32	<p>Completed No results published yet</p>	<p>Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium</p> <p>Condition: Pterygium of the Conjunctiva and Cornea</p> <p>Interventions: Drug: Fluorometholone; Drug: Bevacizumab</p>

33	Completed No results published yet	Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Condition: Viral Conjunctivitis Intervention: Drug: 2% povidone-iodine
34	Completed No results published yet	Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Condition: Dry Eye Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution
35	Completed No results published yet	Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
36	Completed No results published yet	Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivitis (VKC) Condition: Keratoconjunctivitis, Vernal Interventions: Drug: tacrolimus; Drug: cyclosporins
37	Terminated	<u>The Application of Cultured Cornea Stem Cells in Patients Suffering From Corneal Stem Cell Insufficiency</u> Condition: Unilateral Limbal Stem Cell Insufficiency Intervention: Procedure: Transplant of cultured limbal stem cells on cornea
38	Terminated	<u>The Application of Oral Mucosal Epithelial Cell Sheets Cultivated on Amino Membrane in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon.</u> Conditions: Limbal Insufficiency; Symblepharon Intervention: Procedure: Cultured oral mucosa cell sheet transplantation
39	Active, not recruiting	<u>A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome</u> Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Placebo
40	Withdrawn	<u>The Application of Fibrin Glue in Ocular Surface Diseases</u> Conditions: Pterygium; Corneal Ulcer

		Intervention: Drug: tissue fibrin glue application (Tisseel)
41	Enrolling by invitation	TearLab Core Validation Study Condition: Dry Eye Disease Intervention:
42	Recruiting	Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases Conditions: Corneal Dystrophies, Hereditary; Corneal Disease Intervention:
43	Recruiting	Influence of Cosmetic Color Tinted Contact Lenses on the Ocular Surface Conditions: Conjunctival Infections, Irritations and Inflammations; Hypertrophy; Conjunctiva; Corneal Pannus; Corneal Epithelial Wound Intervention: Other: contact lens wear
44	Recruiting	The Asia Cornea Society Infectious Keratitis Study Condition: Corneal Ulcer Intervention:
45	Recruiting	Xenogenic Keratoplasty From Porcine Cornea Condition: Corneal Transplantation Interventions: Genetic: Xenogenic cornea; Genetic: homogenic cornea
46	Recruiting	The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis Condition: Dry Eye Intervention:
47	Recruiting	Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer Condition: Corneal Ulcer Intervention: Device: acellular corneal matrix
48	Recruiting	Study of DE-089 Ophthalmic Solution in Patients With Dry Eye Condition: Dry Eye Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.
49	Recruiting	Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of

		<p>Moderate and Severe Dry Eye Disease</p> <p>Condition: Moderate to Severe Dry Eye Disease</p> <p>Interventions: Drug: nonsteroid anti-inflammatory drops plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute</p>
50	Recruiting	<p>The Asia Cornea Society Infectious Keratitis Study</p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
51	Recruiting	<p>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Intervention: Device: Punctal Plug</p>
52	Recruiting	<p>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
53	Recruiting	<p>The Asia Cornea Society Infectious Keratitis Study</p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
54	Recruiting	<p>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: EyeGiene</p>
55	Recruiting	<p>The Asia Cornea Society Infectious Keratitis Study</p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
56	Recruiting	<p>The Asia Cornea Society Infectious Keratitis Study</p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
57	Recruiting	<p>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034 3%; Drug: DA-6034 5%; Drug: DA-6034 Placebo</p>

58	Recruiting	Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye Interventions: Drug: Hydroxychloroquine; Drug: Placebo
59	Recruiting	The Asia Cornea Society Infectious Keratitis Study Condition: Corneal Ulcer Intervention:
60	Recruiting	Safety and Efficacy Study of Artificial Cornea Condition: Corneal Transplantation Intervention: Device: Auro KPro (Keratoprosthesis)
61	Recruiting	Mycotic Ulcer Treatment Trial II Conditions: Corneal Ulcer; Eye Infections, Fungal Interventions: Drug: Voriconazole; Drug: Placebo
62	Recruiting	Confirmatory Study of OPC-12759 Ophthalmic Solution Condition: Dry Eye Interventions: Drug: OPC-12759; Drug: Placebo
63	Recruiting	The Asia Cornea Society Infectious Keratitis Study Condition: Corneal Ulcer Intervention:
64	Recruiting	The Asia Cornea Society Infectious Keratitis Study Condition: Corneal Ulcer Intervention:
65	Unknown †	Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia Condition: Corneal Ectasia Interventions: Procedure: riboflavin-induced collagen cross-linking treatment; Device: Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia
66	Recruiting	A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

		<p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
67	Unknown †	<p>Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound</p> <p>Condition: Keratitis</p> <p>Intervention:</p>
68	Unknown †	<p>Bevacizumab for the Treatment of Corneal Neovascularization</p> <p>Condition: Corneal Neovascularization</p> <p>Intervention: Drug: Bevacizumab</p>
69	Unknown †	<p>The Pathogenesis of Superior Limbic Keratoconjunctivitis</p> <p>Condition: Superior Limbic Keratoconjunctivitis</p> <p>Intervention:</p>
70	Unknown †	<p>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye</p> <p>Condition: Stevens-Johnson Syndrome</p> <p>Intervention:</p>
71	Unknown †	<p>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin in eye drop</p>
725	Unknown †	<p>Intacs for Keratoconus</p> <p>Condition: Keratoconus</p> <p>Intervention: Device: Intacs intracorneal ring insertions</p>
73	Unknown †	<p>The SNEC DSAEK EndoGlide Clinical Trial</p> <p>Condition: Bullous Keratopathy</p> <p>Intervention: Device: Endoglide</p>
74	Unknown †	<p>The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients</p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
75	Unknown †	<p>Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients</p> <p>Condition: Bacterial Keratitis</p> <p>Intervention:</p>

76	Unknown †	Corneal Thinning During Topical Bevacizumab Therapy Condition: Corneal Neovascularization Intervention: Drug: bevacizumab (Avastin)
----	-----------	---

19. Dacryocystitis

Rank	Status	Study
1	Completed No results published yet	The Microbiological Spectrum in Acute Dacryocystitis Condition: Dacryocystitis Intervention:

20. Diabetic Retinopathy

Rank	Status	Study
1	Complete Has Results published in journals	Diabetic Retinopathy Candesartan Trials Condition: Type 1 Diabetes Intervention: Drug: candesartan cilexetil
2	Completed Has Results published in journals	Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries Conditions: Corneal Epithelial Defect; Diabetic Retinopathy; Penetrating Keratoplasty Interventions: Other: autologous serum; Other: Non-autologous serum
3	Completed no results published yet	The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong Condition: Diabetic Retinopathy Interventions: Other: charging a co-payment for Diabetic Retinopathy screening; Other: free without charging a co-payment
4	Completed no results published yet	A Study on Traditional Chinese Medicine (TCM) Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy Condition: Diabetic Retinopathy Interventions: Drug: Qi ming granula; Drug: Placebo Comparator
5	Completed no results published yet	Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Condition: Diabetic Retinopathy Intervention: Drug: bevacizumab
6	Completed no results published yet	Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy Conditions: Proliferative Diabetic Retinopathy; Vitrectomy Intervention: Drug: Bevacizumab
7	Completed no results published yet	Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME) Conditions: Diabetic Retinopathy; Macular Edema Intervention: Procedure: Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation

8	Completed no results published yet	<p>Macular Hole in Diabetic Retinopathy</p> <p>Conditions: Macular Hole; Proliferative Diabetic Retinopathy</p> <p>Intervention:</p>
9	Completed no results published yet	<p>Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis</p> <p>Conditions: Proliferative Diabetic Retinopathy;</p> <p>Intervention:</p>
10	Completed no results published yet	<p>Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy</p> <p>Condition: Proliferative Diabetic Retinopathy</p> <p>Intervention:</p>
11	Completed no results published yet	<p>Bevacizumab and Long Acting Gas in Diabetic Vitrectomy</p> <p>Condition: Proliferative Diabetic Retinopathy</p> <p>Intervention: Drug: Bevacizumab</p>
12	Completed no results published yet	<p>Reduction in the Occurrence of Center-Involved Diabetic Macular Edema</p> <p>Condition: Diabetic Retinopathy</p> <p>Interventions: Drug: ruboxistaurin; Drug: placebo</p>
13	Completed no results published yet	<p>Macular Appearance After Diabetic Vitrectomy</p> <p>Conditions: Proliferative Diabetic Retinopathy;</p> <p>Intervention:</p>
14	Completed no results published yet	<p>Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries</p> <p>Condition: Corneal Epithelial Defects After Ocular Surgeries</p> <p>Interventions: Drug: Topical insulin eye drops; Drug: Conventional postoperative eye drops</p>
15	Completed no results published yet	<p>Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy</p> <p>Condition: Proliferative Diabetic Retinopathy</p> <p>Intervention: Procedure: Vitrectomy</p>
16	Completed no results published yet	<p>Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage</p> <p>Conditions: Vitreous Hemorrhage; Diabetic Retinopathy</p>

		<p>opathy</p> <p>Intervention: Drug: Vitrase (ovine hyaluronidase)</p>
17	Completed no results published yet	<p>Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: 2304 Eye Drops High Dose; Drug: 2304 Eye Drops Low Dose; Drug: Placebo Eye Drops</p>
18	Completed no results published yet	<p>Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy</p> <p>Condition: Diabetic Retinopathy</p> <p>Interventions: Device: Green Laser (AuroLas, A urolab); Device: Green Laser (I ridex)</p>
19	Completed no results published yet	<p>Diabetic Retinopathy and Diabetic Macular Edema Screening by Non-Physicians With Limited Training</p> <p>Condition: Diabetic Retinopathy</p> <p>Interventions: Device: Digital retina image; Device: direct ophthalmoscopy; Procedure: comprehensive eye exam</p>
20	Terminated	<p><u>Clinical Research on Retinal Neovascularization of Diabetic Retinopathy</u></p> <p>Conditions: The Mechanism of Retinal Neovascularization of Diabetic; Retinopathy.</p> <p>Intervention: Genetic: genetic analyzer</p>
21	Terminated	<p>A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects</p> <p>Condition: Diabetic Retinopathy</p> <p>Intervention: Drug: Vitreosolve</p>
22	Terminated	<p>Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema</p> <p>Conditions: Diabetic Retinopathy; Diabetes Complications</p> <p>Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF</p>

		-04523655 middle; Drug: PF-04 523655 low
23	Active, not recruiting	<p>Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy</p> <p>Conditions: Diabetic Retinopathy; Diabetic Eye Problems; Retinal Disorders</p> <p>Interventions: Drug: Qideng Mingmu capsule; Drug: Placebo Comparator</p>
24	Recruiting	<p>Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy</p> <p>Condition: Macular Edema</p> <p>Intervention: Procedure: Intravitreal injection</p>
25	Recruiting	<p>Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy</p> <p>Condition: Diabetes Complications</p> <p>Intervention: Drug: Avastin (bevacizumab)</p>
26	Recruiting	<p>Genetic Association of Diabetic Retinopathy-1</p> <p>Conditions: Diabetes; Diabetic Retinopathy</p> <p>Intervention:</p>
27	Recruiting	<p><u>Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema</u></p> <p>Conditions: Diabetic Retinopathy; Macular Edema</p> <p>Interventions: Drug: bevacizumab; Drug: dexamethasone</p>
28	Recruiting	<p><u>Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy</u></p> <p>Condition: Diabetes</p> <p>Interventions: Drug: Actos (Pioglitazone); Drug: Acarbose</p>
29	Recruiting	<p><u>A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema</u></p> <p>Condition: Retinopathy, Diabetic</p> <p>Interventions: Drug: darapladib; Drug: placebo</p>
30	Recruiting	<p>Effect of the Adjunctive IVB Before PRP</p> <p>Condition: Diabetic Retinopathy</p> <p>Intervention: Drug: bevacizumab</p>

31	Recruiting	<p>Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy</p> <p>Condition: Proliferative Diabetic Retinopathy</p> <p>Intervention:</p>
32	Not yet recruiting	<p>Biomarkers of Diabetic Retinopathy Progression</p> <p>Conditions: Type 2 Diabetes Mellitus; Mild Non-proliferative Diabetic Retinopathy</p> <p>Intervention:</p>
33	Unknown †	<p>Shiga Progression of Diabetes, Nephropathy and Retinopathy</p> <p>Condition: Type 2 Diabetes Mellitus</p> <p>Interventions: Drug: Pioglitazone add on to SU or biguanide; Drug: SU or Biguanide</p>
34	Unknown †	<p>A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects</p> <p>Condition: Diabetic Retinopathy</p> <p>Intervention: Drug: Vitreosolve</p>
35	Unknown †	<p>To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation</p> <p>Conditions: Macular Edema; Diabetic Retinopathy; Visual Field Loss</p> <p>Interventions: Procedure: PASCAL laser; Procedure: Conventional laser</p>
36	Unknown †	<p>Intravitreal Bevacizumab for Retinal Disorders</p> <p>Conditions: Wet AMD; Macular Oedema; Proliferative Diabetic Retinopathy</p> <p>Intervention: Drug: Bevacizumab (Avastin)</p>
37	Unknown †	<p>Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics</p> <p>Condition: Diabetes Mellitus</p> <p>Intervention:</p>
38	Unknown †	<p>Diabetic Retinopathy Sulodexide Study</p> <p>Condition: Diabetic Retinopathy</p> <p>Intervention: Drug: sulodexide</p>
39	Unknown †	<p>Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy</p> <p>Conditions: Diabetes Mellitus; Diabetic Retinopathy; Vitreous Hemorrhage</p>

		<p>orrhage</p> <p>Intervention: Procedure: Intravitreal long acting gas</p>
40	Unknown †	<p>Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation</p> <p>Condition: Diabetic Retinopathy With Premacular Hemorrhage</p> <p>Intervention: Drug: Intravitreal Bevacizumab</p>
412	Unknown †	<p>Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling</p> <p>Condition: Patients With Proliferative Diabetic Retinopathy Who Have Active Fibrovascular Proliferation</p> <p>Intervention: Procedure: ILM peeling</p>

21. Diplopia

Rank	Status	Study
1	Recruiting	Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial Conditions: Fractures; Enophthalmos; Diplopia Interventions: Device: Polycaprolactone / Tri-Calcium Phosphate; Device: Titanium Mesh

22. Dry Eye Syndromes

Rank	Status	Study
1	Completed Has Results published in journals	Acupuncture for Dry Eye Syndrome Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupuncture; Device: Non-acupuncture point shallow penetration acupuncture
2	Completed Has Results published on website	Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; Drug : Refresh eye drops
3	Completed Has Results published on website	Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypromellose; Drug: Post-LASIK 0.3% hypromellose
4	Completed no results published yet	Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
5	Completed no results published yet	A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Drug: C
6	Completed no results published yet	CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome Condition: Dry Eye Syndrome Intervention:
7	Completed no results published yet	Acupuncture for Dry Eye Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus
8	Completed no results published yet	Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome Condition: Dry Eye Syndrome

		Interventions: Drug: Umbilical cord serum eyedrops; Drug: Autologous serum eyedrops
9	Completed no results published yet	A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers Condition: Dry Eye Syndrome Interventions: Drug: DA-6034; Drug: Placebo
10	Completed no results published yet	Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eyedrops
11	Completed no results published yet	Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes Condition: Dry Eye Syndromes Interventions: Drug: Placebo; Drug: KLS-0611
12	Completed no results published yet	A Study of KCT-0809 in Patients With Dry Eye Syndromes Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Placebo
13	Completed no results published yet	Confirmatory Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension; Drug: Hyalein Mini Ophthalmic solution
14	Completed no results published yet	Long Term Administration Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759 Ophthalmic suspension
15	Completed no results published yet	Late Phase 2 Study of OPC-12759 Ophthalmic Suspension Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
16	Completed no results published yet	Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye Condition: Dry Eye Interventions: Drug: DE-089 ophthalmic solution; Drug: Placebo ophthalmic solution
17	Completed	Phase III Confirmatory Study of DE-089 Ophthalmic Solution in

	no results published yet	<p>Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: 3% DE-089 ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution</p>
18	Completed no results published yet	<p>Dose-Response Study of OPC-12759 Ophthalmic Suspension</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759</p>
19	Completed no results published yet	<p>Safety Study of OPC-12759 Ophthalmic Solution</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: OPC-12759 Ophthalmic solution; Drug: OPC-12759 Ophthalmic suspension</p>
20	Completed no results published yet	<p>Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time</p> <p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Hydroxypropyl Guar Galactomannan; Drug: 0.1% sodium hyaluronate ophthalmic solution</p>
21	Completed no results published yet	<p>Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome</p> <p>Conditions: Xerostomia; Sjogren's Syndrome</p> <p>Intervention: Drug: Rebamipide</p>
22	Completed no results published yet	<p>Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) - 1; Drug: Formulation 2: EDNP - 2; Drug: carboxymethylcellulose sodium based artificial tear</p>
23	Completed no results published yet	<p>The Effect of Punctal Plugs on Tear Volume and Osmolality</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: Temporary Collagen Inserts</p>
24	Completed no results published yet	<p>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</p> <p>Condition: Dry Eye</p> <p>Interventions: Other: Systane; Other: Refresh Tears</p>

25	Completed no results published yet	Moisture Chamber Glasses for Dry Eye in Asian Population Condition: Dry Eye Intervention: Device: 7eye(Panoptx) TM moisture chamber glasses
26	Completed no results published yet	Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye Condition: Xerophthalmia Intervention: Drug: Autologous serum eyedrops
27	Completed no results published yet	Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
28	Completed no results published yet	Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes Condition: Dry Eye Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution
29	Completed no results published yet	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Condition: Stevens-Johnson Syndrome Intervention: Drug: 0.05% cyclosporin eye drop
30	Enrolling by invitation	TearLab Core Validation Study Condition: Dry Eye Disease Intervention:
31	Enrolling by invitation	Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome Condition: Primary Sjogren's Syndrome Intervention:
32	Active, not recruiting	A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Placebo
33	Recruiting	The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis Condition: Dry Eye Intervention:
34	Recruiting	Study of DE-089 Ophthalmic Solution in Patients With Dry Eye Condition: Dry Eye

		<p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
35	Recruiting	<p>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: EyeGiene</p>
36	Recruiting	<p>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</p> <p>Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye</p> <p>Interventions: Drug: Hydroxychloroquine; Drug: Placebo</p>
37	Recruiting	<p>Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders</p> <p>Conditions: Pterygium; Dry Eye; Tumor</p> <p>Intervention:</p>
38	Recruiting	<p>A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes</p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
39	Recruiting	<p>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</p> <p>Condition: Dry Eye</p> <p>Intervention: Device: Punctal Plug</p>
40	Recruiting	<p>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034 3%; Drug: DA-6034 5%</p>
41	Recruiting	<p>Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease</p> <p>Condition: Moderate to Severe Dry Eye Disease</p> <p>Interventions: Drug: nonsteroid anti-inflammatory drops plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute</p>
42	Not yet recruiting	<p>A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease</p>

		<p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops</p>
43	Unknown †	<p>Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)</p> <p>Conditions: Sjogren's Syndrome; Mesenchymal Stem Cells</p> <p>Intervention: Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)</p>
44	Unknown †	<p>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye</p> <p>Condition: Stevens-Johnson Syndrome</p> <p>Intervention:</p>
45	Unknown †	<p><u>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin eye drop</p>
46	Unknown †	<p><u>The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>

23. Enophthalmos

Rank	Status	Study
1	Recruiting	Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial Conditions: Fractures; Enophthalmos; Diplopia Interventions: Device: Polycaprolactone / Tri-Calcium Phosphate; Device: Titanium Mesh

24. Epiretinal Membrane

Rank	Status	Study
1	<p>Completed no results published yet</p>	<p><u>Macular Appearance After Diabetic Vitrectomy</u> Conditions: Proliferative Diabetic Retinopathy; V trectomy Intervention:</p>
2	<p>Completed no results published yet</p>	<p><u>Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery</u> Condition: Epiretinal Membrane Intervention: Device: optical coherence tomography</p>
3	<p>Recruiting</p>	<p><u>Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane</u> Condition: Epiretinal Membrane Interventions: Procedure: Vitrectomy only group; P ocedure: Combined therapy group</p>

25. Esotropia

Rank	Status	Study
1	Completed no results published yet	<u>Under-correction in Refractive Accommodative Esotropia</u> Condition: Accommodative Esotropia Intervention: Device: Glasses prescription
1	Completed no results published yet	<u>Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin</u> Condition: Esotropia Intervention:

26. Exfoliation Syndrome

Rank	Status	Study
1	Active, not recruiting	<u>Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome</u> Condition: Cataract With Exfoliation Syndrome Intervention:
2	Recruiting	<u>LOXL1 Polymorphism in Pseudoexfoliation Syndrome</u> Condition: Pseudoexfoliation Syndrome Intervention:

27. Exophthalmos

Rank	Status	Study
1	Completed no results published yet	<u>Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients</u> Condition: Graves' Disease Intervention: Drug: Dexamethasone
2	Completed no results published yet	<u>Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)</u> Condition: Thyroid-Related Eye Disease Interventions: Drug: LIPO-102; Drug: Placebo
3	Completed no results published yet	<u>Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies</u> Condition: Graves' Ophthalmopathy Intervention: Drug: Carbimazole, radio-active iodine (I131)
4	Completed no results published yet	<u>Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)</u> Condition: Thyroid-Related Eye Disease Interventions: Drug: LIPO-102; Drug: Placebo
5	Completed no results published yet	<u>Thyroid Treatment Trial</u> Condition: Graves Ophthalmopathy Intervention: Drug: Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo
6	Completed no results published yet	<u>Is the Routine Pressure Dressing After Thyroidectomy Necessary?</u> Conditions: Thyroid Neoplasms; Thyroid Nodules; Graves Disease; Goiter Interventions: Procedure: Pressure dressing; Procedure: Normal dressing
7	Recruiting	<u>The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions</u> Conditions: Hypothyroidism; Exophthalmos Intervention: Radiation: Iodine 131
8	Recruiting	<u>Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease</u> Condition: Graves' Disease Intervention:

9	Recruiting	<p><u>Doxycycline Treatment in Graves' Orbitopathy</u></p> <p>Conditions: Graves Ophthalmopathy; Graves Disease; Eye Diseases; Thyroid Diseases; Endocrine System Diseases; Eye Diseases, Hereditary; Hyperthyroidism; Autoimmune Diseases; Immune System Diseases</p> <p>Intervention: Drug: Doxycycline</p>
10	Recruiting	<p><u>Differential Diagnosis Value of PSV of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis</u></p> <p>Conditions: Thyrotoxicosis; Peak Systolic Velocity of Superior Thyroid Artery; Thyroiditis; Graves Disease</p> <p>Intervention:</p>
11	Recruiting	<p><u>Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections</u></p> <p>Condition: Thyroid-associated Ophthalmopathy</p> <p>Intervention: Drug: subconjunctival triamcinolone injection</p>
12	Unknown [†]	<p><u>The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves' Ophthalmopathy</u></p> <p>Condition: Graves' Ophthalmopathy</p> <p>Intervention:</p>

28. Exotropia

Rank	Status	Study
1	Completed no results published yet	<u>Surgery and Convergence Insufficiency Intermittent Exotropia</u> Condition: Complications Interventions: Procedure: Post exercise Surgery; Procedure: Orthoptics; Procedure: Postop orthoptics; Procedure: Post exercises surgery
1	Recruiting	<u>Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia</u> Condition: Intermittent Exotropia Intervention: Procedure: Non surgical therapy

29. Eye Abnormalities

Rank	Status	Study
1	Unknown †	<u>The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma</u> Condition: Primary Congenital Glaucoma Intervention:

30. Eye Diseases, Hereditary

Rank	Status	Study
1	Completed no results published yet	<u>Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmentosa</u> Condition: Retinitis Pigmentosa Intervention:
2	Completed no results published yet	<u>Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies</u> Condition: Graves' Ophthalmopathy Intervention: Drug: Carbimazole, radio-active iodine (I131)
3	Completed no results published yet	<u>The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction</u> Conditions: Retinitis Pigmentosa; Cataract Intervention: Procedure: IOL surgery
4	Completed no results published yet	<u>Thyroid Treatment Trial</u> Condition: Graves Ophthalmopathy Intervention: Drug: Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo
5	Recruiting	<u>Doxycycline Treatment in Graves' Orbitopathy</u> Conditions: Graves Ophthalmopathy; Graves Disease; Eye Diseases; Thyroid Diseases; Endocrine System Diseases; Eye Diseases, Hereditary; Hypertension; Autoimmune Diseases; Immune System Diseases Intervention: Drug: Doxycycline
6	Recruiting	<u>Molecular Genetics of Retinal Degenerations</u> Conditions: Retinal Degeneration; Retinitis Pigmentosa Intervention:
7	Recruiting	<u>Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)</u> Condition: Leber Hereditary Optic Neuropathy Intervention: Drug: rAAV2-ND4
8	Recruiting	<u>Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases</u> Conditions: Corneal Dystrophies, Hereditary;

		Corneal Disease Intervention:
9	Recruiting	<u>Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China</u> Condition: Spinal Cord Injuries Interventions: Procedure: rehabilitation of limb function; Pr
10	Recruiting	<u>Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</u> Conditions: Retinal Degeneration,; Retinitis Pigmentosa Intervention: Procedure: surgical implantation of subretinal device
11	Recruiting	<u>Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections</u> Condition: Thyroid-associated Ophthalmopathy Intervention: Drug: subconjunctival triamcinolone injection
12	Recruiting	<u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u> Condition: Spinal Cord Injury Interventions: Device: ReJoyce Workstation; Other: Standard Care
13	Recruiting	<u>Pilot Study of a Suprachoroidal Retinal Prosthesis</u> Conditions: Retinitis Pigmentosa; Choroideremia Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis
14	Recruiting	<u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u> Condition: Spinal Cord Injury Interventions: Device: ReJoyce Workstation; Other: Standard Care
15	Recruiting	<u>Molecular Genetics of Retinal Degenerations</u> Conditions: Retinal Degeneration; Retinitis Pigmentosa Intervention:
16	Recruiting	<u>Molecular Genetics of Retinal Degenerations</u> Conditions: Retinal Degeneration; Retinitis Pigmentosa Intervention:

17	Active, not recruiting	<p><u>Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Intervention Biological: Umbilical Cord Blood Mononuclear Cell; s: Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone; Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone, Lithium Carbonate</p>
18	Active, not recruiting	<p><u>Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Drug: Methylprednisolone; Drug: Lithium</p>
19	Active, not recruiting	<p><u>Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Procedure: Conventional Treatment; Drug: Lithium Carbonate; Biological: Cord Blood Cell; Other: Placebo</p>
20	Enrolling by invitation	<p><u>Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa</u></p> <p>Conditions: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degeneration</p> <p>Intervention: Drug: Valproic Acid</p>
21	Enrolling by invitation	<p><u>Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa</u></p> <p>Condition: Retinitis Pigmentosa</p> <p>Intervention: Other: Intravitreal injection of bone marrow-derived mesenchymal stem cells</p>
22	Unknown †	<p><u>A Randomized, Double-Blind, Placebo-Controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)</u></p> <p>Condition: Optic Atrophy, Hereditary, Leber</p> <p>Intervention: Drug: curcumin</p>
23	Unknown †	<p><u>Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma</u></p> <p>Condition: Lung Adenocarcinoma</p>

		Intervention:
24	Unknown †	<u>The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves' Ophthalmopathy</u> Condition: Graves' Ophthalmopathy Intervention:

31. Eye Infections

Rank	Status	Study
1	Completed Has Results published on website	<u>The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis</u> Condition: Chlamydial Conjunctivitis Intervention: Drug: Azithromycin
2	Completed Has Results published on website	<u>A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis</u> Condition: Bacterial Conjunctivitis Interventions: Drug: Gatifloxacin 0.5% eye drops; Drug: placebo eye drops
3	Completed no results published yet	<u>Mycotic Ulcer Treatment Trial I</u> Conditions: Corneal Ulcer; Eye Infections, Fungal Interventions: Drug: Natamycin; Drug: Voriconazole
4	Completed no results published yet	<u>Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers</u> Conditions: Acute Bacterial Corneal Ulcers; Bacterial Keratitis Interventions: Drug: Gatifloxacin 0.3% ophthalmic solution; Drug: Ciprofloxacin 0.3% ophthalmic solution
5	Completed no results published yet	<u>Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer</u> Condition: Fungal Keratitis Interventions: Drug: Natamycin 5%; Drug: Voriconazole Corneal de-epithelialization
6	Completed no results published yet	<u>Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine</u> Condition: Viral Conjunctivitis Intervention: Drug: 2% povidone-iodine
7	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
8	Recruiting	<u>Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer</u> Condition: Corneal Ulcer Intervention: Device: acellular corneal matrix
9	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer

		Intervention:
10	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
11	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
12	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
13	Recruiting	<u>Mycotic Ulcer Treatment Trial II</u> Conditions: Corneal Ulcer; Eye Infections, Fungal Interventions: Drug: Voriconazole; Drug: Placebo
14	Not yet recruiting	<u>FST-100 in the Treatment of Acute Adenoviral Conjunctivitis</u> Condition: Acute Adenoviral Conjunctivitis Interventions: Drug: FST-100; Drug: FST-100 (Control); Drug: FST-100 Vehicle
15	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
16	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
17	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u> Condition: Corneal Ulcer Intervention:
18	Active, not recruiting	<u>Steroids for Corneal Ulcers Trial</u> Conditions: Corneal Ulcer; Eye Infections, Bacterial Interventions: Drug: Antibiotics; Drug: Topical corticosteroid; Drug: Placebo
19	Withdrawn	<u>The Application of Fibrin Glue in Ocular Surface Diseases</u> Conditions: Pterygium; Corneal Ulcer Intervention: Drug: tissue fibrin glue application (Tisseel)
20	Unknown †	<u>Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage</u> Condition: Hordeolum

		Interventions: Drug: neomycin sulfate, polymyxin B sulfate and gramicidin; Drug: Artificial tear
--	--	---

32. Eye Injuries

Rank	Status	Study
1	Completed no results published yet	<p><u>Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Auto-Serum and Cord Blood Serum</u></p> <p>Condition: Eye Injuries</p> <p>Interventions: Procedure: venous puncture; Other: obtain serum from peripheral blood or cord blood</p>
1	Unknown †	<p><u>Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease</u></p> <p>Condition: Eye Injury</p> <p>Interventions: Biological: conservative; Procedure: Medical Therapy</p>

33. Eye Neoplasms

Rank	Status	Study
1	Completed no results published yet	<u>Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation</u> Conditions: Neuroblastoma; Brain Tumor; Retinoblastoma; Wilms Tumor; Mycoses Intervention: Drug: itraconazole
2	Completed no results published yet	<u>Rebexamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma</u> Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Retinoblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific Intervention: Drug: becatecarin
3	Completed no results published yet	<u>Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma</u> Condition: Retinoblastoma Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
4	Completed no results published yet	<u>Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma</u> Condition: Retinoblastoma Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
5	Completed no results published yet	<u>Rebexamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma</u> Conditions: Brain and Central Nervous System Tumors; Neuroblastoma; Retinoblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific Intervention: Drug: becatecarin
6	Completed no results published yet	<u>Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma</u> Condition: Retinoblastoma Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation

		clinical observation
7	Active, not recruiting	<p><u>Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma</u></p> <p>Condition: Intraocular Retinoblastoma</p> <p>Intervention: Drug: carboplatin</p>
8	Active, not recruiting	<p><u>Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors</u></p> <p>Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma</p> <p>Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis</p>
9	Active, not recruiting	<p><u>Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser surgery</p>
10	Recruiting	<p><u>Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With Newly Diagnosed Retinoblastoma in Both Eyes</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Procedure: laser therapy; Procedure:</p>
11	Recruiting	<p><u>Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure:</p>

		<p>peripheral blood stem cell transplantation; Radiation: radiation therapy</p>
12	Recruiting	<p><u>Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With Newly Diagnosed Retinoblastoma in Both Eyes</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclosporine; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser therapy; Procedure: neoadjuvant therapy</p>
13	Unknown †	<p><u>Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas</u></p> <p>Conditions: Brain and Central Nervous System Tumor; Germ Cell Tumor; Kidney Cancer; Lymphoma; Neuroblastoma; Retinoblastoma; Unspecified Childhood Solid Tumor; Unspecified</p> <p>Intervention: Drug: alvocidib</p>

34. Eye Pain

Rank	Status	Study
1	Completed no results published yet	<u>Nepafenac Compared to Placebo for Ocular Pain and Inflammation</u> Condition: Cataract Interventions: Drug: Nepafenac; Other: Nepafenac Vehicle

35. Eyelid Diseases

Rank	Status	Study
1	Completed Has Results published on website	<u>Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes</u> Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; Drug: Refresh eye drops
2	Completed Has Results published in journals	<u>Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis</u> Conditions: Conjunctivitis; Keratitis; Blepharitis Interventions: Drug: Loteprednol and tobramycin; Drug: Tobramycin and dexamethasone
3	Completed no results published yet	<u>Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm</u> Condition: Essential Blepharospasm Intervention: Drug: Botulinum Toxin Type A
4	Completed no results published yet	<u>Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm</u> Condition: Blepharospasm Intervention: Drug: Korean Botulinum toxin type A (KbtxA) and Botox injection
5	Completed no results published yet	<u>Efficacy of Aurosling in Frontalis Sling Suspension Surgery</u> Condition: Ptosis, Eyelid Intervention: Procedure: Aurosling
6	Unknown †	<u>Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage</u> Condition: Hordeolum Interventions: Drug: neomycin sulfate, polymyxin B sulfate and gramicidin; Drug: Artificial tear

36. Geographic Atrophy

Rank	Status	Study
1	Completed no results published yet	<u>Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)</u> Condition: Macular Degeneration Interventions: Drug: Brimonidine Tartrate Implant;
2	Completed no results published yet	<u>A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population</u> Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen Intervention: Other: Follow-up observation
3	Completed no results published yet	<u>Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)</u> Condition: Macular Degeneration Interventions: Drug: Brimonidine Tartrate Implant; rug: Sham
4	Completed no results published yet	<u>Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)</u> Condition: Macular Degeneration Interventions: Drug: Brimonidine Tartrate Implant;

37. Glaucoma

Rank	Status	Study
1	Completed Has Results published on website	<u>Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension</u> Conditions: Open-angle Glaucoma; Ocular Hypertension Interventions: Drug: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution; Drug: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
2	Completed Has Results published on website	<u>Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension</u> Conditions: Glaucoma; Ocular Hypertension Interventions: Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution; Drug: brimonidine tartrate ophthalmic solution; Drug: timolol ophthalmic solution; Other: fixed combination vehicle
3	Completed Has Results published on website	<u>Systemic Glutathione Level in Normal Tension Glaucoma</u> Condition: Normal Tension Glaucoma Intervention:
4	Completed Has Results published on website	<u>A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.</u> Condition: Glaucoma Interventions: Drug: Timolol; Drug: latanoprost
5	Completed Has Results published in journals	<u>Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India</u> Conditions: Glaucoma; Cataract Intervention: Device: OculusGen Biodegradable
6	Completed Has Results published on website	<u>A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).</u> Conditions: Glaucoma, Primary Open Angle (POAG); Ocular Hypertension Interventions: Drug: Xalacom (KP2035)

		; Drug: Xalatan
7	Completed no results published yet	<u>Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension</u> Conditions: Glaucoma, Open Angle; Ocular H Interventions: Drug: Xalacom; Drug: unfixed Lat
8	Completed no results published yet	<u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital</u> Conditions: Glaucoma; Pterygium Intervention: Device: OculusGen Biodegradable
9	Completed no results published yet	<u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital</u> Conditions: Glaucoma; Pterygium Intervention: Device: OculusGen Biodegradable
10	Completed no results published yet	<u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital</u> Conditions: Glaucomas; Pterygium Intervention: Device: OculusGen Biodegradable
11	Completed no results published yet	<u>Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.</u> Conditions: Myopia; Maculopathy; Glaucom Intervention:
12	Completed no results published yet	<u>5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy</u> Conditions: Glaucoma; Trabeculectomy; W Interventions: Drug: 5 Fluorouracil with hyaluronic
13	Completed no results published yet	<u>The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes</u> Conditions: Glaucoma Patient; Glaucoma Su Intervention:
14	Completed no results published yet	<u>A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension</u> Conditions: Primary Open Angle Glaucoma; O Interventions: Drug: latanoprost 75 ug; Drug: lat
15	Completed no results published	<u>Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension</u>

	yet	<p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: Azopt; Drug: Cosopt</p>
16	Completed no results published yet	<p><u>Study of PGA Suture in Ophthalmology</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Device: Polyglycolic acid suture</p>
17	Completed no results published yet	<p><u>Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Intervention: Drug: bimatoprost/brimonidine tartrate</p>
18	Completed no results published yet	<p><u>DuoTrav® Eye Drops As Replacement Therapy Program</u></p> <p>Conditions: Open-angle Glaucoma; Ocular Hypertension</p> <p>Intervention: Drug: DuoTrav</p>
19	Completed no results published yet	<p><u>Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients</u></p> <p>Condition: Single-nucleotide Polymorphism (SNP)</p> <p>Intervention: Genetic: SNP analysis of the DNA</p>
20	Completed no results published yet	<p><u>Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma</u></p> <p>Condition: Open-Angle Glaucoma</p> <p>Intervention:</p>
21	Completed no results published yet	<p><u>Screening for Glaucoma in Namil Area, South Korea</u></p> <p>Conditions: Glaucoma; Intraocular Pressure; Intraocular Pressure</p> <p>Intervention:</p>
22	Completed no results published yet	<p><u>Long-Term IOP Fluctuation and VF Progression After Triple Procedure</u></p> <p>Conditions: Glaucoma; Filtering Surgery; Intraocular Pressure</p> <p>Intervention:</p>
23	Completed no results published yet	<p><u>ELAZOP Switching Study in Korea</u></p> <p>Condition: Open Angle Glaucoma</p> <p>Intervention: Drug: Elazop (Azarga)</p>
24	Completed no results published yet	<p><u>Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma</u></p> <p>Conditions: Glaucoma; Acute Primary Angle-closure Glaucoma</p>

		Intervention:
25	Completed no results published yet	<p><u>A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)</p>
26	Completed no results published yet	<p><u>A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.</u></p> <p>Conditions: Primary Open Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: PF-03187207; Drug: Latanoprost</p>
27	Completed no results published yet	<p><u>To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Open-Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-104 ophthalmic solution; Drug: DE-104 vehicle</p>
28	Completed no results published yet	<p><u>Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Open-Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-104 ophthalmic solution, low concentration; Drug: DE-104 ophthalmic solution, medium concentration; Drug: DE-104 ophthalmic solution, high concentration; Drug: DE-104 vehicle</p>
29	Completed no results published yet	<p><u>DE-111 Against Timolol Ophthalmic Solution 0.5%</u></p> <p>Conditions: Open Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-111 ophthalmic solution; Drug: Timolol ophthalmic solution 0.5%</p>
30	Completed	<u>DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone</u>

	no results published yet	<p><u>and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%</u></p> <p>Conditions: Open Angle Glaucoma; Ocular Hypertension</p> <p>Interventions Drug: DE-111 ophthalmic solution; Drug: g: Tafluprost ophthalmic solution 0.0015%; Drug: Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%</p>
31	Completed no results published yet	<p><u>Safety and Efficacy of Travoprost/Timolol BAC-free</u></p> <p>Conditions: Open-angle Glaucoma; Ocular Hypertension</p> <p>Interventions Drug: Travoprost 0.004%/Timolol 0.5%; BAC-free Ophthalmic Solution; Drug: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution (DuoTrav®)</p>
32	Completed no results published yet	<p><u>A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension</u></p> <p>Conditions: Primary Open Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: latanoprost 75 ug; Drug: latanoprost 100 ug; Drug: latanoprost 125 ug; Drug: latanoprost 50 ug</p>
33	Completed no results published yet	<p><u>A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension</u></p> <p>Conditions: Glaucoma, Open-Angle; Ocular Hypertension</p> <p>Intervention: Drug: Xalacom</p>
34	Completed no results published yet	<p><u>A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma</u></p> <p>Conditions: Glaucoma, Angle-Closure; Ocular Hypertension</p> <p>Interventions: Drug: Travoprost (0.004%); Drug: Latanoprost (0.005%)</p>
35	Completed no results published yet	<p><u>Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: bimatoprost /timolol formulation ophthalmic solution; Drug: Ganfort® (bimatoprost/timolol ophthalmic solution)</p>

36	Completed no results published yet	<u>IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy</u> Condition: Glaucoma Intervention: Drug: Azopt
37	Completed no results published yet	<u>Optic Nerve Compliance Study</u> Condition: Glaucoma Intervention: Procedure: Brief Elevation of IOP
38	Completed no results published yet	<u>To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure</u> Condition: Uncontrolled Intraocular Pressure Intervention: Drug: Travacom
39	Completed no results published yet	<u>A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension</u> Conditions: Primary Open Angle Glaucoma; Ocular Hypertension Interventions: Drug: latanoprost 75 ug; Drug: latanoprost 100 ug; Drug: latanoprost 125 ug; Drug: xalatan 50 ug
40	Completed no results published yet	<u>Ologen (OculusGen)-Glaucoma MMC Control in Pakistan</u> Conditions: Glaucoma; Trabeculectomy Interventions: Device: ologen collagen matrix in glaucoma surgery; Drug: MMC in glaucoma
41	Completed no results published yet	<u>A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</u> Conditions: Ocular Hypertension; Primary Open Angle Glaucoma Interventions: Drug: Ganfort; Drug: Duotrav
42	Completed no results published yet	<u>Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study</u> Conditions: Chronic Angle Closure Glaucoma; Ocular Hypertension Intervention: Procedure: Q-switched fd Nd:yag ir
43	Completed no results published yet	<u>Results of Mass Switch From Latanoprost to Travoprost</u> Condition: Glaucoma Intervention:
44	Completed no results published yet	<u>Role of Polymorphisms in the IL-1 Gene Cluster</u> Condition: Glaucoma Intervention:

45	Completed no results published yet	<u>Laser Iridotomy Versus Phacoemulsification in Acute Angle Closure</u> Condition: Angle Closure Glaucoma Intervention: Procedure: Laser Preipheral Iridotomy
46	Terminated	<u>Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients</u> Condition: Glaucoma, Angle-Closure Interventions: Drug: brimonidine 0.2%/timolol 0.5%
47	Terminated	<u>OculusGen-Glaucoma Historical Control Study in Taiwan</u> Condition: Glaucoma Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
48	Enrolling by invitation	<u>The High Cup/Disc Ratio in Children</u> Condition: Glaucoma Intervention:
49	Active, not recruiting	<u>SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma</u> Conditions: Glaucoma; Glaucoma, Open Angle Interventions: Device: SOLX Gold Shunt GMS-plus
50	Enrolling by invitation	<u>Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India</u> Conditions: Patient Noncompliance; Health Literacy Intervention:
51	Active, not recruiting	<u>Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost</u> Conditions: Glaucoma, Open-Angle; Ocular Hypertension Interventions: Drug: refrigeration free latanoprost;
52	Active, not recruiting	<u>A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)</u> Conditions: Glaucoma, Open-Angle; Ocular Hypertension Intervention: Drug: Bimatoprost 0.01%
53	Recruiting	<u>Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome</u> Condition: Glaucoma Interventions: Drug: Bevacizumab; Drug: Mitomycin
54	Recruiting	<u>The Effect of "Eye Drop Guide" on the Success Rate of Eye</u>

		<p><u>Drops Self-instillation in Glaucoma Patients</u></p> <p>Condition: Eye Drops Self-instillation</p> <p>Interventions: Device: Eye Drop Guide technique;</p>
55	Recruiting	<p><u>Clinical and Molecular Studies in Families With Glaucoma and Related Diseases</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
56	Recruiting	<p><u>Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma</u></p> <p>Conditions: Ocular Surface Disease; Glaucoma</p> <p>Interventions: Drug: hydroxypropylmethylcellulose</p>
57	Recruiting	<p><u>Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: Latanoprost; Procedure: SLT</p>
58	Recruiting	<p><u>Analysis of Clinical Profiles of Chinese Patients With Normal Tension Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
59	Recruiting	<p><u>A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months</u></p> <p>Conditions: Ocular Hypertension; Open-angle</p> <p>Interventions: Drug: AR-12286 Ophthalmic Solution maleate ophthalmic solution 0.5%</p>
60	Recruiting	<p><u>Ologen (OculusGen)-Glaucoma Case Control Trial in India</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Device: OculusGen Biodegradable</p>
61	Recruiting	<p><u>A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution</p>
52	Recruiting	<p><u>DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension</u></p> <p>Condition: Open Angle Glaucoma</p>

		<p>or Ocular Hypertension</p> <p>Intervention: Drug: DE-111 ophthalmic solution</p>
62	Recruiting	<p><u>Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Device: Artificial drainage implant</p>
63	Recruiting	<p><u>Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002 AM1)</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: Preservative-Free Tafluprost</p>
64	Recruiting	<p><u>Ologen (OculusGen)-Glaucoma MMC Control Trial in India</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Device: OculusGen Biodegradable Implant; Drug: Trabeculectomy w</p>
65	Recruiting	<p><u>Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma</u></p> <p>Condition: Normal Tension Glaucoma</p> <p>Interventions: Drug: Brimonidine/Timolol mixed co</p>
66	Recruiting	<p><u>Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension</u></p> <p>Conditions: Open-Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: bimatoprost ophthalmic formulation A; Drug: bimatoprost ophthalmic formulation B; Drug: bimatoprost ophthalmic formulation C; Drug: bimatoprost ophthalmic formulation D; Drug: bimatoprost ophthalmic formulation E; Drug: bimatoprost ophthalmic formulation F; Drug: Sham;</p> <p>Drug: timolol 0.5%; Drug: bimatoprost ophthalmic solution 0.03%; Drug: latanoprost 0.005%; Drug: timolol vehicle (placebo)</p>
67	Recruiting	<p><u>A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma</u></p>

		<p>Condition: Glaucoma</p> <p>Interventions: Drug: bimatoprost ophthalmic solution</p>
68	Recruiting	<p><u>A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution</p>
69	Unknown †	<p><u>Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
70	Unknown †	<p><u>Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital</u></p> <p>Conditions: Glaucomas; Pterygium</p> <p>Intervention: Device: ologen™ Collagen matrix implant</p>
71	Unknown †	<p><u>Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Procedure: pattern scanning laser iridotomy</p>
72	Unknown †	<p><u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
73	Unknown †	<p><u>Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma</u></p> <p>Condition: Normal Tension Glaucoma</p> <p>Interventions: Drug: dorzolamide/timolol fixed combination</p>
74	Unknown †	<p><u>Relationship Between Topiramate Use and Ocular Angle Status</u></p> <p>Condition: Glaucoma, Angle-Closure</p> <p>Intervention: Drug: Topiramate</p>
75	Unknown †	<p><u>Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients</u></p> <p>Condition: Primary Open Angle Glaucoma</p>

		Intervention:
76	Unknown †	<u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.</u> Condition: Primary Open Angle Glaucoma Intervention:
77	Unknown †	<u>Corneal Endothelium After Glaucoma Surgery</u> Conditions: Glaucoma; Corneal Damage; I Intervention:
78	Unknown †	<u>Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma</u> Conditions: Advanced Glaucoma; Refractory Interventions: Procedure: Micropulse Transscleral
79	Unknown †	<u>Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma</u> Condition: Glaucoma Interventions: Procedure: Selective Laser Trabecu
80	Unknown †	<u>External Micropulse Diode Laser Transscleral Trabeculoplasty (EMDLT) for Severe Open Angle Glaucoma</u> Condition: Primary Open Angle Glaucoma Intervention: Device: EXTERNAL MICROPULSE
81	Unknown †	<u>Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study</u> Condition: Glaucoma, Angle-Closure Interventions: Drug: Latanoprost-Bimatoprost; D
82	Unknown †	<u>Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study</u> Conditions: Cataract; Glaucoma Intervention: Device: ologen™ Collagen Matrix Im
83	Unknown †	<u>Imaging Ahmed Glaucoma Tubes With a Pericardial Graft and Tissue Glue or Partial-Thickness Scleral Flap and Sutures</u> Conditions: Advanced Glaucoma; Failed Trab Interventions: Procedure: Pericardial graft & tissu
84	Unknown †	<u>Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma</u>

		<p>Condition: Glaucoma</p> <p>Interventions: Procedure: Argon Laser Iridoplasty;</p>
85	Unknown †	<p><u>Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial</u></p> <p>Conditions: Glaucoma; Cataract</p> <p>Interventions: Procedure: Glaucoma Implant Surg</p>
86	Unknown †	<p><u>The Genetic Study of Primary Angle-Closure Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
87	Unknown †	<p><u>Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: Combigan Ophthalmic Solution</p>
88	Unknown †	<p><u>The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma</u></p> <p>Condition: Primary Congenital Glaucoma</p> <p>Intervention:</p>
89	Unknown †	<p><u>Discriminating Ability of the Cirrus High Definition (HD) Optical Coherence Tomography (OCT) for Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
90	Unknown †	<p><u>Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: Subconjunctival Bevacizumab</p>
91	Unknown †	<p><u>ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Procedure: Argon laser Iridoplasty;</p>
92	Unknown †	<p><u>Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
93	Unknown †	<p><u>Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus Optical Coherence Tomography (OCT)</u></p>

		<p>Condition: Glaucoma</p> <p>Intervention:</p>
94	Unknown †	<p><u>Personality Characteristics and Compliance With Antiglaucoma Medication</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
95	Unknown †	<p><u>Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With the Cirrus High-Definition (HD) Optical Coherence Tomography (OCT)</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
96	Unknown †	<p><u>Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
97	Unknown †	<p><u>The Effect of Bevacizumab on the Trabeculectomy</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: intraocular injections of bevacizumab</p>
98	Not yet recruiting	<p><u>Post-operative Satisfaction With Glaucoma Surgery Trial</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Behavioral: film and trained counse</p>
99	Not yet recruiting	<p><u>Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Intervention: Drug: dorzolamide hydrochloride 2. ophthalmic solution (Triple Combina</p>

38. Graves Disease

Rank	Status	Study
1	Completed no results published yet	<u>Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies</u> Condition: Graves' Ophthalmopathy Intervention: Drug: Carbimazole, radio-active iodine (I131)
2	Completed no results published yet	<u>Thyroid Treatment Trial</u> Condition: Graves Ophthalmopathy Intervention: Drug: Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo
3	Recruiting	<u>Doxycycline Treatment in Graves' Orbitopathy</u> Conditions: Graves Ophthalmopathy; Graves Disease; Eye Diseases; Thyroid Diseases; Endocrine System Diseases; Eye Diseases, Hereditary; Hyperthyroidism; Autoimmune Diseases; Immune System Diseases Intervention: Drug: Doxycycline
4	Recruiting	<u>Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections</u> Condition: Thyroid-associated Ophthalmopathy Intervention: Drug: subconjunctival triamcinolone injection
5	Unknown †	<u>The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves' Ophthalmopathy</u> Condition: Graves' Ophthalmopathy Intervention:

39. Hordeolum

Rank	Status	Study
1	Unknown [†]	<p><u>Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage</u></p> <p>Condition: Hordeolum</p> <p>Interventions: Drug: neomycin sulfate, polymyxin B sulfate and gramicidin; Drug: Artificial tear</p>

40. Hydrophthalmos

Rank	Status	Study
1	Recruiting	<u>Clinical and Molecular Studies in Families With Glaucoma and Related Diseases</u> Condition: Glaucoma Intervention:
2	Unknown †	<u>The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma</u> Condition: Primary Congenital Glaucoma Intervention:

41. Hyperopia

Rank	Status	Study
1	Completed no results published yet	<p><u>Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles</u></p> <p>Conditions: Myopia; Hyperopia; Astigmatism</p> <p>Interventions: Device: Ready-made spectacles; Device: Spectacles</p>
2	Completed no results published yet	<p><u>Time Course Comparison of Contact Lens Maintenance Systems for Hydrogel Lenses</u></p> <p>Conditions: Myopia; Hyperopia</p> <p>Interventions: Device: Silicone Hydrogel Contact Lenses; Device: 1x PMBH preserved MPS; Device: 1x Polyquad/Aldox MPS</p>
3	Completed no results published yet	<p><u>Comparison of Contact Lens Maintenance Systems for Silicone Hydrogel Lenses</u></p> <p>Conditions: Myopia; Hyperopia</p> <p>Intervention: Device: Silicone hydrogel contact lens</p>
4	Recruiting	<p><u>Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes</u></p> <p>Conditions: Myopia; Hyperopia; Presbyopia</p> <p>Intervention: Device: Supracor</p>
5	Recruiting	<p><u>Randomized, Non-inferiority Trial Comparing SMILE and LASIK</u></p> <p>Conditions: Myopia; Astigmatism; Hypermetropia</p> <p>Interventions: Procedure: Femtosecond LASIK; Procedure: Small incision lenticule extraction (SMILE)</p>
6	Unknown [†]	<p><u>Ocular Imaging With Spectral Domain Optical Coherence Tomography</u></p> <p>Conditions: Healthy; Myopia; Hypermetropia</p> <p>Intervention: Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)</p>

42. Iridocyclitis

Rank	Status	Study
1	Completed no results published yet	<p data-bbox="539 333 1430 412"><u>A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis</u></p> <p data-bbox="762 427 1334 461" style="text-align: center;">Conditions: Uveitis, Anterior; Panuveitis</p> <p data-bbox="735 479 1342 512" style="text-align: center;">Interventions: Drug: Placebo; Drug: LX211</p>
2	Completed no results published yet	<p data-bbox="539 528 1401 607"><u>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</u></p> <p data-bbox="778 622 1158 656" style="text-align: center;">Condition: Uveitis, Anterior</p> <p data-bbox="735 674 1441 1014" style="text-align: center;">Interventions: Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System; Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System; Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System; Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System</p>
3	Recruiting	<p data-bbox="539 1037 1422 1115"><u>Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis</u></p> <p data-bbox="762 1131 1441 1209" style="text-align: center;">Conditions: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis</p> <p data-bbox="746 1227 1174 1261" style="text-align: center;">Intervention: Drug: Ganciclovir</p>

43. Keratitis

Rank	Status	Study
1	Completed Has Results published on website	<u>Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis</u> Condition: Atopic Conjunctivitis Interventions: Drug: Cyclosporine Vehicle; Drug: Cyclosporine 0.010%
2	Completed Has Results Published in journals	<u>Acupuncture for Dry Eye Syndrome</u> Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupunc- ture; Device: Non-acupuncture point shallow penetration acupuncture
3	Completed Has Results published on website	<u>Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery</u> Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypro- mellose; Drug: Post-LASIK 0.3% hypromellose
4	Completed Has Results published in journals	<u>Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis</u> Conditions: Conjunctivitis; Keratitis; Bl- eopharitis Interventions: Drug: Loteprednol and tobram- ycin; Drug: Tobramycin and dexamethasone
5	Completed no results published yet	<u>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</u> Condition: Dry Eye Interventions: Other: Systane; Other: Refr- esh Tears
6	Completed no results published yet	<u>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Drug: CP-690,550 Eye dro- ps-vehicle; Drug: Sodium H

		yaluronate
7	Completed no results published yet	<u>Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</u> Conditions: Keratoconjunctivitis; Conjunctivitis Intervention: Drug: FK506
8	Completed no results published yet	<u>Late Phase 2 Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
9	Completed no results published yet	<u>Long Term Administration Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759 Ophthalmic suspension
10	Completed no results published yet	<u>Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes</u> Condition: Dry Eye Syndromes Interventions: Drug: Placebo; Drug: KLS-0611
11	Completed no results published yet	<u>Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</u> Conditions: Keratoconjunctivitis; Conjunctivitis Interventions: Drug: FK506; Drug: placebo
12	Completed no results published yet	<u>Acupuncture for Dry Eye</u> Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus
13	Completed no results published yet	<u>Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients</u> Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eyedrops
14	Completed no results published yet	<u>Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine</u> Condition: Viral Conjunctivitis Intervention: Drug: 2% povidone-iodine

15	Completed no results published yet	<u>Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes</u> Condition: Dry Eye Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution
16	Completed no results published yet	<u>Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye</u> Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
17	Completed no results published yet	<u>Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivitis (VKC)</u> Condition: Keratoconjunctivitis, Vernal Interventions: Drug: tacrolimus; Drug: cyclosporins
18	Completed no results published yet	<u>Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u> Condition: Dry Eye Interventions: Drug: DE-089 ophthalmic solution; Drug: Placebo ophthalmic solution
19	Completed no results published yet	<u>Confirmatory Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension; Drug: Hyalein Mini Ophthalmic solution
20	Completed no results published yet	<u>A Study of KCT-0809 in Patients With Dry Eye Syndromes</u> Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Placebo
21	Completed no results published yet	<u>Dose-Response Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
22	Completed no results	<u>Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u>

	published yet	<p>Condition: Dry Eye</p> <p>Interventions: Drug: 3% DE-089 ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution</p>
23	Completed no results published yet	<p><u>Safety Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: OPC-12759 Ophthalmic solution; Drug: OPC-12759 Ophthalmic suspension</p>
24	Completed no results published yet	<p><u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
25	Completed no results published yet	<p><u>Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome</u></p> <p>Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca</p> <p>Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04</p>
26	Completed no results published yet	<p><u>A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034; Drug: Placebo</p>
27	Completed no results published yet	<p><u>Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: Umbilical cord serum eyedrops; Drug: Autologous serum eyedrops</p>
28	Completed no results published yet	<p><u>CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Intervention:</p>
29	Withdrawn	<p><u>The Application of Fibrin Glue in Ocular Surface Diseases</u></p> <p>Conditions: Pterygium; Corneal Ulcer</p>

		<p>Intervention: Drug: tissue fibrin glue application (Tisseel)</p>
30	Completed no results published yet	<p><u>The Effect of Punctal Plugs on Tear Volume and Osmolality</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: Temporary Collagen Inserts</p>
31	Completed no results published yet	<p><u>Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) - 1; Drug: Formulation 2: EDNP - 2; Drug: carboxymethylcellulose sodium based artificial tear</p>
32	Completed no results published yet	<p><u>Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer</u></p> <p>Condition: Fungal Keratitis</p> <p>Interventions: Drug: Natamycin 5%; Drug: Voriconazole; Procedure: Corneal de-epithelialization</p>
33	Completed no results published yet	<p><u>Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers</u></p> <p>Conditions: Acute Bacterial Corneal Ulcers; Bacterial Keratitis</p> <p>Interventions: Drug: Gatifloxacin 0.3% ophthalmic solution; Drug: Ciprofloxacin 0.3% ophthalmic solution</p>
34	Completed no results published yet	<p><u>Mycotic Ulcer Treatment Trial I</u></p> <p>Conditions: Corneal Ulcer; Eye Infections, Fungal</p> <p>Interventions: Drug: Natamycin; Drug: Voriconazole</p>
35	Completed no results published yet	<p><u>Moisture Chamber Glasses for Dry Eye in Asian Population</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Device: 7eye(Panoptx)™ moi</p>

		sture chamber glasses
36	Completed no results published yet	<p><u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
37	Active, not recruiting	<p><u>A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
38	Active, not recruiting	<p><u>Steroids for Corneal Ulcers Trial</u></p> <p>Conditions: Corneal Ulcer; Eye Infections, Bacterial</p> <p>Interventions: Drug: Antibiotics; Drug: Topical corticosteroid; Drug: Placebo</p>
39	Enrolling by invitation	<p><u>TearLab Core Validation Study</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
40	Recruiting	<p><u>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: EyeGiene</p>
41	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
42	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
43	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
44	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p>

		Intervention:
45	Recruiting	<p><u>Confirmatory Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: OPC-12759; Drug: Placebo</p>
46	Recruiting	<p><u>Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease</u></p> <p>Condition: Moderate to Severe Dry Eye Disease</p> <p>Interventions: Drug: nonsteroid anti-inflammatory drops plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute</p>
47	Recruiting	<p><u>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</u></p> <p>Conditions: Autoimmune Diseases; Sjögren's Syndrome; Dry Eye</p> <p>Interventions: Drug: Hydroxychloroquine; Drug: Placebo</p>
48	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
49	Recruiting	<p><u>A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
50	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
51	Recruiting	<p><u>The Asia Cornea Society Infectious Keratitis Study</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
52	Recruiting	<p><u>Mycotic Ulcer Treatment Trial II</u></p> <p>Conditions: Corneal Ulcer; Eye Infections, Fungal</p> <p>Interventions: Drug: Voriconazole; Drug: Placebo</p>
53	Recruiting	<u>The Asia Cornea Society Infectious Keratitis Study</u>

		<p>Condition: Corneal Ulcer</p> <p>Intervention:</p>
54	Recruiting	<p><u>The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis</u></p> <p>Condition: Dry Eye</p> <p>Intervention:</p>
55	Recruiting	<p><u>Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer</u></p> <p>Condition: Corneal Ulcer</p> <p>Intervention: Device: acellular corneal matrix</p>
56	Recruiting	<p><u>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034 3%; Drug: DA-6034 5%; Drug: DA-6034 Placebo</p>
57	Recruiting	<p><u>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Device: Punctal Plug</p>
58	Not yet recruiting	<p><u>A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease</u></p> <p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops</p>
59	Unknown †	<p><u>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin eye drop</p>
60	Unknown †	<p><u>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome</u></p>

		<p><u>With Dry Eye</u></p> <p>Condition: Stevens-Johnson Syndrome</p> <p>Intervention:</p>
61	Unknown †	<p><u>The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
62	Unknown †	<p><u>Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients</u></p> <p>Condition: Bacterial Keratitis</p> <p>Intervention:</p>
63	Unknown †	<p><u>Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound</u></p> <p>Condition: Keratitis</p> <p>Intervention:</p>
64	Unknown †	<p><u>The Pathogenesis of Superior Limbic Keratoconjunctivitis</u></p> <p>Condition: Superior Limbic Keratoconjunctivitis</p> <p>Intervention:</p>

44. Keratoconjunctivitis

Rank	Status	Study
1	Completed Has Results published in journals	<u>Acupuncture for Dry Eye Syndrome</u> Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupuncture; Device: Non-acupuncture point shallow penetration acupuncture
2	Completed Has Results published on website	<u>Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis</u> Condition: Atopic Conjunctivitis Interventions: Drug: Cyclosporine Vehicle; Drug: Cyclosporine 0.010%
3	Completed Has Results published on website	<u>Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery</u> Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypromellose; Drug: Post-LASIK 0.3% hypromellose
4	Completed no results published yet	<u>Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome</u> Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
5	Completed no results published yet	<u>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Drug: CP-690,550 Eye drops-vehicle; Drug: Sodium Hyaluronate
6	Completed no results published yet	<u>Acupuncture for Dry Eye</u> Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus
7	Completed no results published yet	<u>Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients</u> Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eye drops
8	Completed no results	<u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u>

	published yet	<p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
9	Completed no results published yet	<p><u>The Effect of Punctal Plugs on Tear Volume and Osmolality</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: Temporary Collagen Inserts</p>
10	Completed no results published yet	<p><u>A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034; Drug: Placebo</p>
11	Completed no results published yet	<p><u>Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: Umbilical cord serum eyedrops; Drug : Autologous serum eyedrops</p>
12	Completed no results published yet	<p><u>CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Intervention:</p>
13	Completed no results published yet	<p><u>Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</u></p> <p>Conditions: Keratoconjunctivitis; Conjunctivitis</p> <p>Interventions: Drug: FK506; Drug: placebo</p>
14	Completed no results published yet	<p><u>Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) - 1; Drug: Formulation 2: EDNP - 2; Drug: carboxymethylcellulose sodium based artificial tear</p>
15	Completed no results published yet	<p><u>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Other: Systane; Other: Refresh Tears</p>
16	Completed no results	<p><u>Moisture Chamber Glasses for Dry Eye in Asian Population</u></p>

	published yet	<p>Condition: Dry Eye</p> <p>Intervention: Device: 7eye(Panoptx)TM moisture chamber glasses</p>
17	Completed no results published yet	<p><u>Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</u></p> <p>Conditions: Keratoconjunctivitis; Conjunctivitis</p> <p>Intervention: Drug: FK506</p>
18	Completed no results published yet	<p><u>Late Phase 2 Study of OPC-12759 Ophthalmic Suspension</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759</p>
19	Completed no results published yet	<p><u>Long Term Administration Study of OPC-12759 Ophthalmic Suspension</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759 Ophthalmic suspension</p>
20	Completed no results published yet	<p><u>Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: Placebo; Drug: KLS-0611</p>
21	Completed no results published yet	<p><u>Confirmatory Study of OPC-12759 Ophthalmic Suspension</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: OPC-12759 Ophthalmic suspension; D lein Mini Ophthalmic solution</p>
22	Completed no results published yet	<p><u>Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: DE-089 ophthalmic solution; Drug: Pl acebo ophthalmic solution</p>
23	Completed no results published yet	<p><u>A Study of KCT-0809 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
24	Completed no results published yet	<p><u>Dose-Response Study of OPC-12759 Ophthalmic Suspension</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759</p>
25	Completed no results	<p><u>Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p>

	published yet	<p>Condition: Dry Eye</p> <p>Interventions: Drug: 3% DE-089 ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution</p>
26	Completed no results published yet	<p><u>Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivitis (VKC)</u></p> <p>Condition: Keratoconjunctivitis, Vernal</p> <p>Interventions: Drug: tacrolimus; Drug: cyclosporins</p>
27	Completed no results published yet	<p><u>Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine</u></p> <p>Condition: Viral Conjunctivitis</p> <p>Intervention: Drug: 2% povidone-iodine</p>
28	Completed no results published yet	<p><u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
29	Completed no results published yet	<p><u>Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution</p>
30	Completed no results published yet	<p><u>Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxchlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone</p>
31	Completed no results published yet	<p><u>Safety Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: OPC-12759 Ophthalmic solution; Drug: OPC-12759 Ophthalmic suspension</p>
32	Enrolling by invitation	<p><u>TearLab Core Validation Study</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
33	Active, not recruiting	<p><u>A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
34	Recruiting	<p><u>The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis</u></p>

		<p>Condition: Dry Eye</p> <p>Intervention:</p>
35	Recruiting	<p><u>Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease</u></p> <p>Condition: Moderate to Severe Dry Eye Disease</p> <p>Interventions: Drug: nonsteroid anti-inflammatory drops plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute</p>
36	Recruiting	<p><u>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</u></p> <p>Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye</p> <p>Interventions: Drug: Hydroxychloroquine; Drug: Placebo</p>
37	Recruiting	<p><u>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034 3%; Drug: DA-6034 5%; Drug: DA-6034 Placebo</p>
38	Recruiting	<p><u>Confirmatory Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: OPC-12759; Drug: Placebo</p>
39	Recruiting	<p><u>A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
40	Not yet recruiting	<p><u>A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease</u></p> <p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops</p>
41	Recruiting	<p><u>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Device: Punctal Plug</p>
42	Recruiting	<p><u>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</u></p> <p>Condition: Dry Eye Syndromes</p>

		Intervention: Device: EyeGiene
43	Unknown †	<p><u>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin eye drop</p>
44	Unknown †	<p><u>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye</u></p> <p>Condition: Stevens-Johnson Syndrome</p> <p>Intervention:</p>
45	Unknown †	<p><u>The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
46	Unknown †	<p><u>The Pathogenesis of Superior Limbic Keratoconjunctivitis</u></p> <p>Condition: Superior Limbic Keratoconjunctivitis</p> <p>Intervention:</p>

45. Keratoconjunctivitis Sicca

Rank	Status	Study
1	Completed Has Results published in journals	<u>Acupuncture for Dry Eye Syndrome</u> Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupuncture; Non-acupuncture point shall be used for control; Penetration acupuncture
2	Completed Has Results published on website	<u>Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery</u> Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypromellose; Post-LASIK 0.3% hypromellose
3	Completed Has Results published on website	<u>Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes</u> Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; eye drops
4	Completed no results published yet	<u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u> Condition: Dry Eye Interventions: Drug: diquafosol ophthalmic solution; 0.1% sodium hyaluronate ophthalmic solution.
5	Completed no results published yet	<u>Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome</u> Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT04
6	Completed no results published yet	<u>Acupuncture for Dry Eye</u> Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Placebo
7	Completed no results published yet	<u>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Eye drops-vehicle; Drug: Sodium Chloride Eye Drops
8	Completed no results published yet	<u>CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome</u>

	published yet	Condition: Dry Eye Syndrome Intervention:
9	Completed no results published yet	<u>Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome</u> Condition: Dry Eye Syndrome Interventions: Drug: Umbilical cord serum eye tologous serum eyedrops
10	Completed no results published yet	<u>A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers</u> Condition: Dry Eye Syndrome Interventions: Drug: DA-6034; Drug: Placeb
11	Completed no results published yet	<u>Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients</u> Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Dr drops
12	Completed no results published yet	<u>Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes</u> Condition: Dry Eye Syndromes Interventions: Drug: Placebo; Drug: KLS-06
13	Completed no results published yet	<u>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; drops-vehicle; Drug: Sodium
14	Completed no results published yet	<u>A Study of KCT-0809 in Patients With Dry Eye Syndromes</u> Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Place
15	Completed no results published yet	<u>Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u> Condition: Dry Eye Interventions: Drug: DE-089 ophthalmic soluti phthalmic solution
16	Completed no results published	<u>Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u> Condition: Dry Eye

	yet	Interventions: Drug: 3% DE-089 ophthalmic solution sodium hyaluronate ophthalmic solution
17	Completed no results published yet	<u>Confirmatory Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension alein Mini Ophthalmic solution
18	Completed no results published yet	<u>Long Term Administration Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759 Ophthalmic suspension
19	Completed no results published yet	<u>Late Phase 2 Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
20	Completed no results published yet	<u>Dose-Response Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
21	Completed no results published yet	<u>Safety Study of OPC-12759 Ophthalmic Solution</u> Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension 2759 Ophthalmic suspension
22	Completed no results published yet	<u>Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time</u> Condition: Dry Eye Disease Interventions: Drug: Hydroxypropyl Guar Galacturonate % sodium hyaluronate ophthalmic solution
23	Completed no results published yet	<u>Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome</u> Conditions: Xerostomia; Sjogren's Syndrome Intervention: Drug: Rebamipide
24	Completed no results published yet	<u>Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: Formulation 1: Eye Drops Platform (EDNP) - 1; Drug: Formulation 2: EDNP

		Drug: carboxymethylcellulose so based artificial tear
25	Completed no results published yet	<u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u> Condition: Dry Eye Interventions: Drug: diquafosol ophthalmic sol : 0.1% sodium hyaluronate oph solution.
26	Completed no results published yet	<u>Moisture Chamber Glasses for Dry Eye in Asian Population</u> Condition: Dry Eye Intervention: Device: 7eye(Panoptx) TM mois asses
27	Completed no results published yet	<u>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</u> Condition: Dry Eye Interventions: Other: Systane; Other: Refresh
28	Completed no results published yet	<u>The Effect of Punctal Plugs on Tear Volume and Osmolality</u> Condition: Dry Eye Syndromes Intervention: Device: Temporary Collagen In
29	Completed no results published yet	<u>Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye</u> Condition: Xerophthalmia Intervention: Drug: Autologous serum eyedro
30	Completed no results published yet	<u>Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes</u> Condition: Dry Eye Interventions: Drug: 0.18% sodium hyaluronat chloride solution
31	Completed no results published yet	<u>Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye</u> Condition: Stevens-Johnson Syndrome Intervention: Drug: 0.05% cyclosporin eye dro
32	Completed no results published yet	<u>Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxchlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye</u> Condition: Dry Eye Syndromes

		<p>Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone</p>
33	Enrolling by invitation	<p><u>TearLab Core Validation Study</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
34	Enrolling by invitation	<p><u>Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome</u></p> <p>Condition: Primary Sjogren's Syndrome</p> <p>Intervention:</p>
35	Active, not recruiting	<p><u>A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
36	Recruiting	<p><u>The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis</u></p> <p>Condition: Dry Eye</p> <p>Intervention:</p>
37	Recruiting	<p><u>Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease</u></p> <p>Condition: Moderate to Severe Dry Eye Disease</p> <p>Interventions: Drug: nonsteroid anti-inflammatory plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute</p>
38	Recruiting	<p><u>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034 3%; Drug: DA-6034 Placebo</p>
39	Recruiting	<p><u>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</u></p> <p>Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye</p> <p>Interventions: Drug: Hydroxychloroquine; Drug: Placebo</p>
40	Recruiting	<p><u>Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders</u></p> <p>Conditions: Pterygium; Dry Eye; Tumors</p> <p>Intervention:</p>

41	Recruiting	<p><u>A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
42	Recruiting	<p><u>Confirmatory Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: OPC-12759; Drug: Placebo</p>
43	Recruiting	<p><u>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Device: Punctal Plug</p>
44	Recruiting	<p><u>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: EyeGiene</p>
45	Not yet recruiting	<p><u>A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease</u></p> <p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops</p>
46	Unknown †	<p><u>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin eye drops</p>
47	Unknown †	<p><u>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye</u></p> <p>Condition: Stevens-Johnson Syndrome</p> <p>Intervention:</p>
48	Unknown †	<p><u>The Evaluation of Thiol Redox Status in Conjunctiva of Dry</u></p>

		<p><u>Eye Patients</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
49	Unknown †	<p><u>Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)</u></p> <p>Conditions: Sjogren's Syndrome; Mesenchymal cells</p> <p>Intervention: Biological: Allogeneic Mesenchymal Cells (AlloMSC)</p>

46. Keratoconus

Rank	Status	Study
1	Completed no results published yet	<p><u>A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients</u></p> <p>Condition: Keratoconus</p> <p>Intervention:</p>
2	Unknown †	<p><u>Intacs for Keratoconus</u></p> <p>Condition: Keratoconus</p> <p>Intervention: Device: Intacs intracorneal ring insertion for the treatment of keratoconus</p>
3	Unknown †	<p><u>Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia</u></p> <p>Condition: Corneal Ectasia</p> <p>Interventions: Procedure: riboflavin-induced collagen cross-linking treatment; Device: Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia</p>

47. Lacrimal Apparatus Diseases

Rank	Status	Study
1	Completed Has Results published on website	<u>Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery</u> Condition: Dry Eye Syndromes Interventions: Drug: Pre-LASIK 0.3% hypromellose; Drug: Post-LASIK 0.3% hypromellose
2	Completed Has Results published on journals	<u>Acupuncture for Dry Eye Syndrome</u> Condition: Dry Eye Syndromes Interventions: Device: Standardized Acupuncture; Device: Non-acupuncture point shallow penetration acupuncture
3	Completed Has Results published on website	<u>Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes</u> Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; Drug: Refresh eye drops
4	Completed no results published yet	<u>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Drug: CP-690,550 Eye drops-vehicle; Drug: Sodium Hyaluronate
5	Completed no results published yet	<u>Acupuncture for Dry Eye</u> Condition: Dry Eye Interventions: Device: Acupuncture; Drug: Refresh Plus
6	Completed no results published yet	<u>Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients</u> Condition: Allergic Conjunctivitis Interventions: Drug: NAABAK eyedrops; Drug: Saline eyedrops
7	Completed no results published yet	<u>Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: Formulation 1: Eye Drops New Platform (EDNP) -

		1; Drug: Formulation 2: EDNP - 2; Drug: carboxymethylcellulose sodium based artificial tear
8	Completed no results published yet	<u>The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora</u> Condition: Epiphora Intervention: Device: Lacrimal Tube
9	Completed no results published yet	<u>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</u> Condition: Dry Eye Interventions: Other: Systane; Other: Refresh T ears
10	Completed no results published yet	<u>Moisture Chamber Glasses for Dry Eye in Asian Population</u> Condition: Dry Eye Intervention: Device: 7eye(Panoptx) TM moisture chamber glasses
11	Completed no results published yet	<u>Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome</u> Conditions: Dry Eye Syndromes; Keratoconjunctivitis Sicca Interventions: Drug: AT01; Drug: AT02; Drug: AT03; Drug: AT04
12	Completed no results published yet	<u>A Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers</u> Condition: Dry Eye Syndrome Interventions: Drug: DA-6034; Drug: Placebo
13	Completed no results published yet	<u>Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes</u> Condition: Dry Eye Interventions: Drug: 0.18% sodium hyaluronate; Drug: 0.9% sodium chloride solution
14	Completed no results published yet	<u>Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITETM) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye</u> Condition: Dry Eye Syndromes Intervention: Drug: 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
15	Completed no results	<u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u> Condition: Dry Eye

	published yet	Interventions: Drug: diquafosol ophthalmic solution ; Drug: 0.1% sodium hyaluronate ophthalmic solution.
16	Completed no results published yet	<u>Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome</u> Condition: Dry Eye Syndrome Interventions: Drug: Umbilical cord serum eyedrops; Drug: Autologous serum eyedrops
17	Completed no results published yet	<u>CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome</u> Condition: Dry Eye Syndrome Intervention:
18	Completed no results published yet	<u>A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease</u> Condition: Dry Eye Syndromes Interventions: Drug: CP-690,550 Eye drops; Drug: CP-690,550 Eye drops-vehicle; Drug: Sodium Hyaluronate
19	Completed no results published yet	<u>Late Phase 2 Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759
20	Completed no results published yet	<u>Long Term Administration Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Intervention: Drug: OPC-12759 Ophthalmic suspension
21	Completed no results published yet	<u>Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes</u> Condition: Dry Eye Syndromes Interventions: Drug: Placebo; Drug: KLS-0611
22	Completed no results published yet	<u>Confirmatory Study of OPC-12759 Ophthalmic Suspension</u> Condition: Dry Eye Syndromes Interventions: Drug: OPC-12759 Ophthalmic suspension; Drug: Hyalein Mini Ophthalmic solution
23	Completed no results	<u>Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u>

	published yet	<p>Condition: Dry Eye</p> <p>Interventions: Drug: DE-089 ophthalmic solution; Drug: Placebo ophthalmic solution</p>
24	Completed no results published yet	<p><u>A Study of KCT-0809 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
25	Completed no results published yet	<p><u>Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome</u></p> <p>Conditions: Xerostomia; Sjogren's Syndrome</p> <p>Intervention: Drug: Rebamipide</p>
26	Completed no results published yet	<p><u>Dose-Response Study of OPC-12759 Ophthalmic Suspension</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Drug: OPC-12759</p>
27	Completed no results published yet	<p><u>Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: 3% DE-089 ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution</p>
28	Completed no results published yet	<p><u>Safety Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: OPC-12759 Ophthalmic solution; Drug: OPC-12759 Ophthalmic suspension</p>
29	Completed no results published yet	<p><u>The Effect of Punctal Plugs on Tear Volume and Osmolality</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Intervention: Device: Temporary Collagen Inserts</p>
30	Completed no results published yet	<p><u>Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: diquafosol ophthalmic solution; Drug: 0.1% sodium hyaluronate ophthalmic solution.</p>
31	Completed no results published yet	<p><u>Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye</u></p> <p>Condition: Xerophthalmia</p> <p>Intervention: Drug: Autologous serum eyedrops</p>

32	Completed no results published yet	<u>The Microbiological Spectrum in Acute Dacryocystitis</u> Condition: Dacryocystitis Intervention:
33	Enrolling by invitation	<u>Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome</u> Condition: Primary Sjogren's Syndrome Intervention:
34	Enrolling by invitation	<u>TearLab Core Validation Study</u> Condition: Dry Eye Disease Intervention:
35	Active, not recruiting	<u>A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome</u> Condition: Dry Eye Syndromes Interventions: Drug: KCT-0809; Drug: Placebo
36	Recruiting	<u>Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography</u> Condition: Dry Eye Syndromes Intervention: Device: EyeGiene
37	Recruiting	<u>Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease</u> Condition: Moderate to Severe Dry Eye Disease Interventions: Drug: nonsteroid anti-inflammatory drops plus artificial tear substitute; Drug: corticosteroids plus artificial tear substitute; Drug: artificial tear substitute
38	Recruiting	<u>Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye</u> Condition: Dry Eye Intervention: Device: Punctal Plug
39	Recruiting	<u>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</u> Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye Interventions: Drug: Hydroxychloroquine; Drug: Placebo
40	Recruiting	<u>The Effect of Hinge Location on Corneal Sensation and Dry Eye</u>

		<p><u>After LASIK: A Systematic Review and Meta-analysis</u></p> <p>Condition: Dry Eye</p> <p>Intervention:</p>
41	Recruiting	<p><u>A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes</u></p> <p>Condition: Dry Eye Syndromes</p> <p>Interventions: Drug: KCT-0809; Drug: Placebo</p>
42	Recruiting	<p><u>Confirmatory Study of OPC-12759 Ophthalmic Solution</u></p> <p>Condition: Dry Eye</p> <p>Interventions: Drug: OPC-12759; Drug: Placebo</p>
43	Recruiting	<p><u>Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome</u></p> <p>Condition: Dry Eye Syndrome</p> <p>Interventions: Drug: DA-6034 3%; Drug: DA-6034</p>
44	Not yet recruiting	<p><u>A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease</u></p> <p>Condition: Dry Eye Disease</p> <p>Interventions: Drug: Carboxymethylcellulose Based Eye Drop Formulation A; Drug: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops</p>
45	Unknown †	<p><u>Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)</u></p> <p>Conditions: Sjogren's Syndrome; Mesenchymal Stem Cells</p> <p>Intervention: Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)</p>
46	Unknown †	<p><u>The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients</u></p> <p>Condition: Dry Eye Disease</p> <p>Intervention:</p>
47	Unknown †	<p><u>Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05% Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes</u></p> <p>Condition: Dry Eye</p> <p>Intervention: Drug: 0.05% cyclosporin eye drop</p>
48	Unknown †	<p><u>Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry</u></p>

		<u>Eye</u> Condition: Stevens-Johnson Syndrome Intervention:
--	--	--

48. Lens Diseases

Rank	Status	Study
1	Completed Has Results published in journals	<u>Guangdong Uptake of Surgery Trial</u> Condition: Cataract Intervention: Behavioral: Video and counseling for cataract patients
2	Completed Has Results published in journals	<u>Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India</u> Conditions: Glaucoma; Cataract Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
3	Completed Has Results published on website	<u>Study of Phacodepth Required for Safe and Effective Chop During Phacoemulsification for Cataract.</u> Condition: Cataract Intervention:
4	Completed no results published yet	<u>Effect of Phacoemulsification on Ocular Blood Flow in Human</u> Conditions: Cataract; Hypertension; Diabetes Intervention:
5	Completed no results published yet	<u>Effect of Mobile Communication on Childhood Cataract Follow-up Adherence</u> Condition: Cataract Intervention: Other: Mobile short message service
6	Completed no results published yet	<u>Outcomes of 3 Incision-size-dependent Phacoemulsification Systems</u> Condition: Cataract Intervention:
7	Completed no results published yet	<u>Evaluation of the Rotational Stability of The AcrySof Toric Intraocular Lens in the Capsular Bag in High Myopic Subjects</u> Condition: Cataract Intervention: Procedure: Cataract Surgery
8	Completed no results published yet	<u>Combined Intracameral Lidocaine for Manual Small Incision Cataract Surgery Under Topical Anesthesia</u> Condition: Cataract Interventions: Procedure: MSICS under topical anesthesia with intracameral lidocaine; Procedure: MSICS under topical anesthesia with intracameral balanced salt solution.
9	Completed	<u>Study of Intracameral Adrenaline for Pupil Dilation Without Topical</u>

	no results published yet	<u>Mydriatics in Refractive Cataract Surgery</u> Condition: Cataract Intervention: Drug: adrenalin
10	Completed no results published yet	<u>Nepafenac Compared to Placebo for Ocular Pain and Inflammation</u> Condition: Cataract Interventions: Drug: Nepafenac; Other: Nepafenac Vehicle
11	Completed no results published yet	<u>Comparative Study of Three IOL Power Calculation Formulae for Asian Eyes Shorter Than 22mm or Longer Than 25mm</u> Condition: Cataract Intervention: Procedure: IOL calculation formula
12	Completed no results published yet	<u>Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses</u> Condition: Cataract Interventions: Device: Tecnis Z9000 intraocular lens; Device: MA60 intraocular lens
13	Completed no results published yet	<u>Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification</u> Condition: Cataract Intervention: Procedure: Honan balloon application
14	Completed no results published yet	<u>Effect on Wound Healing of Vigamox Versus Cravit</u> Condition: Cataract Extraction Interventions: Drug: Moxifloxacin 0.5% ophthalmic solution (Vigamox); Drug: Levofloxacin 0.5% ophthalmic solution (Cravit)
15	Completed no results published yet	<u>The Effect of a Blue Light Filtering IOL</u> Conditions: to Compare the Effect of Two Types of IOLs; on the Incidence of Cystoid Macular Edema; After Cataract Surgery Intervention: Procedure: intraocular lens implantation
16	Completed no results published yet	<u>DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery</u> Condition: Mature Cataracts Intervention: Drug: DYME

17	Completed no results published yet	<u>DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery</u> Condition: Mature Cataracts Intervention: Drug: DYME
18	Completed no results published yet	<u>AquaLase Capsule Wash for Pediatric Eyes</u> Conditions: Cataract; Pediatric Cataract Intervention:
19	Completed no results published yet	<u>Clinical Evaluation of a New Cartridge for the Implantation of Foldable Intraocular Lenses</u> Condition: Cataract Intervention: Procedure: cartridge
20	Completed no results published yet	<u>Posterior Capsule Opacification (PCO) With Single Piece Hydrophobic Versus Hydrophilic Intraocular Lens (IOL)</u> Condition: Posterior Capsule Opacification Intervention: Procedure: Phacoemulsification
21	Completed no results published yet	<u>Outcome Following Phacoemulsification Versus Small Incision Cataract Surgery (SICS)</u> Conditions: Visual Outcomes; Quality of Life Interventions: Procedure: phacoemulsification and SICS; Procedure: manual small incision surgery; Procedure: phacoemulsification
22	Completed no results published yet	<u>Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction</u> Condition: Cataract Interventions: Device: Crystalens AO; Device: ReS TOR 3.0; Device: AMO Tecnis Multifocal
23	Completed no results published yet	<u>CME With Different Fluidic Parameters</u> Condition: Cystoid Macular Edema Following Cataract Surgery Intervention: Procedure: microcoaxial phacoemulsification
24	Completed no results published yet	<u>Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery</u> Condition: Congenital Cataract Interventions: Device: Intraocular Lens (Acrysof IOL);

		Device: No IOL
25	Completed no results published yet	<u>A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery</u> Condition: Cataract Interventions: Procedure: Lens Fragmentation by means of a femtosecondlaser; Procedure: Manual Phacoemulsification
26	Completed no results published yet	<u>Prospective Study of Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses</u> Condition: Lens Subluxation Intervention: Device: Cionni Modified Capsule Tension Ring
27	Completed no results published yet	<u>Aurolab Hydrophobic Foldable Intraocular Lens Study</u> Condition: Cataract Intervention: Device: Intraocular Lens
28	Completed no results published yet	<u>Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery</u> Condition: Inflammation Interventions: Drug: Enoxaparin; Drug: Balanced Salt Solution
29	Completed no results published yet	<u>The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction</u> Conditions: Retinitis Pigmentosa; Cataract Intervention: Procedure: IOL surgery
30	Completed no results published yet	<u>Intraoperative and Postoperative Outcomes of Three Ophthalmic Viscosurgical Devices During Phacoemulsification</u> Condition: Intraoperative Performance and Postoperative Outcomes Following Cataract Surgery Intervention: Procedure: Microcoaxial Phacoemulsification
31	Completed no results published yet	<u>Outcomes of Phacoemulsification With Torsional Ultrasound</u> Condition: Cataract Interventions: Procedure: Torsional ultrasound (INFINITI, Alcon, USA); Procedure: Longitudinal U/S (Infiniti system, Alcon, USA); Procedure: Longitudinal U/S (LEGACY 20000, Alcon,

		USA)
32	Completed no results published yet	<u>Posterior Capsule Opacification (PCO) With AcrySof Single-Piece IOL</u> Condition: Posterior Capsule Opacification Intervention: Procedure: Phaco
33	Completed no results published yet	<u>Posterior Capsule Opacification Study</u> Condition: Cataract Interventions: Device: Square edge PMMA IOL; Device: AcrySof IOL; Device: AcrySof IOL; Device: square edge PMMA IOL; Device: Square Edge PMMA IOL
34	Completed no results published yet	<u>Posterior Assisted Levitation of Dropped Nucleus</u> Condition: Cataract Intervention:
35	Terminated	<u>Visual Function After Implantation of AcrySof® Toric Lens</u> Condition: Cataract Intervention: Device: AcrySof Toric Intraocular Lens
36	Enrolling by invitation	<u>Antioxidants for Prevention of Cataracts Follow-up Study</u> Condition: Effect of Antioxidants on Occurrence of Cataracts Intervention:
37	Enrolling by invitation	<u>The Effect of Cataract Extraction on the Contractility of Ciliary Muscle</u> Conditions: Presbyopia; Cataract Intervention: Other: UBM with pilocarpine in presbyopia
38	Active, not recruiting	<u>Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome</u> Condition: Cataract With Exfoliation Syndrome Intervention:
39	Active, not recruiting	<u>Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study</u> Conditions: Aphakia; Cataract Interventions: Device: Study IOL; Device: Hoya iSert 751; Device: Negatively aspheric IOL
40	Recruiting	<u>Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts</u>

		<p>Condition: Cataract</p> <p>Intervention:</p>
41	Recruiting	<p><u>Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema</u></p> <p>Conditions: Macular Edema, Cystoid; Vision Disorders; Diabetic Macular Edema; Cystoid Macular Edema Following Cataract Surgery; Cataract</p> <p>Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surgery</p>
42	Recruiting	<p><u>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy</u></p> <p>Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer</p> <p>Interventions: Biological: Denosumab; Biological: Placebo</p>
43	Recruiting	<p><u>Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts</u></p> <p>Condition: Cataract</p> <p>Intervention:</p>
44	Recruiting	<p><u>Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial</u></p> <p>Condition: Cataract</p> <p>Intervention: Procedure: Microcoaxial Phacoemulsification</p>
45	Recruiting	<p><u>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy</u></p> <p>Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer</p> <p>Interventions: Biological: Denosumab; Biological: Placebo</p>
46	Recruiting	<p><u>A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab</u></p>

		<p><u>for Bone Loss Due to Androgen-Deprivation Therapy</u></p> <p>Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer</p> <p>Interventions: Biological: Denosumab; Biological: Placebo</p>
47	Recruiting	<p><u>Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre</u></p> <p>Condition: Primary Disease: Cataract</p> <p>Interventions: Device: Femtosecond Laser (VICTUS™ Femtosecond Laser Platform); Device: Manual (CCC technique with Utrata forceps)</p>
48	Recruiting	<p><u>Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia</u></p> <p>Conditions: Astigmatism; Cataract</p> <p>Interventions: Procedure: phacoemulsification; Device: (IOLMaster 700, Germany) examination</p>
49	Recruiting	<p><u>Evaluate Capsular Apposition to Intraocular Lens</u></p> <p>Conditions: Capsule Opacification; Tissue Adhesions; Capsule Present; Opacification of Intraocular Lens</p> <p>Intervention:</p>
50	Recruiting	<p><u>Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts</u></p> <p>Condition: Cataract</p> <p>Intervention:</p>
51	Not yet recruiting	<p><u>Effects of Vitamin C and Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population</u></p> <p>Condition: Lens Opacity</p> <p>Interventions: Dietary Supplement: Starch; Dietary Supplement: Vitamin C; Dietary Supplement: Lycium Barbarum</p>
52	Unknown †	<p><u>Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation</u></p> <p>Conditions: Pterygium; Cataract; Astigmatism</p> <p>Intervention: Procedure: pterygium excision</p>
53	Unknown †	<p><u>Surgical Treatment of Concurrent Cataract and Primary Pterygium</u></p> <p>Conditions: Pterygium; Cataract; Lenses, Intraocular</p>

		<p>Interventions: Procedure: combined pterygium and cataract operation; Procedure: pterygium excision followed by cataract operation</p>
54	Unknown †	<p><u>Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study</u></p> <p>Conditions: Cataract; Glaucoma</p> <p>Intervention: Device: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery</p>
55	Unknown †	<p><u>Combined Phacotube vs Phacotrabeculectomy: A Randomized Controlled Trial</u></p> <p>Conditions: Glaucoma; Cataract</p> <p>Interventions: Procedure: Glaucoma Implant Surgery; Procedure: Phacotrabeculectomy; Procedure: phacoemulsification</p>
56	Unknown †	<p><u>Dose-Ranging Study of an Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract</u></p> <p>Condition: Nuclear Cataract</p> <p>Interventions: Drug: LiquiTears; Drug: C-KAD Ophthalmic Solution</p>
57	Unknown †	<p><u>Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification</u></p> <p>Conditions: Cataract; Phacoemulsification</p> <p>Interventions: Procedure: MSSICS; Procedure: Phacoemulsification</p>
58	Unknown †	<p><u>Effect of Minimising Ultrasound Power to 1% During Cataract Surgery on Corneal Endothelium.</u></p> <p>Condition: Cataract</p> <p>Interventions: Procedure: one percent ultrasound power in MSSICS; Procedure: 40 percent ultrasound power in CMICS</p>
59	Unknown †	<p><u>Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof</u></p> <p>Condition: Cataract</p> <p>Interventions: Device: AMO Tecnis Z9000; Device: Alcon SA60AT Acrysof</p>

49. Low Tension Glaucoma

Rank	Status	Study
1	Completed Has Results no results published yet	<u>Systemic Glutathione Level in Normal Tension Glaucoma</u> Condition: Normal Tension Glaucoma Intervention:
2	Recruiting	<u>Analysis of Clinical Profiles of Chinese Patients With Normal Tension Glaucoma</u> Condition: Glaucoma Intervention:
3	Recruiting	<u>Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma</u> Condition: Normal Tension Glaucoma Interventions: Drug: Brimonidine/Timolol mix g: Timolol
4	Unknown †	<u>Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient</u> Condition: Glaucoma Intervention:
5	Unknown †	<u>Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma</u> Condition: Normal Tension Glaucoma Interventions: Drug: dorzolamide/timolol fixe atanoprost

50. Macular Degeneration

Rank	Status	Study
1	Completed Has Results published in journal	<u>Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy</u> Condition: Polypoidal Choroidal Vasculopathy Interventions: Drug: Verteporfin Photodynamic Therapy; Drug: Ranibizumab
2	Completed Has Results published on website	<u>Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Interventions: Drug: Ranibizumab; Procedure: Laser photocoagulation; Drug: Sham ranibizumab; Procedure: Sham laser photocoagulation
3	Completed Has Results published on website	<u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</u> Condition: Macular Degeneration Interventions: Drug: Ranibizumab; Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
4	Completed Has Results published on website	<u>Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)</u> Conditions: Choroidal Neovascularization; Age-Related Maculopathy Interventions: Drug: dexamethasone; Biological: ranibizumab; Other: sham
5	Completed Has Results published on website	<u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u> Condition: Retinal Vein Occlusion Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Other: Sham treatment
6	Completed Has Results published on	<u>Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration</u> Condition: Macular Degeneration

	website	Intervention: Drug: pegaptanib sodium
7	Terminated Has Results published on website	<u>A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration</u> Conditions: Choroid Neovascularization; Age-Related Macular Degeneration Interventions: Drug: AGN 211745; Drug: Ranibizumab 500µg
8	Completed Has Results published in journal	<u>Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</u> Condition: Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) Intervention: Drug: Ranibizumab
9	Completed Has Results published on website	<u>Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)</u> Conditions: Choroidal Neovascularization; Age-Related Maculopathy Interventions: Drug: dexamethasone; Biological: ranibizumab
10	Completed Has Results published in journal	<u>Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration</u> Condition: Age-related Macular Degeneration Intervention: Drug: ranibizumab
11	Completed Has Results published on website	<u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion</u> Conditions: Macular Edema; Retinal Vein Occlusion Interventions: Drug: Dexamethasone; Drug: Sham injection
12	Completed Has Results published on website	<u>A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.</u> Condition: Macular Edema Associated With Diabetes Mellitus

		Interventions: Drug: Standard of Care; Drug: Macugen
13	Terminated Has Results published on website	<u>Macugen Observational Study</u> Conditions: Vascular Endothelial Growth Factor; Macular Degeneration Intervention: Other: No intervention
14	Completed no results published yet	<u>Bevacizumab for Neovascular Age-related Macular Degeneration</u> Condition: Exudative Age-related Macular Degeneration Interventions: Drug: Bevacizumab 1; Drug: Bevacizumab
15	Completed no results published yet	<u>Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients</u> Condition: Age Related Macular Degeneration Intervention: Drug: ranibizumab 0.5 mg
16	Completed no results published yet	<u>A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD</u> Condition: Neovascular Age-related Macular Degeneration Intervention: Biological: Intravitreal injection of KH902
17	Completed no results published yet	<u>A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population</u> Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen Intervention: Other: Follow-up observation
18	Completed no results published yet	<u>Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Interventions: Drug: 0.59 mg fluocinolone acetonide intravitreal implant; Drug: 2.1 mg fluocinolone acetonide intravitreal implant; Procedure: standard of care laser photocoagulation
19	Completed no results published	<u>Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).</u>

	yet	<p>Condition: Age Related Macular Degeneration</p> <p>Interventions: Drug: 0.5 mg ranibizumab; Drug: 3 mg PF-04523655; Drug: 1 mg PF-04523655</p>
20	Completed no results published yet	<p><u>EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</u></p> <p>Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab</p>
21	Completed no results published yet	<p><u>Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration</u></p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab</p>
22	Completed no results published yet	<p><u>Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)</u></p> <p>Condition: Macular Degeneration</p> <p>Interventions: Drug: Brimonidine Tartrate Implant; Drug: Sham</p>
23	Completed no results published yet	<p><u>LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy</u></p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention:</p>
24	Completed no results published yet	<p><u>Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy</u></p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention:</p>
25	Completed no results published yet	<p><u>LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population</u></p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention: Genetic: LOC387715/HTRA1 genotyping</p>
26	Completed no results published	<p><u>Major and Macular Branched Retinal Venous Occlusion</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Procedure: intravitreal bevacizumab</p>

	yet	
27	Completed no results published yet	<u>Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy</u> Condition: Diabetic Macular Edema Intervention: Procedure: Pars Plana Vitrectomy
28	Completed no results published yet	<u>Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Interventions: Procedure: vitrectomy; Drug: intravitreal triamcinolone acetonide; Procedure: macular focal laser photocoagulation
29	Completed no results published yet	<u>Reduction in the Occurrence of Center-Involved Diabetic Macular Edema</u> Condition: Diabetic Retinopathy Interventions: Drug: ruboxistaurin; Drug: placebo
30	Completed no results published yet	<u>Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)</u> Condition: Macular Degeneration Intervention: Drug: pegaptanib sodium
31	Completed no results published yet	<u>Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration</u> Condition: Age-Related Macular Degeneration Intervention: Drug: Bevacizumab
32	Completed no results published yet	<u>PDT Study for Exudative AMD With PCV</u> Condition: Age Related Macular Degeneration Intervention: Procedure: Ocular photodynamic therapy with verteporfin
33	Completed no results published yet	<u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion</u> Conditions: Macular Degeneration; Macular Edema; Branch Retinal Vein Occlusion Intervention: Drug: dexamethasone
34	Completed no results published yet	<u>Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy</u> Conditions: Neovascular Maculopathy; Age Related Macular Degeneration

		Intervention: Biological: VEGFR1 and VEGFR2
35	Completed no results published yet	<u>A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema</u> Conditions: Macular Edema; Diabetic Mellitus; Retinal Disease Interventions: Drug: pegaptanib sodium; Other: sham injection
36	Completed no results published yet	<u>A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Intervention: Drug: dexamethasone
37	Completed no results published yet	<u>The Effect of a Blue Light Filtering IOL</u> Conditions: to Compare the Effect of Two Types of IOLs; on the Incidence of Cystoid Macular Edema; After Cataract Surgery Intervention: Procedure: intraocular lens implantation
38	Completed no results published yet	<u>Vitrectomy for Branch Retinal Vein Occlusion</u> Condition: Vitrectomy Intervention: Procedure: Vitrectomy w/o ILM peeling for macular edema with BRVO
39	Completed no results published yet	<u>A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration</u> Condition: Macular Degeneration Intervention: Drug: rhuFab V2 (ranibizumab)
40	Completed no results published yet	<u>Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)</u> Condition: Wet Age-Related Macular Degeneration Interventions: Drug: PTK787; Drug: Placebo
41	Completed no results published yet	<u>An Extension to Study MD7108240</u> Condition: Macular Degeneration Intervention: Drug: Pazopanib

42	Completed no results published yet	<p><u>Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</u></p> <p>Conditions: Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration (AMD)</p> <p>Intervention: Drug: ranibizumab</p>
43	Completed no results published yet	<p><u>To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD</u></p> <p>Condition: Macular Degeneration</p> <p>Intervention: Drug: Pazopanib</p>
44	Completed no results published yet	<p><u>Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration</u></p> <p>Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment</p> <p>Intervention: Drug: Ranibizumab</p>
45	Completed no results published yet	<p><u>Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: 2304 Eye Drops High Dose; Drug: 2304 Eye Drops Low Dose; Drug: Placebo Eye Drops</p>
46	Completed no results published yet	<p><u>Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)</u></p> <p>Condition: Diabetic Macular Oedema</p> <p>Intervention: Drug: Triamcinolone acetate</p>
47	Completed no results published yet	<p><u>Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Macular Edema; Vitrectomy</p> <p>Intervention: Drug: Dexamethasone</p>
48	Completed	<p><u>Open Label Extension of a Clinical Trial of Intravitreal</u></p>

	no results published yet	<p><u>Triamcinolone for Diabetic Macular Oedema-TDMX Study</u></p> <p>Condition: Diabetic Macular Oedema</p> <p>Intervention: Drug: Triamcinolone acetate</p>
49	Completed no results published yet	<p><u>A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema</u></p> <p>Condition: Diabetic Macular Oedema</p> <p>Intervention: Drug: Triamcinolone acetate</p>
50	Completed no results published yet	<p><u>Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Procedure: Intravitreal injection</p>
51	Completed no results published yet	<p><u>Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Branch Retinal Vein Occlusion</p> <p>Interventions: Procedure: Arteriovenous Crossing Sheathotomy; Procedure: Intravitreal Triamcinolone Acetonide Injection</p>
52	Completed no results published yet	<p><u>Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)</u></p> <p>Conditions: Diabetic Retinopathy; Macular Edema</p> <p>Intervention: Procedure: Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation</p>
53	Completed no results published yet	<p><u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u></p> <p>Condition: Macular Edema Secondary to Central Retinal Vein Occlusion</p> <p>Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham</p>
64	Completed no results published yet	<p><u>Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Macular Edema; Macular Edema, Cystoid; Vision Disorders; Clinically Significant M</p>

		<p>acular Edema</p> <p>Intervention: Drug: long acting intravitreal dexamethasone implant</p>
65	Completed no results published yet	<p><u>CME With Different Fluidic Parameters</u></p> <p>Condition: Cystoid Macular Edema Following Cataract Surgery</p> <p>Intervention: Procedure: microcoaxial phacoemulsification</p>
66	Completed no results published yet	<p><u>Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Macular Edema; Vision Disorders</p> <p>Intervention: Drug: Dexamethasone Drug delivery system (Ozurdex)</p>
67	Terminated	<p><u>A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration</u></p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention: Drug: AG-013,958</p>
68	Terminated	<p><u>Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Retinopathy; Diabetes Complications</p> <p>Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low</p>
69	Enrolling by invitation	<p><u>Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
70	Withdrawn	<p><u>Combination Therapy for Neovascular Age Related Macular Degeneration</u></p> <p>Condition: Macular Degeneration</p> <p>Intervention: Drug: intravitreal bevacizumab and tria</p>
71	Active, not recruiting	<p><u>Study to Assess the Effectiveness of Existing Anti vascular Endothelial Growth Factor (Anti VEGF) in Patients With Wet</u></p>

		<p><u>Age-related Macular Degeneration (wAMD) (AURA)</u></p> <p>Condition: Ophthalmology, Macular Degeneration</p> <p>Intervention: Drug: Ranibizumab</p>
72	Active, not recruiting	<p><u>A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: Dexamethasone; Drug: Sham</p>
73	Active, not recruiting	<p><u>Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration</u></p> <p>Condition: Macular Degeneration</p> <p>Interventions: Drug: pazopanib eye drops; Drug: placebo; Biological: ranibizumab intravitreal injection</p>
74	Active, not recruiting	<p><u>Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Biological: VEGF Trap-Eye (BAY86-5321)</p>
75	Active, not recruiting	<p><u>VEGF Trap-Eye in Vision Impairment Due to DME</u></p> <p>Conditions: Diabetes Mellitus; Macular Edema</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment</p>
76	Active, not recruiting	<p><u>Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion</u></p> <p>Condition: Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
77	Active, not recruiting	<p><u>A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD</u></p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: intravitreal injection of KH902</p>
78	Active, not recruiting	<p><u>Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)</u></p> <p>Condition: Diabetic Macular Edema</p>

		Intervention: Biological: KH902
79	Active, not recruiting	<p><u>An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients</u></p> <p>Conditions: Diabetic Macular Edema; Visual Impairment</p> <p>Intervention: Drug: ranibizumab</p>
80	Active, not recruiting	<p><u>Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema</u></p> <p>Conditions: Diabetic Retinopathy; Macular E dema</p> <p>Interventions: Drug: bevacizumab; Drug: dexa methasone</p>
81	Active, not recruiting	<p><u>Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</u></p> <p>Conditions: Macular Edema; Retinal Vein Oc clusion</p> <p>Interventions: Drug: AGN208397 intravitreal injec tion; Drug: dexamethasone intra vitreal implant</p>
82	Recruiting	<p><u>Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration</u></p> <p>Conditions: Macular Degeneration; Age-re lated Maculopathies; Age-relat ed Maculopathy; Maculopathi es, Age-related; Maculopathy, Age-related; Retinal Degenera tion; Retinal Neovascularizatio n; Eye Diseases</p> <p>Interventions: Biological: rAAV.sFlt-1; Other: Control (ranibizumab alone)</p>
83	Recruiting	<p><u>Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)</u></p> <p>Condition: Macular Edema Following Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose; Drug:</p>

		Betamethasone Microsphere (DE-102) High Dose; Drug: Sham
84	Recruiting	<u>Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration</u> Condition: Age-related Macular Degeneration Interventions: Dietary Supplement: placebo; Diets s lutein
85	Recruiting	<u>Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)</u> Condition: Diabetic Macular Edema Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham
86	Recruiting	<u>A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)</u> Condition: Dry Age Related Macular Degeneration Intervention: Biological: MA09-hRPE
87	Recruiting	<u>Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion</u> Condition: Neovascular Age-related Macular Degeneration Intervention: Procedure: Intravitreal expansile gas and ranibizumab injection
88	Recruiting	<u>Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)</u> Condition: Stargardt's Macular Dystrophy Intervention: Biological: MA09-hRPE
89	Recruiting	<u>Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy</u> Condition: Macular Edema Intervention: Procedure: Intravitreal injection

90	Recruiting	<p><u>Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)</u></p> <p>Condition: Macular Edema</p> <p>Interventions: Drug: 700 µg Dexamethasone; Other: Sham</p>
91	Recruiting	<p><u>A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD</u></p> <p>Condition: Neovascular Age-related Macular D egeneration</p> <p>Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein</p>
92	Recruiting	<p><u>VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)</u></p> <p>Condition: Macular Degeneration</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Drug: Visudyne</p>
93	Recruiting	<p><u>Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter</u></p> <p>Condition: Age Related Macular Degeneration</p> <p>Interventions: Drug: Intravitreal Ranibizumab; Dr ug: Intravitreal bevacizumab</p>
94	Recruiting	<p><u>Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration</u></p> <p>Condition: Age-related Macular Degeneration</p> <p>Interventions: Dietary Supplement: lutein; Dietar y Supplement: Lutein; Dietary Sup plement: placebo; Drug: Lutein an d zeaxanthin</p>
95	Recruiting	<p><u>Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema</u></p> <p>Conditions: Macular Edema, Cystoid; Visio n Disorders; Diabetic Macular Edema; Cystoid Macular Edem a Following Cataract Surgery; Cataract</p> <p>Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Catarac t surgery</p>

96	Recruiting	<p><u>Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)</u></p> <p>Condition: Age-related Macular Degeneration</p> <p>Interventions: Drug: AGN-150998; Drug: ranibizumab</p>
97	Recruiting	<p><u>Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting</u></p> <p>Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Other: Ranibizumab</p>
98	Recruiting	<p><u>A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema</u></p> <p>Condition: Retinopathy, Diabetic</p> <p>Interventions: Drug: darapladib; Drug: placebo</p>
99	Recruiting	<p><u>Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure : Laser</p>
100	Recruiting	<p><u>Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Central Retinal Vein Occlusion</p> <p>Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection</p>
101	Unknown †	<p><u>To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation</u></p> <p>Conditions: Macular Edema; Diabetic Retinopathy; Visual Field Loss</p> <p>Interventions: Procedure: PASCAL laser; Procedure: Conventional laser</p>
102	Unknown †	<p><u>Intravitreal Bevacizumab for Retinal Disorders</u></p> <p>Conditions: Wet AMD; Macular Oedema;</p>

		<p>Proliferative Diabetic Retinopathy</p> <p>Intervention: Drug: Bevacizumab (Avastin)</p>
103	Unknown †	<p><u>Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Device: Micropulse 577 nm yellow diode</p>
104	Unknown †	<p><u>Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: macular laser photocoagulation</p>

51. Macular Edema

Rank	Status	Study
1	Completed Has Results published on website	<p><u>Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: Ranibizumab; Procedure: Laser photocoagulation; Drug: Sham ranibizumab; Procedure: Sham laser photocoagulation</p>
2	Completed Has Results published on website	<p><u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u></p> <p>Condition: Retinal Vein Occlusion</p> <p>Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Other: Sham treatment</p>
3	Completed Has Results published on website	<p><u>A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.</u></p> <p>Condition: Macular Edema Associated With Diabetes Mellitus</p> <p>Interventions: Drug: Standard of Care; Drug: Macugen</p>
4	Completed Has Results published on website	<p><u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Interventions: Drug: Dexamethasone; Drug: Sham injection</p>
5	Completed no results published yet	<p><u>Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: 0.59 mg fluocinolone acetonide intravitreal implant; Drug: 2.1 mg fluocinolone acetonide intravitreal implant; Procedure: standard of care laser photocoagulation</p>
6	Completed no results	<p><u>Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)</u></p>

	published yet	<p>Conditions: Diabetic Retinopathy; Macular Edema</p> <p>Intervention: Procedure: Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation</p>
7	Completed no results published yet	<p><u>Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Procedure: Intravitreal injection</p>
8	Completed no results published yet	<p><u>Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Procedure: vitrectomy; Drug: intravitreal triamcinolone acetate; Procedure: macular focal laser photocoagulation</p>
9	Completed no results published yet	<p><u>Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Procedure: Pars Plana Vitrectomy</p>
10	Completed no results published yet	<p><u>Major and Macular Branched Retinal Venous Occlusion</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Procedure: intravitreal bevacizumab</p>
11	Completed no results published yet	<p><u>Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Branch Retinal Vein Occlusion</p> <p>Interventions: Procedure: Arteriovenous Crossing Sheathotomy; Procedure: Intravitreal Triamcinolone Acetate Injection</p>
12	Completed no results published yet	<p><u>Reduction in the Occurrence of Center-Involved Diabetic Macular Edema</u></p> <p>Condition: Diabetic Retinopathy</p> <p>Interventions: Drug: ranibizumab; Drug: placebo</p>
13	Completed no results published yet	<p><u>A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema</u></p>

		<p>Conditions: Macular Edema; Diabetic Mellitus; Retinal Disease</p> <p>Interventions: Drug: pegaptanib sodium; Other: sham injection</p>
14	Completed no results published yet	<p><u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion</u></p> <p>Conditions: Macular Degeneration; Macular Edema; Branch Retinal Vein Occlusion</p> <p>Intervention: Drug: dexamethasone</p>
15	Completed no results published yet	<p><u>A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Drug: dexamethasone</p>
16	Completed no results published yet	<p><u>The Effect of a Blue Light Filtering IOL</u></p> <p>Conditions: to Compare the Effect of Two Types of IOLs; on the Incidence of Cystoid Macular Edema; After Cataract Surgery</p> <p>Intervention: Procedure: intraocular lens implantation</p>
17	Completed no results published yet	<p><u>Vitrectomy for Branch Retinal Vein Occlusion</u></p> <p>Condition: Vitrectomy</p> <p>Intervention: Procedure: Vitrectomy w/o ILM peeling for macular edema with BRVO</p>
18	Completed no results published yet	<p><u>Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: 2304 Eye Drops High Dose; Drug: 2304 Eye Drops Low Dose; Drug: Placebo Eye Drops</p>
19	Completed no results published yet	<p><u>A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema</u></p> <p>Condition: Diabetic Macular Oedema</p> <p>Intervention: Drug: Triamcinolone acetate</p>
20	Completed no results published yet	<p><u>Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)</u></p> <p>Condition: Diabetic Macular Oedema</p> <p>Intervention: Drug: Triamcinolone acetate</p>

21	Completed no results published yet	<u>Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study</u> Condition: Diabetic Macular Oedema Intervention: Drug: Triamcinolone acetate
22	Completed no results published yet	<u>Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Vitrectomy Intervention: Drug: Dexamethasone
23	Completed no results published yet	<u>Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Macular Edema, Cystoid; Vision Disorders; Clinically Significant Macular Edema Intervention: Drug: long acting intravitreal dexamethasone implant
24	Completed no results published yet	<u>Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Vision Disorders Intervention: Drug: Dexamethasone Drug delivery system (Ozurdex)
25	Completed no results published yet	<u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u> Condition: Macular Edema Secondary to Central Retinal Vein Occlusion Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham
26	Completed no results published yet	<u>CME With Different Fluidic Parameters</u> Condition: Cystoid Macular Edema Following Cataract Surgery Intervention: Procedure: microcoaxial phacoemulsification
27	Completed no results published yet	<u>Diabetic Retinopathy and Diabetic Macular Edema Screening by Non-Physicians With Limited Training</u> Condition: Diabetic Retinopathy Interventions: Device: Digital retina image; Device: direct ophthalmoscopy; Procedure: comprehensive eye exam

28	Terminated	<p><u>Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Retinopathy; Diabetes Complications</p> <p>Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low</p>
29	Enrolling by invitation	<p><u>Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
30	Active, not recruiting	<p><u>A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: Dexamethasone; Drug: Sham</p>
31	Active, not recruiting	<p><u>Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion</u></p> <p>Condition: Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
32	Active, not recruiting	<p><u>VEGF Trap-Eye in Vision Impairment Due to DME</u></p> <p>Conditions: Diabetes Mellitus; Macular Edema</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment</p>
33	Active, not recruiting	<p><u>Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Interventions: Drug: AGN208397 intravitreal injection; Drug: dexamethasone intravitreal implant</p>
34	Active, not recruiting	<p><u>Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema</u></p> <p>Conditions: Diabetic Retinopathy; Macular Edema</p> <p>Interventions: Drug: bevacizumab; Drug: dexamethasone</p>
35	Active, not recruiting	<p><u>An Open-label Extension Study to Evaluate the Safety of Ranibizumab</u></p>

	recruiting	<p><u>as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients</u></p> <p>Conditions: Diabetic Macular Edema; Visual Impairment</p> <p>Intervention: Drug: ranibizumab</p>
36	Active, not recruiting	<p><u>Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Biological: KH902</p>
37	Active, not recruiting	<p><u>Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Biological: VEGF Trap-Eye (BAY86-5321)</p>
38	Recruiting	<p><u>Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting</u></p> <p>Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Other: Ranibizumab</p>
39	Recruiting	<p><u>Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: Laser</p>
40	Recruiting	<p><u>Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema</u></p> <p>Conditions: Macular Edema, Cystoid; Vision Disorders; Diabetic Macular Edema; Cystoid Macular Edema Following Cataract Surgery; Cataract</p> <p>Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surgery</p>
41	Recruiting	<p><u>Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: Betamethasone Microsphere (DE</p>

		-102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham
42	Recruiting	<u>Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)</u> Condition: Macular Edema Following Branch Retinal Vein Occlusion Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham
43	Recruiting	<u>A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema</u> Condition: Retinopathy, Diabetic Interventions: Drug: darapladib; Drug: placebo
44	Recruiting	<u>Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion</u> Conditions: Macular Edema; Central Retinal Vein Occlusion Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection
45	Recruiting	<u>Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion</u> Condition: Branch Retinal Vein Occlusion Interventions: Procedure: intravitreal bevacizumab monotherapy; Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection
46	Recruiting	<u>Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy</u> Condition: Diabetes Complications Intervention: Drug: Avastin (bevacizumab)
47	Recruiting	<u>Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy</u> Condition: Macular Edema Intervention: Procedure: Intravitreal injection

48	Recruiting	<p><u>Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)</u></p> <p>Condition: Macular Edema</p> <p>Interventions: Drug: 700 µg Dexamethasone; Other: Sham</p>
49	Unknown †	<p><u>To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation</u></p> <p>Conditions: Macular Edema; Diabetic Retinopathy; Visual Field Loss</p> <p>Interventions: Procedure: PASCAL laser; Procedure: Conventional laser</p>
50	Unknown †	<p><u>Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: macular laser photocoagulation</p>
51	Unknown †	<p><u>Intravitreal Bevacizumab for Retinal Disorders</u></p> <p>Conditions: Wet AMD; Macular Oedema; Proliferative Diabetic Retinopathy</p> <p>Intervention: Drug: Bevacizumab (Avastin)</p>
52	Unknown †	<p><u>Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Device: Micropulse 577 nm yellow diode laser; Device: 532 nm green diode laser</p>

52. Mydriasis

Rank	Status	Study
1	Completed no results published yet	<u>Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery</u> Condition: Cataract Intervention: Drug: adrenalin
2	Completed no results published yet	<u>Comparison of Instillation and Packing in Mydriasis for Premature Infants</u> Condition: Preterm Infants Intervention: Drug: 1% tropicamide and 2.5% phenylephrine
3	Completed no results published yet	<u>2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides</u> Condition: Diabetes Mellitus Intervention: Drug: 2.5% or 10% phenylephrine
4	Completed no results published yet	<u>Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation</u> Condition: Eye Diseases Intervention: Drug: 1% tropicamide and 10% phenylephrine

53. Myopia

Rank	Status	Study
1	Completed Has Results published on website	<u>Comparative Performance of PureVision Lens Designs</u> Condition: Myopia Interventions: Device: Currently Marketed PureVision Contact Lens.; Device: Alternate Design of the PureVision Contact Lens.
2	Completed Has Results published on website	<u>Product Performance of a Toric Contact Lens</u> Conditions: Myopia; Astigmatism Interventions: Device: SofLens DD Toric; Device: Ciba Vision Focus Dailies Toric Contact Lens
3	Completed Has Results published on website	<u>Two Week Cross-Over Study Comparing Two Daily Disposable Contact Lenses</u> Condition: Myopia Interventions: Device: etafilcon A; Device: omafilcon A
4	Completed no results published yet	<u>Contact Lens in Pediatrics (CLIP) in an Asian Population Study</u> Condition: Myopia Intervention: Device: Johnson&Johnson Acuevue daily disposable lenses
5	Completed no results published yet	<u>Comparative Study of Cycloplegic Refraction and Subjective Refraction With Fogging in School Age Children</u> Conditions: Myopia; Refractive Error Intervention:
6	Completed no results published yet	<u>Myopia Control With Simultaneous Vision Approach</u> Condition: Myopia Intervention: Device: Defocus Incorporated Soft Contact (DISC) lens
7	Completed no results published yet	<u>Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles</u> Conditions: Myopia; Hyperopia; Astigmatism Interventions: Device: Ready-made spectacles; Device: Spectacles
8	Completed no results published yet	<u>A Comprehensive Assessment of Anterior Corneal Power by Different Devices</u> Condition: Myopia Intervention: Device: Corneal power measurement

9	Completed no results published yet	<u>Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</u> Condition: Pathological Myopia Interventions: Drug: 0.5 mg ranibizumab driven by disease activity; Drug: 0.5 mg ranibizumab driven by stabilization criteria; Drug: verteporfin PDT
10	Completed no results published yet	<u>The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test</u> Condition: Myopia Intervention:
11	Completed no results published yet	<u>Myopia Control by Combining Auricular Acupoint and Atropine Eyedrops</u> Condition: Myopia Interventions: Drug: 0.25 % atropine; Drug: 0.5 % atropine; Procedure: 0.25 % atropine+auricular acupoints
12	Completed no results published yet	<u>Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes</u> Conditions: Maculopathy; High Myopia; Surgery Intervention: Procedure: vitrectomy
13	Completed no results published yet	<u>Changes in Invitro and ex Vivo Lens Metrology With Daily Wear Contact Lenses</u> Condition: Myopia Interventions: Device: Air Optix Aqua; Device: Biofinity; Device: Proclear; Device: Acuvue Oasys; Device: Acuvue 2; Device: Purevision
14	Completed no results published yet	<u>Time Course Comparison of Contact Lens Maintenance Systems for Hydrogel Lenses</u> Conditions: Myopia; Hyperopia Interventions: Device: Silicone Hydrogel Contact Lenses; Device: 1x PMBH preserved MPS; Device: 1x Polyquad/Aldox MPS
15	Completed no results	<u>Comparative Study of Three IOL Power Calculation Formulae for Asian Eyes Shorter Than 22mm or Longer Than 25mm</u>

	published yet	<p>Condition: Cataract</p> <p>Intervention: Procedure: IOL calculation formula</p>
16	Completed no results published yet	<p><u>Myopic Macular Haemorrhages</u></p> <p>Condition: Myopic Macular Haemorrhages</p> <p>Intervention:</p>
17	Completed no results published yet	<p><u>Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: galyfilcon A; Device: galyfilcon A plus; Device: lotrafilcon A; Device: polymacon; Other: spectacles</p>
18	Completed no results published yet	<p><u>Comparison of Contact Lens Maintenance Systems for Silicone Hydrogel Lenses</u></p> <p>Conditions: Myopia; Hyperopia</p> <p>Intervention: Device: Silicone hydrogel contact lens</p>
19	Completed no results published yet	<p><u>Clinical Performance of Extended Wear Silicone Hydrogel Lenses</u></p> <p>Condition: Myopia</p> <p>Intervention: Device: Silicone hydrogel contact lens</p>
20	Completed no results published yet	<p><u>The Effect of Silicone Hydrogel Contact Lenses on Conjunctival Flora</u></p> <p>Condition: Myopia</p> <p>Intervention: Device: Silicone hydrogel contact lens</p>
21	Completed no results published yet	<p><u>Clinical Evaluation of Ocular Responses With Contact Lens Wear</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: narafilcon B; Device: Polymacon; Device: Lotrafilcon A; Other: Spectacles</p>
22	Completed no results published yet	<p><u>Investigation of the Clinical Performance of Silicone Hydrogel Contact Lenses During Continuous Wear</u></p> <p>Condition: Myopia</p> <p>Intervention: Device: Silicone hydrogel contact lens</p>
23	Completed no results published yet	<p><u>A Study to Assess the Safety, Tolerability and Effect of Nexagon™ Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness</u></p> <p>Condition: Corneal re-Epithelialization</p>

		Intervention: Drug: Nexagon™ or Nexagon™ vehicle
24	Completed no results published yet	<u>Clinical Trial of Several Contact Lenses in Extended Wear</u> Condition: Myopia Interventions: Device: senofilcon A; Device: lotrafilcon A; Device: lotrafilcon B; Device: balafilcon A; Device: comfilcon A; Device: etafilcon A
25	Completed no results published yet	<u>Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction</u> Condition: Cataract Interventions: Device: Crystalens AO; Device: ReST
26	Completed no results published yet	<u>Pilot Study of Neurovision to Improve Vision and Slow Myopia Progression in Children With Myopia</u> Condition: Myopia Intervention: Device: NeuroVision
27	Completed no results published yet	<u>A Singapore Pilot Study to Assess Neurovision in Treatment of Low Myopia</u> Condition: Myopia Intervention: Device: Neurovision
28	Completed no results published yet	<u>A Singapore Study to Assess How Neurovision Improve the Vision of Adults With Low to Moderate Myopia</u> Condition: Myopia Intervention: Device: Neurovision
29	Completed no results published yet	<u>Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia</u> Condition: Myopia Interventions: Procedure: Laser in Situ Keratomileusis (LASIK); Procedure: Photorefractive Keratectomy (PRK)
30	Completed no results published yet	<u>Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.</u> Conditions: Myopia; Maculopathy; Glaucoma Intervention:
31	Completed no results published yet	<u>Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children</u> Condition: Myopia Intervention: Device: Hyperopic lens
32	Terminated	<u>Silicone Hydrogel Contact Lenses on Low Astigmatism in Japan</u>

		<p>Conditions: Refractive Error; Myopia; Astigmatism</p> <p>Interventions: Device: senofilcon A toric soft contact lens; Device: senofilcon A sphere soft contact lens</p>
33	Active, not recruiting	<p><u>Trial of a Novel Family-Based Intervention to Increase Outdoor Time and Fitness</u></p> <p>Conditions: Myopia; Obesity</p> <p>Intervention: Behavioral: Family-based Outdoor program</p>
34	Active, not recruiting	<p><u>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)</u></p> <p>Condition: Myopia, Pathological</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: No Drug</p>
35	Enrolling by invitation	<p><u>Guangzhou Outdoor Activity Longitudinal Study</u></p> <p>Condition: Myopia</p> <p>Intervention: Behavioral: Outdoor activity</p>
36	Enrolling by invitation	<p><u>The Children's WEAR Trial(Phase 1&2)</u></p> <p>Condition: Myopia</p> <p>Interventions: Procedure: group1; Procedure: group2; Procedure: group3; Procedure: group4</p>
37	Active, not recruiting	<p><u>Toric Orthokeratology - Slowing Eye Elongation</u></p> <p>Conditions: Myopia; Astigmatism</p> <p>Interventions: Device: Toric Orthokeratology lenses; Device: Single-vision spectacles</p>
38	Active, not recruiting	<p><u>Peripheral Optics in Myopia and Orthokeratology</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Orthokeratology lenses; Device:</p>
39	Recruiting	<p><u>Clinical and Genetic Studies in Families With Myopia and Related Diseases</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
40	Recruiting	<p><u>Randomized, Non-inferiority Trial Comparing SMILE and LASIK</u></p> <p>Conditions: Myopia; Astigmatism; Hypermetropia</p> <p>Interventions: Procedure: Femtosecond LASIK; Procedure:</p>

		cedure: Small incision lenticule extraction (SMILE)
41	Recruiting	<p><u>Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes</u></p> <p>Conditions: Myopia; Hyperopia; Presbyopia</p> <p>Intervention: Device: Supracor</p>
42	Recruiting	<p><u>Evaluate Capsular Apposition to Intraocular Lens</u></p> <p>Conditions: Capsule Opacification; Tissue Adhesions; Aphakia - Lens Capsule Present; Opacification of Intraocular Lens</p> <p>Intervention:</p>
43	Recruiting	<p><u>Discontinuation of Orthokeratology on Eyeball Elongation in Myopic Children</u></p> <p>Condition: Myopia</p> <p>Intervention: Procedure: Switching of orthokeratology and single-vision glasses</p>
44	Recruiting	<p><u>Discontinuation of Lens Wear in New Ortho-k Children (DOEE2)</u></p> <p>Condition: Myopia</p> <p>Intervention: Procedure: Switching of single-vision spectacles to orthokeratology</p>
45	Recruiting	<p><u>Early Vitrectomy for Macular Tractional Maculopathy</u></p> <p>Condition: Myopia, Degenerative</p> <p>Intervention: Procedure: Early vitrectomy</p>
46	Unknown †	<p><u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
47	Unknown †	<p><u>Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children</u></p> <p>Condition: Myopia</p> <p>Intervention: Drug: Atropine Eye drops</p>
48	Unknown †	<p><u>Comparison of Intralase and Visumax Femtosecond Laser for Laser In Situ Keratomileusis</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>

49	Unknown †	<p><u>The Role of SNP of ECM and MMP on the Development of Pathological High Myopia</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
50	Unknown †	<p><u>Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment</u></p> <p>Conditions: Myopia; Anisometropia</p> <p>Intervention:</p>
51	Unknown †	<p><u>Aberration-Free Refraction Correction</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
52	Unknown †	<p><u>Compare Anterior Chamber Biometry in Healthy and Post-LASIK Patients</u></p> <p>Conditions: Myopia; Astigmatism</p> <p>Intervention:</p>
53	Unknown †	<p><u>Ocular Imaging With Spectral Domain Optical Coherence Tomography</u></p> <p>Conditions: Healthy; Myopia; Hypermetropia</p> <p>Intervention: Device: Spectral domain-OCT (Cirrus™ Carl Zeiss Meditec AG)</p>
54	Unknown †	<p><u>Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
55	Unknown †	<p><u>Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
56	Unknown †	<p><u>Genomewide Screening of Pathological Myopia</u></p> <p>Condition: Pathological Myopia</p> <p>Intervention:</p>
57	Unknown †	<p><u>Study of Myopia Prevention in Children With Low Concentration of Atropine</u></p> <p>Condition: Myopia</p> <p>Interventions: Drug: atropine; Drug: tropicamide</p>
58	Unknown †	<p><u>Randomized, Prospective Comparison of the Outcome of Toric</u></p>

		<p><u>Implantable Contact Lens (TICL) and Q-LASIK for the Correction of Myopia With Astigmatism</u></p> <p>Conditions: Myopia; Astigmatism</p> <p>Interventions: Procedure: the implantation of toric implantable collamer lens; Procedure: customized laser-assisted in situ keratomileusis</p>
59	Unknown †	<p><u>Retardation of Myopia in Orthokeratology</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Orthokeratology lenses, Menicon Z Night Lens; Device: spherical plastic lenses</p>
60	Unknown †	<p><u>Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs.</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Currently marketed PureVision soft contact lens.; Device: Alternate design of PureVision soft contact lens.</p>
61	Unknown †	<p><u>Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia</u></p> <p>Condition: Myopic Choroidal Neovascular Membrane</p> <p>Intervention: Drug: Intravitreal Pegaptanib</p>
62	Unknown †	<p><u>Myopic Control for High Myopes Using Orthokeratology</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Orthokeratology lenses, DreamLite lenses; Device: Single-vision spectacle lenses</p>

54. Neuromyelitis Optica

Rank	Status	Study
1	Recruiting	<p><u>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica</u></p> <p>Conditions: Progressive Multiple Sclerosis; Neuromyelitis Optica.</p> <p>Intervention: Biological: human umbilical cord mesenchymal stem cells</p>

55. Night Blindness

Rank	Status	Study
1	Completed Has Results published in journals	<u>Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh</u> Conditions: Vitamin A Deficiency; Maternal Mortality; Infant Mortality Intervention: Dietary Supplement: Vitamin A or Beta-Carotene Supplements
2	Completed no results published yet	<u>Dietary Vitamin A Requirement in Chinese Children and the New Technology of Dietary Assessment</u> Condition: Vitamin A Deficiency Intervention:
3	Completed no results published yet	<u>Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status</u> Condition: Vitamin A Deficiency Interventions: Other: 0 mg retinol activity equivalents; Other: 12 mg of B C; Other: 6 mg of CX; Other: 1.0 mg RAE
4	Completed no results published yet	<u>A Study on Immunological Effect of Vitamin A and Zinc in a Placebo Controlled 4 Cell Trial</u> Conditions: Immunity; Diarrhea; Respiratory Tract Infections Intervention: Drug: Zinc, or Vitamin A or both
5	Completed no results published yet	<u>Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan</u> Condition: Vitamin A Deficiency Interventions: Dietary Supplement: Vitamin A; Dietary Supplement: Placebo
6	Completed no results published yet	<u>Efficacy of Vitamin A in Fortified Extruded Rice in School Children</u> Condition: Vitamin A Deficiency Intervention: Dietary Supplement: Triple fortified extruded rice (Fe, Zn and vitamin A)
7	Completed no results published	<u>An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand</u>

	yet	<p>Conditions: Vitamin A Deficiency; Iron Deficiency; Zinc Deficiency</p> <p>Intervention: Dietary Supplement: fortified extruded rice</p>
8	Terminated	<p><u>Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh</u></p> <p>Conditions: Infant Mortality; Vitamin A Deficiency</p> <p>Intervention: Drug: vitamin A supplementation (50,000 IU)</p>
9	Recruiting	<p><u>Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function</u></p> <p>Condition: Vitamin A Deficiency</p> <p>Interventions: Dietary Supplement: retinyl palmitate; Dietary Supplement: Placebo</p>

56. Nystagmus, Pathologic

Rank	Status	Study
1	<p>Completed Has Results published in journals</p>	<p><u>Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo</u></p> <p style="text-align: right;">Condition: HC-BPPV</p> <p style="text-align: right;">Interventions: Procedure: Gufoni maneuver; Procedure: Head-shaking maneuver; Procedure: sham maneuver</p>
2	<p>Completed no results published yet</p>	<p><u>Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo</u></p> <p style="text-align: right;">Condition: Benign Paroxysmal Positional Vertigo</p> <p style="text-align: right;">Interventions: Procedure: Gufoni; Procedure: Shaking; Procedure: Barbecue</p>

57. Ocular Hypertension

Rank	Status	Study
1	Completed Has Results published on website	<p><u>Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution; Drug: brimonidine tartrate ophthalmic solution; Drug: timolol ophthalmic solution; Other: fixed combination vehicle</p>
2	Completed Has Results published on website	<p><u>Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Open-angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution; Drug: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution</p>
3	Completed Has Results published on website	<p><u>Systemic Glutathione Level in Normal Tension Glaucoma</u></p> <p>Condition: Normal Tension Glaucoma</p> <p>Intervention:</p>
4	Completed Has Results published on website	<p><u>A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: Timolol; Drug: latanoprost</p>
5	Completed Has Results published on website	<p><u>A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).</u></p> <p>Conditions: Glaucoma, Primary Open Angle (POAG); Ocular Hypertension</p> <p>Interventions: Drug: Xalacom (KP2035); Drug : Xalatan</p>
6	Completed Has Results	<p><u>Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India</u></p>

	published in journals	<p>Conditions: Glaucoma; Cataract</p> <p>Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant</p>
7	Completed no results published yet	<p><u>Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients</u></p> <p>Condition: Single-nucleotide Polymorphism (SNP) for Glaucoma</p> <p>Intervention: Genetic: SNP analysis of the DNA</p>
8	Completed no results published yet	<p><u>Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension</u></p> <p>Conditions: Glaucoma, Open Angle; Ocular Hypertension</p> <p>Interventions: Drug: Xalacom; Drug: unfixed Latanoprost and Timolol</p>
9	Completed no results published yet	<p><u>DuoTrav® Eye Drops As Replacement Therapy Program</u></p> <p>Conditions: Open-angle Glaucoma; Ocular Hypertension</p> <p>Intervention: Drug: DuoTrav</p>
10	Completed no results published yet	<p><u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital</u></p> <p>Conditions: Glaucoma; Pterygium</p> <p>Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant</p>
11	Completed no results published yet	<p><u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital</u></p> <p>Conditions: Glaucomas; Pterygium</p> <p>Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant</p>
12	Completed no results published yet	<p><u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital</u></p> <p>Conditions: Glaucoma; Pterygium</p> <p>Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant</p>

13	Completed no results published yet	<u>Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension</u> Conditions: Glaucoma; Ocular Hypertension Intervention: Drug: bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution
14	Completed no results published yet	<u>A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension</u> Conditions: Primary Open Angle Glaucoma; Ocular Hypertension Interventions: Drug: latanoprost 75 ug; Drug: latanoprost 100 ug; Drug: latanoprost 125 ug; Drug: latanoprost 50 ug
15	Completed no results published yet	<u>Ologen (OculusGen)-Glaucoma MMC Control in Pakistan</u> Conditions: Glaucoma; Trabeculectomy Interventions: Device: ologen collagen matrix in glaucoma filtering surgery; Drug: MMC in glaucoma filtering surgery
16	Completed no results published yet	<u>Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma</u> Condition: Open-Angle Glaucoma Intervention:
17	Completed no results published yet	<u>ELAZOP Switching Study in Korea</u> Condition: Open Angle Glaucoma Intervention: Drug: Elazop (Azarga)
18	Completed no results published yet	<u>Long-Term IOP Fluctuation and VF Progression After Triple Procedure</u> Conditions: Glaucoma; Filtering Surgery; Intraocular Pressure Intervention:
19	Completed no results published yet	<u>Screening for Glaucoma in Namil Area, South Korea</u> Conditions: Glaucoma; Intraocular Pressure; Optic Nerve Head; Visual Field

		Intervention:
20	Completed no results published yet	<u>A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients</u> Condition: Glaucoma Intervention: Drug: carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
21	Terminated	<u>OculusGen-Glaucoma Historical Control Study in Taiwan</u> Condition: Glaucoma Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
22	Completed no results published yet	<u>Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma</u> Conditions: Glaucoma; Acute Primary Angle-closure Glaucoma Intervention:
23	Completed no results published yet	<u>A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension</u> Conditions: Glaucoma, Open-Angle; Ocular Hypertension Intervention: Drug: Xalacom
24	Completed no results published yet	<u>Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension</u> Condition: Ocular Hypertension Intervention: Drug: SAD448
25	Completed no results published yet	<u>Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</u> Conditions: Glaucoma; Ocular Hypertension Interventions: Drug: bimatoprost /timolol formulation A ophthalmic solution; Drug: Ganfort® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution)

26	Completed no results published yet	<u>A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma</u> Conditions: Glaucoma, Angle-Closure; Ocular Hypertension Interventions: Drug: Travoprost (0.004%); Drug: Latanoprost (0.005%)
27	Completed no results published yet	<u>IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy</u> Condition: Glaucoma Intervention: Drug: Azopt
28	Completed no results published yet	<u>Optic Nerve Compliance Study</u> Condition: Glaucoma Intervention: Procedure: Brief Elevation of IOP
29	Completed no results published yet	<u>A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</u> Conditions: Ocular Hypertension; Primary Open Angle Glaucoma Interventions: Drug: Ganfort; Drug: Duotrav
30	Completed no results published yet	<u>Results of Mass Switch From Latanoprost to Travoprost</u> Condition: Glaucoma Intervention:
31	Completed no results published yet	<u>Laser Iridotomy Versus Phacoemulsification in Acute Angle Closure</u> Condition: Angle Closure Glaucoma Intervention: Procedure: Laser Preipheral Iridotomy and phacoemulsification
32	Completed no results published yet	<u>Role of Polymorphisms in the IL-1 Gene Cluster</u> Condition: Glaucoma Intervention:
33	Completed no results published yet	<u>Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.</u> Conditions: Myopia; Maculopathy; Glaucoma

		Intervention:
34	Completed no results published yet	<u>5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy</u> Conditions: Glaucoma; Trabeculectomy; Wound Healing Interventions: Drug: 5 Fluorouracil with hyaluronic acid; Drug: 5 Fluorouracil
35	Completed no results published yet	<u>Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study</u> Conditions: Chronic Angle Closure Glaucoma ; Primary Angle Closure; Primary Angle Closure Suspect; Fellow Eyes of Acute Angle Closure Glaucoma Intervention: Procedure: Q-switched Nd:Yag Laser Iridotomy
36	Completed no results published yet	<u>The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes</u> Conditions: Glaucoma Patient; Glaucoma Suspect Patient; Normal Population; RNFL Thickness by Location; Macular Thickness by Location Intervention:
37	Terminated	<u>Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients</u> Condition: Glaucoma, Angle-Closure Interventions: Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution; Drug: latanoprost
38	Completed no results published yet	<u>A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.</u> Conditions: Primary Open Angle Glaucoma; Ocular Hypertension Interventions: Drug: PF-03187207; Drug: Latanoprost
39	Completed no results	<u>To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular</u>

	published yet	<p><u>Hypertension</u></p> <p>Conditions: Open-Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-104 ophthalmic solution; Drug: DE-104 vehicle</p>
40	Completed no results published yet	<p><u>Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Open-Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-104 ophthalmic solution, low concentration; Drug: DE-104 ophthalmic solution, medium concentration; Drug: DE-104 ophthalmic solution, high concentration; Drug: DE-104 vehicle</p>
41	Completed no results published yet	<p><u>DE-111 Against Timolol Ophthalmic Solution 0.5%</u></p> <p>Conditions: Open Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-111 ophthalmic solution; Drug: Timolol ophthalmic solution 0.5%</p>
42	Completed no results published yet	<p><u>DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%</u></p> <p>Conditions: Open Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: DE-111 ophthalmic solution; Drug: Tafluprost ophthalmic solution 0.0015%; Drug: Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%</p>
43	Completed no results published yet	<p><u>Safety and Efficacy of Travoprost/Timolol BAC-free</u></p> <p>Conditions: Open-angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: Travoprost 0.004%/Timolol 0.5% BAC-free Ophthalmic</p>

		Solution; Drug: Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution (DuoTrav®)
44	Completed no results published yet	<u>Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension</u> Conditions: Glaucoma; Ocular Hypertension Interventions: Drug: Azopt; Drug: Cosopt
45	Completed no results published yet	<u>Study of PGA Suture in Ophthalmology</u> Condition: Glaucoma Intervention: Device: Polyglycolic acid suture
46	Enrolling by invitation	<u>The High Cup/Disc Ratio in Children</u> Condition: Glaucoma Intervention:
47	Active, not recruiting	<u>Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost</u> Conditions: Glaucoma, Open-Angle; Ocular Hypertension Interventions: Drug: refrigeration free latanoprost; Drug: latanoprost eye drops
48	Active, not recruiting	<u>SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma</u> Conditions: Glaucoma; Glaucoma, Open Angle Interventions: Device: SOLX Gold Shunt GMS-plus; Device: Ahmed FP7 Glaucoma Valve
49	Enrolling by invitation	<u>Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India</u> Conditions: Patient Noncompliance; Health Literacy; Glaucoma Intervention:
50	Active, not recruiting	<u>A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)</u> Conditions: Glaucoma, Open-Angle; Ocular Hypertension Intervention: Drug: Bimatoprost 0.01%

51	Not yet recruiting	<p><u>Post-operative Satisfaction With Glaucoma Surgery Trial</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Behavioral: film and trained counseling; Other: traditional counseling</p>
52	Not yet recruiting	<p><u>Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Intervention: Drug: dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution (Triple Combination Therapy)</p>
53	Recruiting	<p><u>Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Device: Artificial drainage implant</p>
54	Recruiting	<p><u>Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: Latanoprost; Procedure: SLT</p>
55	Recruiting	<p><u>Clinical and Molecular Studies in Families With Glaucoma and Related Diseases</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
56	Recruiting	<p><u>Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension</u></p> <p>Conditions: Open-Angle Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: bimatoprost ophthalmic formulation A; Drug: bimatoprost ophthalmic formulation B; Drug: bimatoprost ophthalmic formulation C;</p>

		<p>Drug: bimatoprost ophthalmic formulation D; Drug: bimatoprost ophthalmic formulation E; Drug: bimatoprost ophthalmic formulation F; Drug: Sham; Drug: timolol 0.5%; Drug: bimatoprost ophthalmic solution 0.03%; Drug: latanoprost 0.005%; Drug: timolol vehicle (placebo)</p>
57	Recruiting	<p><u>Ologen (OculusGen)-Glaucoma Case Control Trial in India</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant</p>
58	Recruiting	<p><u>DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension</u></p> <p>Condition: Open Angle Glaucoma or Ocular Hypertension</p> <p>Intervention: Drug: DE-111 ophthalmic solution</p>
59	Recruiting	<p><u>Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002 AM1)</u></p> <p>Conditions: Glaucoma; Ocular Hypertension</p> <p>Interventions: Drug: Preservative-Free Tafluprost or vehicle; Drug: Preservative-Free Timolol maleate</p>
60	Recruiting	<p><u>Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: Bevacizumab; Drug: Mito­mycin C</p>
61	Recruiting	<p><u>Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma</u></p> <p>Condition: Normal Tension Glaucoma</p> <p>Interventions: Drug: Brimonidine/Timolol mixed combination; Drug: Timolol</p>
62	Recruiting	<p><u>Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate</u></p>

		<p><u>0.18% for Ocular Surface Disease in Glaucoma</u></p> <p>Conditions: Ocular Surface Disease; Glaucoma</p> <p>Interventions: Drug: hydroxypropylmethylcellulose; Drug: sodium hyaluronate</p>
63	Recruiting	<p><u>The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients</u></p> <p>Condition: Eye Drops Self-instillation</p> <p>Interventions: Device: Eye Drop Guide technique; Behavioral: Routine self-instillation technique</p>
64	Recruiting	<p><u>Analysis of Clinical Profiles of Chinese Patients With Normal Tension Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
65	Recruiting	<p><u>A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months</u></p> <p>Conditions: Ocular Hypertension; Open-angle Glaucoma</p> <p>Interventions: Drug: AR-12286 Ophthalmic Solution 0.7%; Drug: AR-12286 Ophthalmic Solution 0.5%; Drug: Timolol maleate ophthalmic solution 0.5%</p>
66	Recruiting	<p><u>Ologen (OculusGen)-Glaucoma MMC Control Trial in India</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Device: OculusGen Biodegradable Collagen Matrix Implant; Drug: Trabeculectomy with MMC</p>
67	Recruiting	<p><u>A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution</p>

68	Recruiting	<p><u>A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution</p>
69	Recruiting	<p><u>A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Drug: bimatoprost ophthalmic solution formulation A, bimatoprost vehicle; Drug: timolol ophthalmic solution</p>
70	Unknown †	<p><u>The Effect of Bevacizumab on the Trabeculectomy</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: intraocular injections of bevacizumab</p>
71	Unknown †	<p><u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
72	Unknown †	<p><u>Personality Characteristics and Compliance With Antiglaucoma Medication</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
73	Unknown †	<p><u>Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With the Cirrus High-Definition (HD) Optical Coherence Tomography (OCT)</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
74	Unknown †	<p><u>Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: Combigan Ophthalmic Sol</p>

		utiom
75	Unknown †	<p><u>Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma</u></p> <p>Condition: Normal Tension Glaucoma</p> <p>Interventions: Drug: dorzolamide/timolol fixed combination; Drug: latanoprost</p>
76	Unknown †	<p><u>Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
77	Unknown †	<p><u>Corneal Endothelium After Glaucoma Surgery</u></p> <p>Conditions: Glaucoma; Corneal Damage; I</p> <p>Intervention:</p>
78	Unknown †	<p><u>The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma</u></p> <p>Condition: Primary Congenital Glaucoma</p> <p>Intervention:</p>
79	Unknown †	<p><u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.</u></p> <p>Condition: Primary Open Angle Glaucoma</p> <p>Intervention:</p>
80	Unknown †	<p><u>Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
81	Unknown †	<p><u>Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital</u></p> <p>Conditions: Glaucomas; Pterygium</p> <p>Intervention: Device: ologen™ Collagen matrix implantation in glaucoma filtering surgery</p>
82	Unknown †	<p><u>The Genetic Study of Primary Angle-Closure Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
83	Unknown †	<p><u>Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT</u></p>

		<p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
84	Unknown †	<p><u>Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study</u></p> <p>Condition: Glaucoma, Angle-Closure</p> <p>Interventions: Drug: Latanoprost-Bimatoprost; Drug: Bimatoprost-Latanoprost</p>
85	Unknown †	<p><u>Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study</u></p> <p>Conditions: Cataract; Glaucoma</p> <p>Intervention: Device: ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery</p>
86	Unknown †	<p><u>Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Procedure: Selective Laser Trabeculoplasty; Drug: Travoprost/ Timolol/ Azopt/ Brimonidine</p>
87	Unknown †	<p><u>Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma</u></p> <p>Conditions: Advanced Glaucoma; Refractory</p> <p>Interventions: Procedure: Micropulse Transscleral Cyclophotocoagulation; Procedure: Conventional Transscleral Cyclophotocoagulation</p>
88	Unknown †	<p><u>Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial</u></p> <p>Conditions: Glaucoma; Cataract</p> <p>Interventions: Procedure: Glaucoma Implant Surgery; Procedure: trabeculectomy ; Procedure: phacoemulsification</p>
89	Unknown †	<p><u>Imaging Ahmed Glaucoma Tubes With a Pericardial Graft and Tissue Glue or Partial-Thickness Scleral Flap and Sutures</u></p> <p>Conditions: Advanced Glaucoma; Failed Tr</p>

		<p>abeculectomies</p> <p>Interventions: Procedure: Pericardial graft & tissue glue; Procedure: scleral flap & sutures</p>
90	Unknown †	<p><u>Relationship Between Topiramate Use and Ocular Angle Status</u></p> <p>Condition: Glaucoma, Angle-Closure</p> <p>Intervention: Drug: Topiramate</p>
91	Unknown †	<p><u>Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Drug: Subconjunctival Bevacizumab</p>
92	Unknown †	<p><u>Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Procedure: Argon Laser Iridoplasty; Drug: Travatan/ Timolol/Azopt</p>
93	Unknown †	<p><u>ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function</u></p> <p>Condition: Glaucoma</p> <p>Interventions: Procedure: Argon laser Iridoplasty; etazolamide</p>
94	Unknown †	<p><u>External Micropulse Diode Laser Transscleral Trabeculoplasty (EMDLT) for Severe Open Angle Glaucoma</u></p> <p>Condition: Primary Open Angle Glaucoma</p> <p>Intervention: Device: EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY</p>
95	Unknown †	<p><u>Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study</u></p> <p>Condition: Glaucoma</p> <p>Intervention: Procedure: pattern scanning laser iridotomy and iridoplasty</p>
96	Unknown †	<p><u>Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In</u></p>

		<p><u>Glaucoma Patients</u></p> <p>Condition: Primary Open Angle Glaucoma</p> <p>Intervention:</p>
97	Unknown †	<p><u>Discriminating Ability of the Cirrus High Definition (HD) Optical Coherence Tomography (OCT) for Glaucoma</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
98	Unknown †	<p><u>Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus Optical Coherence Tomography (OCT)</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>

58. Ocular Motility Disorders

Rank	Status	Study
1	Completed no results published yet	<u>Under-correction in Refractive Accommodative Esotropia</u> Condition: Accommodative Esotropia Intervention: Device: Glasses prescription
2	Completed no results published yet	<u>Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin</u> Condition: Esotropia Intervention:
3	Completed no results published yet	<u>Surgery and Convergence Insufficiency Intermittent Exotropia</u> Condition: Complications Interventions: Procedure: Post exercise Surgery; Procedure: Orthoptics; Procedure: Postop orthoptics; Procedure: Post exercises surgery
4	Active, not recruiting	<u>Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy</u> Condition: Progressive Supranuclear Palsy Interventions: Drug: Davunetide; Drug: Placebo
5	Recruiting	<u>The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery</u> Condition: Strabismus Interventions: Drug: Dexmedetomidine; Drug: placebo group
6	Recruiting	<u>A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery</u> Conditions: Child; Anesthesia Morbidity; Delirium on Emergence Interventions: Drug: Midazolam 0.03mg/kg; Drug: Midazolam 0.05mg/kg; Drug: Placebo
7	Recruiting	<u>Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus</u> Condition: Strabismus Intervention: Drug: GSK1358820
8	Recruiting	<u>International Guillain-Barré Syndrome Outcome Study</u>

		<p>Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome</p> <p>Intervention:</p>
9	Recruiting	<p><u>Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma</u></p> <p>Condition: Neuroblastoma</p> <p>Interventions: Biological: therapeutic immune globulin; Other: clinical observation</p>
10	Recruiting	<p><u>International Guillain-Barré Syndrome Outcome Study</u></p> <p>Conditions: Guillain-Barré Syndrome ; Miller Fisher Syndrome</p> <p>Intervention:</p>
11	Recruiting	<p><u>Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia</u></p> <p>Condition: Intermittent Exotropia</p> <p>Intervention: Procedure: Non surgical therapy</p>
12	Recruiting	<p><u>Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires</u></p> <p>Condition: Strabismus</p> <p>Intervention:</p>

59. Ophthalmoplegia

Rank	Status	Study
1	Completed no results published yet	<u>Efficacy of Aurosling in Frontalis Sling Suspension Surgery</u> Condition: Ptosis, Eyelid Intervention: Procedure: Aurosling
2	Active, not recruiting	<u>Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy</u> Condition: Progressive Supranuclear Palsy Interventions: Drug: Davunetide; Drug: Placebo

60. Opsoclonus-Myoclonus Syndrome

Rank	Status	Study
1	Recruiting	<p><u>Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma</u></p> <p>Condition: Neuroblastoma</p> <p>Interventions: Biological: therapeutic immune globulin; Other: clinical observation</p>

61. Optic Atrophies

Rank	Status	Study
1	Recruiting	<p><u>Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)</u></p> <p>Condition: Leber Hereditary Optic Neuropathy</p> <p>Intervention: Drug: rAAV2-ND4</p>
1	Unknown †	<p><u>Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma</u></p> <p>Condition: Lung Adenocarcinoma</p> <p>Intervention:</p>
1	Unknown †	<p><u>A Randomized, Double-Blind, Placebo-Controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)</u></p> <p>Condition: Optic Atrophy, Hereditary, Leber</p> <p>Intervention: Drug: curcumin</p>

62_Optic Nerve Diseases

Rank	Status	Study
1	Completed Has Results published on website	<u>Systemic Glutathione Level in Normal Tension Glaucoma</u> Condition: Normal Tension Glaucoma Intervention:
2	Completed no results published yet	<u>TLR-9 Antagonism in Steroid Resistant Optic Neuritis</u> Condition: Optic Neuritis Intervention: Drug: Mycobacterium w.(Mw)-freeze dried extract 0.5ml
3	Terminated	<u>Atacicept in Optic Neuritis, Phase II</u> Condition: Optic Neuritis Interventions: Drug: Atacicept; Drug: Pla cebo
4	Recruiting	<u>Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)</u> Condition: Leber Hereditary Optic Neur opathy Intervention: Drug: rAAV2-ND4
5	Recruiting	<u>PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)</u> Condition: Anterior Ischemic Optic Neu ropathy Intervention: Drug: Diagnostic procedure s
6	Recruiting	<u>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica</u> Conditions: Progressive Multiple Scleros is; Neuromyelitis Optica. Intervention: Biological: human umbilical cord mesenchymal stem cells
7	Recruiting	<u>Analysis of Clinical Profiles of Chinese Patients With Normal Tension Glaucoma</u> Condition: Glaucoma Intervention:
8	Recruiting	<u>Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma</u>

		<p>Condition: Normal Tension Glaucoma</p> <p>Interventions: Drug: Brimonidine/Timolol mixed combination; Drug: Timolol</p>
9	Not yet recruiting	<p><u>215ON201 BIIB033 In Acute Optic Neuritis (AON)</u></p> <p>Condition: Acute Optic Neuritis</p> <p>Intervention: Biological: BIIB033</p>
10	Unknown †	<p><u>Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient</u></p> <p>Condition: Glaucoma</p> <p>Intervention:</p>
11	Unknown †	<p><u>Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma</u></p> <p>Condition: Normal Tension Glaucoma</p> <p>Interventions: Drug: dorzolamide/timolol fixed combination; Drug: latanoprost</p>
12	Unknown †	<p><u>Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma</u></p> <p>Condition: Lung Adenocarcinoma</p> <p>Intervention:</p>

63. Optic Neuritis

Rank	Status	Study
1	Completed no results published yet	<u>TLR-9 Antagonism in Steroid Resistant Optic Neuritis</u> Condition: Optic Neuritis Intervention: Drug: Mycobacterium w.(Mw)-freeze dried extract 0.5ml
2	Terminated	<u>Atacept in Optic Neuritis, Phase II</u> Condition: Optic Neuritis Interventions: Drug: Atacept; Drug: Placebo
3	Recruiting	<u>Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica</u> Conditions: Progressive Multiple Sclerosis; Neuromyelitis Optica. Intervention: Biological: human umbilical cord mesenchymal stem cells
4	Not yet recruiting	<u>215ON201 BIIB033 In Acute Optic Neuritis (AON)</u> Condition: Acute Optic Neuritis Intervention: Biological: BIIB033

64. Optic Neuropathy, Ischemic

Rank	Status	Study
1	Recruiting	<u>PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)</u> Condition: Anterior Ischemic Optic Neuropathy Intervention: Drug: Diagnostic procedures

65. Orbital Diseases

Rank	Status	Study
1	Completed no results published yet	<u>Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients</u> Condition: Graves' Disease Intervention: Drug: Dexamethasone
2	Completed no results published yet	<u>Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)</u> Condition: Thyroid-Related Eye Disease Interventions: Drug: LIPO-102; Drug: Placebo
3	Completed no results published yet	<u>Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies</u> Condition: Graves' Ophthalmopathy Intervention: Drug: Carbimazole, radio-active iodine (I131)
4	Completed no results published yet	<u>Thyroid Treatment Trial</u> Condition: Graves Ophthalmopathy Intervention: Drug: Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo
5	Completed no results published yet	<u>Is the Routine Pressure Dressing After Thyroidectomy Necessary?</u> Conditions: Thyroid Neoplasms; Thyroid Nodules; Graves Disease; Goiter Interventions: Procedure: Pressure dressing; Procedure: Normal dressing
6	Recruiting	<u>The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions</u> Conditions: Hypothyroidism; Exophthalmos Intervention: Radiation: Iodine 131
7	Recruiting	<u>Doxycycline Treatment in Graves' Orbitopathy</u> Conditions: Graves Ophthalmopathy; Graves Disease; Eye Diseases; Thyroid Diseases; Endocrine System Diseases; Eye Diseases, Hereditary; Hyperthyroidism; Autoimmune Diseases; Immune System Disease

		ses Intervention: Drug: Doxycycline
8	Recruiting	<u>Differential Diagnosis Value of PSV of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis</u> Conditions: Thyrotoxicosis; Peak Systolic Velocity of Superior Thyroid Artery; Thyroiditis; Graves Disease Intervention:
9	Recruiting	<u>Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections</u> Condition: Thyroid-associated Ophthalmopathy Intervention: Drug: subconjunctival triamcinolone injection
10	Recruiting	<u>Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease</u> Condition: Graves' Disease Intervention:
11	Recruiting	<u>Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial</u> Conditions: Fractures; Enophthalmos; Diplopia Interventions: Device: Polycaprolactone / Tri-Calcium Phosphate; Device: Titanium Mesh
12	Unknown [†]	<u>The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves' Ophthalmopathy</u> Condition: Graves' Ophthalmopathy Intervention:

66. Panuveitis

Rank	Status	Study
1	Completed Has Results published in journals	<p><u>A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis</u></p> <p style="text-align: right;">Conditions: Intermediate Uveitis; P osterior Uveitis</p> <p style="text-align: right;">Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection</p>
2	Completed no results published yet	<p><u>Phase III Study in Refractory Behcet's Disease</u></p> <p style="text-align: right;">Condition: Behcet Disease</p> <p style="text-align: right;">Interventions: Drug: AIN457; Drug: Placebo</p>
3	Completed no results published yet	<p><u>A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis</u></p> <p style="text-align: right;">Conditions: Uveitis, Anterior; Panuv eitis</p> <p style="text-align: right;">Interventions: Drug: Placebo; Drug: L X211</p>
4	Completed no results published yet	<p><u>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</u></p> <p style="text-align: right;">Condition: Uveitis, Anterior</p> <p style="text-align: right;">Interventions: Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System; Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System; Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System; Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System</p>
5	Completed no results published yet	<p><u>A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis</u></p> <p style="text-align: right;">Conditions: Uveitis, Posterior; Uv eitis, Intermediate; Pa nuveitis</p> <p style="text-align: right;">Interventions: Drug: Placebo; Drug: LX211</p>
6	Enrolling by invitation	<p><u>A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-,</u></p>

		<p><u>or Pan-uveitis</u></p> <p>Condition: Uveitis</p> <p>Intervention: Drug: adalimumab</p>
7	Active, not recruiting	<p><u>A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease.</u></p> <p>Condition: Intestinal Behçet's Disease</p> <p>Intervention: Biological: Adalimumab</p>
8	Terminated	<p><u>Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Biological: AIN457; Biological: Placebo</p>
9	Terminated	<p><u>Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Biological: AIN457; Biological: Placebo</p>
10	Terminated	<p><u>Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Biological: AIN457; Drug: Placebo</p>
11	Terminated	<p><u>Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis</u></p> <p>Condition: Non-infectious Uveitis</p> <p>Interventions: Biological: AIN457; Drug: Placebo</p>
12	Recruiting	<p><u>Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis</u></p> <p>Conditions: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis</p> <p>Intervention: Drug: Ganciclovir</p>
13	Recruiting	<p><u>Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis</u></p> <p>Condition: Anterior Uveitis</p>

		Intervention:
14	Recruiting	<p><u>Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo</p>
15	Recruiting	<p><u>Efficacy and Safety of Adalimumab in Subjects With Active Uveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo</p>
16	Recruiting	<p><u>Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions</u></p> <p>Conditions: Behcet's Disease; Behcet Syndrome; Neuro-Behcet's Disease</p> <p>Intervention: Drug: TA-650</p>
17	Unknown[†]	<p><u>Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease</u></p> <p>Conditions: Ocular Behcet's Disease; Non-Infectious Uveitis; Refractory Uveitis</p> <p>Intervention: Drug: flucinolone acetonide</p>

67. Pars Planitis

Rank	Status	Study
1	Completed Has Results published in journals	<u>A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis</u> Conditions: Intermediate Uveitis; Posterior Uveitis Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection
2	Completed no results published yet	<u>Phase III Study in Refractory Behcet's Disease</u> Condition: Behcet Disease Interventions: Drug: AIN457; Drug: Placebo
3	Enrolling by invitation	<u>A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis</u> Condition: Uveitis Intervention: Drug: adalimumab
4	Terminated	<u>Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis</u> Condition: Uveitis Interventions: Biological: AIN457; Drug: Placebo
5	Terminated	<u>Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u> Condition: Uveitis Interventions: Biological: AIN457; Biological: Placebo
6	Terminated	<u>Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Study</u> Condition: Non-infectious Uveitis Interventions: Biological: AIN457; Drug: Placebo
7	Terminated	<u>Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u> Condition: Uveitis Interventions: Biological: AIN457; Biological: Placebo

68. Presbyopia

Rank	Status	Study
1	Enrolling by invitation	<p><u>The Effect of Cataract Extraction on the Contractility of Ciliary Muscle</u></p> <p>Conditions: Presbyopia; Cataract</p> <p>Intervention: Other: UBM with pilocarpine in presbyopia</p>
2	Enrolling by invitation	<p><u>Near and Intermediate Vision and Binocular Defocus Curves Before and After the LaserACE® Procedure</u></p> <p>Condition: Presbyopia</p> <p>Intervention: Procedure: LaserACE(R)</p>
3	Active, not recruiting	<p><u>Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes</u></p> <p>Condition: Presbyopia</p> <p>Intervention: Device: AcuFocus Corneal Inlay ACI 7000PDT</p>
4	Recruiting	<p><u>Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes</u></p> <p>Conditions: Myopia; Hyperopia; Presbyopia</p> <p>Intervention: Device: Supracor</p>

69. Pterygium

Rank	Status	Study
1	Completed Has Results published on website	<u>Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium</u> Condition: Pterygium Interventions: Drug: cyclosporine ophthalmic emulsion 0.05%; Drug: Vehicle
2	Completed no results published yet	<u>Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium</u> Condition: Pterygium of the Conjunctiva and Cornea Interventions: Drug: Fluorometholone; Drug: Bevacizumab
3	Completed	<u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital</u> Conditions: Glaucoma; Pterygium Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
4	Completed	<u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital</u> Conditions: Glaucomas; Pterygium Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
5	Completed	<u>To Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation</u> Condition: Pterygium Intervention: Procedure: Amniotic membrane transplantation using fibrin glue
6	Completed	<u>Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital</u> Conditions: Glaucoma; Pterygium Intervention: Device: OculusGen Biodegradable Collagen Matrix Implant
7	Completed	<u>Polyglactin Sutures Versus Nylon Sutures for Suturing of Conjunctival Autograft in Pterygium Surgery: a Randomised Controlled Trial</u>

		<p>Condition: Pterygium</p> <p>Interventions: Procedure: Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery; Procedure: Nylon sutures for suturing of conjunctival autograft in pterygium surgery</p>
8	Completed	<p><u>Rotational Narrow Strip Versus Full Conjunctival Graft in Pterygium Excision</u></p> <p>Condition: Pterygium</p> <p>Interventions: Procedure: Rotational Narrow Strip Conjunctival Graft; Procedure: Full Conjunctival Graft</p>
9	Completed	<p><u>Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery</u></p> <p>Conditions: Pterygium; Ocular Surface Cicatrizing Diseases</p> <p>Intervention: Device: Tisseel fibrin adhesive</p>
10	Completed	<p><u>Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation</u></p> <p>Conditions: Pterygium; Ocular Surface Disease; Stevens Johnson Syndrome; Chemical Injury</p> <p>Intervention: Procedure: Cultivated conjunctival transplantation</p>
11	Withdrawn	<p><u>The Application of Fibrin Glue in Ocular Surface Diseases</u></p> <p>Conditions: Pterygium; Corneal Ulcer</p> <p>Intervention: Drug: tissue fibrin glue application (Tisseel)</p>
12	Recruiting	<p><u>Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders</u></p> <p>Conditions: Pterygium; Dry Eye; Tumor</p> <p>Intervention:</p>
13	Recruiting	<p><u>Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium</u></p>

		<p>Condition: Pterygium</p> <p>Intervention:</p>
14	Recruiting	<p><u>Topical Bevacizumab for Preventing Recurrent Pterygium</u></p> <p>Conditions: Pterygium; Bevacizumab; VEGF; Anti-VEGF</p> <p>Interventions: Drug: bevacizumab eye drop 0.05%; Drug: normal saline 0.9%</p>
15	Recruiting	<p><u>Intralesional Bevacizumab Injection on Primary Pterygium</u></p> <p>Conditions: Pterygium; Inflammation</p> <p>Interventions: Drug: Intralesional injection of bevacizumab; Drug: Topical antihistamine and vasoconstrictor</p>
16	Unknown †	<p><u>Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation</u></p> <p>Conditions: Pterygium; Cataract; Astigmatism</p> <p>Intervention: Procedure: pterygium excision</p>
17	Unknown †	<p><u>Surgical Treatment of Concurrent Cataract and Primary Pterygium</u></p> <p>Conditions: Pterygium; Cataract; Lenses, Intraocular</p> <p>Interventions: Procedure: combined pterygium and cataract operation; Procedure: pterygium excision followed by cataract operation</p>
18	Unknown †	<p><u>Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital</u></p> <p>Conditions: Glaucomas; Pterygium</p> <p>Intervention: Device: ologen™ Collagen matrix implantation in glaucoma filtering surgery</p>
19	Unknown †	<p><u>Comparison of Glue With Sutures for Pterygium Surgery</u></p> <p>Condition: Pterygium</p> <p>Intervention: Procedure: Pterygium excision and conjunctival autograft</p>

70. Refractive Errors

Rank	Status	Study
1	Completed Has Results published on website	<u>Comparative Performance of PureVision Lens Designs</u> Condition: Myopia Interventions: Device: Currently Marketed PureVision Contact Lens.; Device: Alternate Design of the PureVision Contact Lens.
2	Completed Has Results published on website	<u>Product Performance of a Toric Contact Lens</u> Conditions: Myopia; Astigmatism Interventions: Device: SofLens DD Toric; Device: Ciba Vision Focus Dailies Toric Contact Lens
3	Completed Has Results published on website	<u>Clinical Evaluation of Two Daily Disposable Contact Lenses</u> Condition: Refractive Error Interventions: Device: etafilcon A; Device: d
4	Completed Has Results published on website	<u>Two Week Cross-Over Study Comparing Two Daily Disposable Contact Lenses</u> Condition: Myopia Interventions: Device: etafilcon A; Device: d
5	Completed no results published yet	<u>Comparative Study of Cycloplegic Refraction and Subjective Refraction With Fogging in School Age Children</u> Conditions: Myopia; Refractive Error Intervention:
6	Completed no results published yet	<u>Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles</u> Conditions: Myopia; Hyperopia; Astigm Interventions: Device: Ready-made spectacle acles
7	Completed no results published yet	<u>A Singapore Study to Assess How Neurovision Improve the Vision of Adults With Low to Moderate Myopia</u> Condition: Myopia Intervention: Device: Neurovision
6	Completed no results published yet	<u>Myopia Control With Simultaneous Vision Approach</u> Condition: Myopia Intervention: Device: Defocus Incorporated Soft Contact (DISC) lens

9	Completed no results published yet	<u>Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children</u> Condition: Myopia Intervention: Device: Hyperopic lens
10	Completed no results published yet	<u>Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia</u> Condition: Myopia Interventions: Procedure: Laser in Situ Keratotomy; Device: Photorefractive Keratectomy
11	Completed no results published yet	<u>Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.</u> Conditions: Myopia; Maculopathy; Glaucoma Intervention:
12	Completed no results published yet	<u>Changes in In Vitro and ex Vivo Lens Metrology With Daily Wear Contact Lenses</u> Condition: Myopia Interventions: Device: Air Optix Aqua; Device: Acuvue Infinity; Device: Proclear; Device: Acuvue 2; Device: Acuvue Oasys; Device: Acuvue 2; Device: Purevision
13	Completed no results published yet	<u>Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses</u> Condition: Myopia Interventions: Device: galyfilcon A; Device: galyfilcon A plus; Device: lotrafilcon A; Device: polymacon; Other contact lenses
14	Completed no results published yet	<u>Comparison of Contact Lens Maintenance Systems for Silicone Hydrogel Lenses</u> Conditions: Myopia; Hyperopia Intervention: Device: Silicone hydrogel contact lens
15	Completed no results published yet	<u>Clinical Performance of Extended Wear Silicone Hydrogel Lenses</u> Condition: Myopia Intervention: Device: Silicone hydrogel contact lens
17	Completed	<u>The Effect of Silicone Hydrogel Contact Lenses on</u>

	no results published yet	<u>Conjunctival Flora</u> Condition: Myopia Intervention: Device: Silicone hydrogel contact lens
18	Completed no results published yet	<u>Clinical Evaluation of Ocular Responses With Contact Lens Wear</u> Condition: Myopia Interventions: Device: narafilecon B; Device: lymacon; Device: Lotrafilecon; Other: Spectacles
19	Completed no results published yet	<u>Investigation of the Clinical Performance of Silicone Hydrogel Contact Lenses During Continuous Wear</u> Condition: Myopia Intervention: Device: Silicone hydrogel contact lens
20	Completed no results published yet	<u>Clinical Trial of Contact Lenses in Extended Wear</u> Condition: Astigmatism Interventions: Device: senofilcon A toric contact lens; Device: balafilcon A toric contact lens
21	Completed no results published yet	<u>Time Course Comparison of Contact Lens Maintenance Systems for Hydrogel Lenses</u> Conditions: Myopia; Hyperopia Interventions: Device: Silicone Hydrogel Contact lenses; Device: 1x PMBH prepared MPS; Device: 1x Polyquad MPS
22	Completed no results published yet	<u>Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</u> Condition: Pathological Myopia Interventions: Drug: 0.5 mg ranibizumab driven by disease activity; Drug: 0.5 mg ranibizumab driven by stabilization criteria; Drug: verteporfin PDT
23	Completed no results published	<u>Pilot Study of Neurovision to Improve Vision and Slow Myopia Progression in Children With Myopia</u>

	yet	<p>Condition: Myopia</p> <p>Intervention: Device: NeuroVision</p>
24	Completed no results published yet	<p><u>Clinical Trial of Several Contact Lenses in Extended Wear</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: senofilcon A; Device: otrafilcon B; Device: balafilcon A; Device: etafilcon A</p>
25	Completed no results published yet	<p><u>Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction</u></p> <p>Condition: Cataract</p> <p>Interventions: Device: Crystalens AO; Device: TOR 3.0; Device: AMO Technocal</p>
26	Completed no results published yet	<p><u>Construction of Computerized Intraoperative Keratometer and Experimental Study</u></p> <p>Conditions: Corneal Astigmatism; Orientation</p> <p>Intervention: Device: computerized intraoper</p>
27	Completed no results published yet	<p><u>A Comprehensive Assessment of Anterior Corneal Power by Different Devices</u></p> <p>Condition: Myopia</p> <p>Intervention: Device: Corneal power measur</p>
28	Completed no results published yet	<p><u>Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes</u></p> <p>Conditions: Maculopathy; High Myopia;</p> <p>Intervention: Procedure: vitrectomy</p>
29	Completed no results published yet	<p><u>Contact Lens in Pediatrics (CLIP) in an Asian Population Study</u></p> <p>Condition: Myopia</p> <p>Intervention: Device: Johnson&Johnson Acuvue daily disposable lenses</p>
30	Completed no results published yet	<p><u>A Singapore Pilot Study to Assess Neurovision in Treatment of Low Myopia</u></p> <p>Condition: Myopia</p> <p>Intervention: Device: Neurovision</p>
31	Completed no results published yet	<p><u>The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>

32	Completed no results published yet	<u>Myopia Control by Combining Auricular Acupoint and Atropine Eyedrops</u> Condition: Myopia Interventions: Drug: 0.25 % atropine; Drug: edure: 0.25 % atropine+auricul
33	Terminated	<u>Silicone Hydrogel Contact Lenses on Low Astigmatism in Japan</u> Conditions: Refractive Error; Myopia; A Interventions: Device: senofilcon A toric soft c vice: senofilcon A sphere soft c
34	Enrolling by invitation	<u>The Children's WEAR Trial(Phase 1&2)</u> Condition: Myopia Interventions: Procedure: group1; Procedur e: group3; Procedure: group4
35	Enrolling by invitation	<u>The Effect of Cataract Extraction on the Contractility of Ciliary Muscle</u> Conditions: Presbyopia; Cataract Intervention: Other: UBM with pilocarpine in
36	Enrolling by invitation	<u>Near and Intermediate Vision and Binocular Defocus Curves Before and After the LaserACE® Procedure</u> Condition: Presbyopia Intervention: Procedure: LaserACE(R)
37	Enrolling by invitation	<u>Guangzhou Outdoor Activity Longitudinal Study</u> Condition: Myopia Intervention: Behavioral: Outdoor activity
38	Active, not recruiting	<u>Peripheral Optics in Myopia and Orthokeratology</u> Condition: Myopia Interventions: Device: Orthokeratology lenses acles
39	Active, not recruiting	<u>Toric Orthokeratology - Slowing Eye Elongation</u> Conditions: Myopia; Astigmatism Interventions: Device: Toric Orthokeratology l gle-vision spectacles
40	Active, not recruiting	<u>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)</u> Condition: Myopia, Pathological Interventions: Biological: VEGF Trap-Eye (BA dure: No Drug

41	Active, not recruiting	<p><u>Trial of a Novel Family-Based Intervention to Increase Outdoor Time and Fitness</u></p> <p>Conditions: Myopia; Obesity</p> <p>Intervention: Behavioral: Family-based Outdoor</p>
42	Active, not recruiting	<p><u>Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes</u></p> <p>Condition: Presbyopia</p> <p>Intervention: Device: AcuFocus Corneal Inlay</p>
43	Recruiting	<p><u>Discontinuation of Orthokeratology on Eyeball Elongation in Myopic Children</u></p> <p>Condition: Myopia</p> <p>Intervention: Procedure: Switching of orthokeratology and single-vision glasses</p>
44	Recruiting	<p><u>Clinical and Genetic Studies in Families With Myopia and Related Diseases</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
45	Recruiting	<p><u>Clinical Evaluation of Toric Intraocular Lens Made by Aurolab</u></p> <p>Condition: Astigmatism</p> <p>Intervention: Procedure: intra ocular lens</p>
46	Recruiting	<p><u>Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes</u></p> <p>Conditions: Myopia; Hyperopia; Presbyopia</p> <p>Intervention: Device: Supracor</p>
47	Recruiting	<p><u>Early Vitrectomy for Macular Tractional Maculopathy</u></p> <p>Condition: Myopia, Degenerative</p> <p>Intervention: Procedure: Early vitrectomy</p>
48	Recruiting	<p><u>Discontinuation of Lens Wear in New Ortho-k Children (DOEE2)</u></p> <p>Condition: Myopia</p> <p>Intervention: Procedure: Switching of single-vision spectacles to orthokeratology</p>
49	Recruiting	<p><u>Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia</u></p>

		<p>Conditions: Astigmatism; Cataract</p> <p>Interventions: Procedure: phacoemulsification; (Oculus,Germany)examination</p>
50	Recruiting	<p><u>Randomized, Non-inferiority Trial Comparing SMILE and LASIK</u></p> <p>Conditions: Myopia; Astigmatism; Hyperopia</p> <p>Interventions: Procedure: Femtosecond LASIK; Small incision lenticule extraction</p>
51	Unknown †	<p><u>Prospective Evaluation of Limbal Relaxing Incision (LRI) in Conjunction With Phacoemulsification Surgery for Astigmatic Correction in Chinese Eyes</u></p> <p>Condition: Corneal Astigmatism</p> <p>Intervention: Procedure: Limbal relaxing incision</p>
52	Unknown †	<p><u>Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation</u></p> <p>Conditions: Pterygium; Cataract; Astigmatism</p> <p>Intervention: Procedure: pterygium excision</p>
53	Unknown †	<p><u>Comparison of Intralase and Visumax Femtosecond Laser for Laser In Situ Keratomileusis</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
54	Unknown †	<p><u>Randomized, Prospective Comparison of the Outcome of Toric Implantable Contact Lens (TICL) and Q-LASIK for the Correction of Myopia With Astigmatism</u></p> <p>Conditions: Myopia; Astigmatism</p> <p>Interventions: Procedure: the implantation of toric implantable collamer lens; Procedure: customized laser-assisted in situ keratomileusis</p>
55	Unknown †	<p><u>Myopic Control for High Myopes Using Orthokeratology</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Orthokeratology lenses; Device: Single-vision spectacle</p>
56	Unknown †	<p><u>Retardation of Myopia in Orthokeratology</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Orthokeratology lenses; Menicon Z Night</p>

		Lens; Device: spherical plastic
57	Unknown †	<p><u>Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children</u></p> <p>Condition: Myopia</p> <p>Intervention: Drug: Atropine Eye drops</p>
58	Unknown †	<p><u>Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs.</u></p> <p>Condition: Myopia</p> <p>Interventions: Device: Currently marketed PureVision soft contact lens.; Device: Alternate design of PureVision soft contact lens.</p>
59	Unknown †	<p><u>Ocular Imaging With Spectral Domain Optical Coherence Tomography</u></p> <p>Conditions: Healthy; Myopia; Hyperme</p> <p>Intervention: Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)</p>
60	Unknown †	<p><u>Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
61	Unknown †	<p><u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma</u></p> <p>Conditions: Glaucoma; Myopia</p> <p>Intervention:</p>
62	Unknown †	<p><u>Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometric Patients Under Atropine Treatment</u></p> <p>Conditions: Myopia; Anisometropia</p> <p>Intervention:</p>
63	Unknown †	<p><u>Aberration-Free Refraction Correction</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
64	Unknown †	<u>Compare Anterior Chamber Biometry in Healthy and</u>

		<p><u>Post-LASIK Patients</u></p> <p>Conditions: Myopia; Astigmatism</p> <p>Intervention:</p>
65	Unknown †	<p><u>The Role of SNP of ECM and MMP on the Development of Pathological High Myopia</u></p> <p>Condition: Myopia</p> <p>Intervention:</p>
66	Unknown †	<p><u>Genomewide Screening of Pathological Myopia</u></p> <p>Condition: Pathological Myopia</p> <p>Intervention:</p>

71. Retinal Artery Occlusion

Rank	Status	Study
1	Recruiting	<u>Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion</u> Condition: Retinal Vascular Occlusion Intervention: Device: Watchpat 100

72. Retinal Degeneration

Rank	Status	Study
1	Completed Has Results published on website	<p><u>Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema</u></p> <p style="text-align: center;">Condition: Diabetic Macular Edema</p> <p style="text-align: center;">Interventions: Drug: Ranibizumab; Procedure: Laser photocoagulation; Drug: Sham ranibizumab; Procedure: Sham laser photocoagulation</p>
2	Completed Has Results published on website	<p><u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u></p> <p style="text-align: center;">Condition: Retinal Vein Occlusion</p> <p style="text-align: center;">Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Other: Sham treatment</p>
3	Completed Has Results published on website	<p><u>Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)</u></p> <p style="text-align: center;">Conditions: Choroidal Neovascularization; Age-Related Maculopathy</p> <p style="text-align: center;">Interventions: Drug: dexamethasone; Biological: ranibizumab</p>
4	Completed Has Results published on website	<p><u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</u></p> <p style="text-align: center;">Condition: Macular Degeneration</p> <p style="text-align: center;">Interventions: Drug: Ranibizumab; Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</p>
5	Completed Has Results published in journals	<p><u>Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration</u></p> <p style="text-align: center;">Condition: Age-related Macular Degeneration</p> <p style="text-align: center;">Intervention: Drug: ranibizumab</p>
6	Terminated Has Results published on website	<p><u>A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration</u></p> <p style="text-align: center;">Conditions: Choroid Neovascularization; Age-Related Macular Degeneration</p> <p style="text-align: center;">Interventions: Drug: AGN 211745; Drug: Ranib</p>

		izumab 500µg
7	Completed Has Results published on website	<p><u>A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.</u></p> <p>Condition: Macular Edema Associated With Diabetes Mellitus</p> <p>Interventions: Drug: Standard of Care; Drug: Macugen</p>
8	Completed Has Results published on website	<p><u>Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)</u></p> <p>Conditions: Choroidal Neovascularization; Age-Related Maculopathy</p> <p>Interventions: Drug: dexamethasone; Biologically: ranibizumab; Other: sham</p>
9	Terminated Has Results published on website	<p><u>Macugen Observational Study</u></p> <p>Conditions: Vascular Endothelial Growth Factor; Macular Degeneration</p> <p>Intervention: Other: No intervention</p>
10	Completed Has Results published on website	<p><u>Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration</u></p> <p>Condition: Macular Degeneration</p> <p>Intervention: Drug: pegaptanib sodium</p>
11	Completed Has Results published on website	<p><u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Interventions: Drug: Dexamethasone; Drug: Sham injection</p>
12	Completed Has Results published in journals	<p><u>Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</u></p> <p>Condition: Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)</p> <p>Intervention: Drug: Ranibizumab</p>

13	Completed no results published yet	<u>Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients</u> Condition: Age Related Macular Degeneration Intervention: Drug: ranibizumab 0.5 mg
14	Completed no results published yet	<u>Reduction in the Occurrence of Center-Involved Diabetic Macular Edema</u> Condition: Diabetic Retinopathy Interventions: Drug: ruboxistaurin; Drug: placebo
15	Completed no results published yet	<u>Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Macular Edema, Cystoid; Vision Disorders; Clinically Significant Macular Edema Intervention: Drug: long acting intravitreal dexamethasone implant
16	Completed no results published yet	<u>CME With Different Fluidic Parameters</u> Condition: Cystoid Macular Edema Following Cataract Surgery Intervention: Procedure: microcoaxial phacoemulsification
17	Completed no results published yet	<u>Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Interventions: Drug: 0.59 mg fluocinolone acetonide intravitreal implant; Drug: 2.1 mg fluocinolone acetonide intravitreal implant; Procedure: standard of care laser photocoagulation
18	Completed no results published yet	<u>A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD</u> Condition: Neovascular Age-related Macular Degeneration Intervention: Biological: Intravitreal injection of KH902
19	Completed	<u>A Population-based Study of Macular Choroidal</u>

	no results published yet	<p><u>Neovascularization in a Chinese Population</u></p> <p>Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen</p> <p>Intervention: Other: Follow-up observation</p>
20	Completed no results published yet	<p><u>Bevacizumab for Neovascular Age-related Macular Degeneration</u></p> <p>Condition: Exudative Age-related Macular Degeneration</p> <p>Interventions: Drug: Bevacizumab 1; Drug: Bevacizumab</p>
21	Completed no results published yet	<p><u>Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).</u></p> <p>Condition: Age Related Macular Degeneration</p> <p>Interventions: Drug: 0.5 mg ranibizumab; Drug: 3 mg PF-04523655; Drug: 1 mg PF-04523655</p>
22	Completed no results published yet	<p><u>EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</u></p> <p>Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab</p>
23	Completed no results published yet	<p><u>Major and Macular Branched Retinal Venous Occlusion</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Procedure: intravitreal bevacizumab</p>
24	Completed no results published yet	<p><u>Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Procedure: Pars Plana Vitrectomy</p>
25	Completed no results published yet	<p><u>Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Procedure: vitrectomy; Drug: intravitreal triamcinolone acetate;</p> <p>Procedure: macular focal laser photocoagulation</p>

26	Completed no results published yet	<u>Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration</u> Condition: Neovascular Age-related Macular Degeneration Intervention: Drug: ranibizumab
27	Completed no results published yet	<u>LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy</u> Condition: Age-Related Macular Degeneration Intervention:
28	Completed no results published yet	<u>Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)</u> Condition: Macular Degeneration Interventions: Drug: Brimonidine Tartrate Implant ; Drug: Sham
29	Completed no results published yet	<u>Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy</u> Condition: Age-Related Macular Degeneration Intervention:
30	Completed no results published yet	<u>LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population</u> Condition: Age-Related Macular Degeneration Intervention: Genetic: LOC387715/HTRA1 genotyping
31	Completed no results published yet	<u>Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Intervention: Procedure: Intravitreal injection
32	Completed no results published yet	<u>Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion</u> Conditions: Macular Edema; Branch Retinal Vein Occlusion Interventions: Procedure: Arteriovenous Crossing Sheathotomy; Procedure: Intravitreal Triamcinolone

		Acetonide Injection
33	Completed no results published yet	<p><u>Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)</u></p> <p>Conditions: Diabetic Retinopathy; Macular Edema</p> <p>Intervention: Procedure: Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation</p>
34	Completed no results published yet	<p><u>Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmentosa</u></p> <p>Condition: Retinitis Pigmentosa</p> <p>Intervention:</p>
35	Completed no results published yet	<p><u>Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)</u></p> <p>Condition: Wet Age-Related Macular Degeneration</p> <p>Interventions: Drug: PTK787; Drug: Placebo</p>
36	Completed no results published yet	<p><u>Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)</u></p> <p>Condition: Macular Degeneration</p> <p>Intervention: Drug: pegaptanib sodium</p>
37	Completed no results published yet	<p><u>A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema</u></p> <p>Conditions: Macular Edema; Diabetic Mellitus; Retinal Disease</p> <p>Interventions: Drug: pegaptanib sodium; Other: sham injection</p>
38	Completed no results published yet	<p><u>PDT Study for Exudative AMD With PCV</u></p> <p>Condition: Age Related Macular Degeneration</p> <p>Intervention: Procedure: Ocular photodynamic therapy with verteporfin</p>
39	Completed no results published	<p><u>A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema</u></p> <p>Condition: Diabetic Macular Edema</p>

	yet	Intervention: Drug: dexamethasone
40	Completed no results published yet	<u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion</u> Conditions: Macular Degeneration; Macular Edema; Branch Retinal Vein Occlusion Intervention: Drug: dexamethasone
41	Completed no results published yet	<u>Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration</u> Condition: Age-Related Macular Degeneration Intervention: Drug: Bevacizumab
42	Completed no results published yet	<u>The Effect of a Blue Light Filtering IOL</u> Conditions: to Compare the Effect of Two Types of IOLs; on the Incidence of Cystoid Macular Edema; After Cataract Surgery Intervention: Procedure: intraocular lens implantation
43	Completed no results published yet	<u>Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy</u> Conditions: Neovascular Maculopathy; Age Related Macular Degeneration Intervention: Biological: VEGFR1 and VEGFR2
44	Completed no results published yet	<u>Vitreotomy for Branch Retinal Vein Occlusion</u> Condition: Vitrectomy Intervention: Procedure: Vitrectomy w/o ILM peeling for macular edema with BRVO
45	Completed no results published yet	<u>Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy</u> Condition: Diabetic Macular Edema Interventions: Drug: 2304 Eye Drops High Dose; Drug: 2304 Eye Drops Low Dose; Drug: Placebo Eye Drops
46	Completed	<u>A Study to Compare rhuFab V2 With Verteporfin Photodynamic</u>

	no results published yet	<u>in Treating Subfoveal Neovascular Macular Degeneration</u> Condition: Macular Degeneration Intervention: Drug: rhuFab V2 (ranibizumab)
47	Completed no results published yet	<u>To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD</u> Condition: Macular Degeneration Intervention: Drug: Pazopanib
48	Completed no results published yet	<u>An Extension to Study MD7108240</u> Condition: Macular Degeneration Intervention: Drug: Pazopanib
49	Completed no results published yet	<u>Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)</u> Condition: Diabetic Macular Oedema Intervention: Drug: Triamcinolone acetate
50	Completed no results published yet	<u>Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Vitrectomy Intervention: Drug: Dexamethasone
51	Completed no results published yet	<u>Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study</u> Condition: Diabetic Macular Oedema Intervention: Drug: Triamcinolone acetate
52	Completed no results published yet	<u>Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration</u> Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment Intervention: Drug: Ranibizumab
53	Completed no results published yet	<u>Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</u> Conditions: Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration

		(AMD) Intervention: Drug: ranibizumab
54	Completed no results published yet	<u>A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema</u> Condition: Diabetic Macular Oedema Intervention: Drug: Triamcinolone acetate
55	Completed no results published yet	<u>The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction</u> Conditions: Retinitis Pigmentosa; Cataract Intervention: Procedure: IOL surgery
56	Completed no results published yet	<u>Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Vision Disorders Intervention: Drug: Dexamethasone Drug delivery system (Ozurdex)
57	Active, not recruiting	<u>A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Interventions: Drug: Dexamethasone; Drug: Sham
58	Active, not recruiting	<u>Study to Assess the Effectiveness of Existing Anti vascular Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)</u> Condition: Ophthalmology, Macular Degeneration Intervention: Drug: Ranibizumab
59	Active, not recruiting	<u>Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</u> Conditions: Macular Edema; Retinal Vein Occlusion Interventions: Drug: AGN208397 intravitreal injection; Drug: dexamethasone intravitreal implant
60	Active, not recruiting	<u>An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients</u> Conditions: Diabetic Macular Edema; Visual

		Impairment Intervention: Drug: ranibizumab
61	Active, not recruiting	<u>VEGF Trap-Eye in Vision Impairment Due to DME</u> Conditions: Diabetes Mellitus; Macular Edema Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: Laser treatment
62	Active, not recruiting	<u>Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion</u> Condition: Retinal Vein Occlusion Intervention: Drug: ranibizumab
63	Active, not recruiting	<u>Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration</u> Condition: Macular Degeneration Interventions: Drug: pazopanib eye drops; Drug: placebo; Biological: ranibizumab intravitreal injection
64	Active, not recruiting	<u>Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema</u> Conditions: Diabetic Retinopathy; Macular Edema Interventions: Drug: bevacizumab; Drug: dexamethasone
65	Enrolling by invitation	<u>Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa</u> Condition: Retinitis Pigmentosa Intervention: Other: Intravitreal injection of bone marrow-derived mesenchymal stem cells
66	Enrolling by invitation	<u>Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)</u> Conditions: Macular Edema; Retinal Vein Occlusion Intervention: Drug: ranibizumab
67	Enrolling by	<u>Efficacy and Safety of Oral Valproic Acid for Retinitis</u>

	invitation	<p><u>Pigmentosa</u></p> <p>Conditions: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degeneration</p> <p>Intervention: Drug: Valproic Acid</p>
68	Active, not recruiting	<p><u>Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Biological: VEGF Trap-Eye (BAY86-5321)</p>
69	Active, not recruiting	<p><u>Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Intervention: Biological: KH902</p>
70	Active, not recruiting	<p><u>Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone; Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone, Lithium Carbonate</p>
71	Active, not recruiting	<p><u>Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Drug: Methylprednisolone; Drug: Lithium</p>
72	Active, not recruiting	<p><u>A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD</u></p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: intravitreal injection of KH902</p>
73	Active, not	<p><u>Lithium, Cord Blood Cells and the Combination in the Treatment</u></p>

	recruiting	<p><u>of Acute & Sub-acute Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Procedure: Conventional Treatment; Drug: Lithium Carbonate; Biological: Cord Blood Cell; Other: Placebo</p>
74	Withdrawn	<p><u>Combination Therapy for Neovascular Age Related Macular Degeneration</u></p> <p>Condition: Macular Degeneration</p> <p>Intervention: Drug: intravitreal bevacizumab and triamcinolone acetonide</p>
75	Terminated	<p><u>A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration</u></p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention: Drug: AG-013,958</p>
76	Terminated	<p><u>Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Retinopathy; Diabetes Complications</p> <p>Interventions: Procedure: Laser Treatment; Drug: PF-04523655 high; Drug: PF-04523655 middle; Drug: PF-04523655 low</p>
77	Recruiting	<p><u>Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration</u></p> <p>Condition: Age-related Macular Degeneration</p> <p>Interventions: Dietary Supplement: placebo; Diet</p>
78	Recruiting	<p><u>Molecular Genetics of Retinal Degenerations</u></p> <p>Conditions: Retinal Degeneration; Retinitis Pigmentosa</p> <p>Intervention:</p>
79	Recruiting	<p><u>Pilot Study of a Suprachoroidal Retinal Prosthesis</u></p> <p>Conditions: Retinitis Pigmentosa; Choroideremia</p> <p>Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis</p>
80	Recruiting	<p><u>VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese</u></p>

		<p><u>Subjects With Wet AMD (Age-Related Macular Degeneration)</u></p> <p>Condition: Macular Degeneration</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Drug: Visudyne</p>
81	Recruiting	<p><u>A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD</u></p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein</p>
82	Recruiting	<p><u>Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)</u></p> <p>Condition: Macular Edema</p> <p>Interventions: Drug: 700 µg Dexamethasone; Other: Sham</p>
83	Recruiting	<p><u>Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)</u></p> <p>Condition: Age-related Macular Degeneration</p> <p>Interventions: Drug: AGN-150998; Drug: ranibizumab</p>
84	Recruiting	<p><u>Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: Laser</p>
85	Recruiting	<p><u>Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration</u></p> <p>Conditions: Macular Degeneration; Age-related Maculopathies; Age-related Maculopathy; Maculopathies, Age-related; Maculopathy, Age-related; Retinal Degeneration; Retinal Neovascularization; Eye Diseases</p> <p>Interventions: Biological: rAAV.sFlt-1; Other: Control (ranibizumab alone)</p>
86	Recruiting	<p><u>A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema</u></p>

		<p>Condition: Retinopathy, Diabetic</p> <p>Interventions: Drug: darapladib; Drug: placebo</p>
87	Recruiting	<p><u>Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham</p>
88	Recruiting	<p><u>Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)</u></p> <p>Condition: Macular Edema Following Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham</p>
89	Recruiting	<p><u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Device: ReJoyce Workstation; Other: Standard Care</p>
90	Recruiting	<p><u>Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting</u></p> <p>Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Other: Ranibizumab</p>
91	Recruiting	<p><u>Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Central Retinal Vein Occlusion</p> <p>Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection</p>
92	Recruiting	<p><u>Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter</u></p>

		<p>Condition: Age Related Macular Degeneration</p> <p>Interventions: Drug: Intravitreal Ranibizumab; Drug: Intravitreal bevacizumab</p>
93	Recruiting	<p><u>Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema</u></p> <p>Conditions: Macular Edema, Cystoid; Vision Disorders; Diabetic Macular Edema; Cystoid Macular Edema Following Cataract Surgery; Cataract</p> <p>Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surgery</p>
94	Recruiting	<p><u>Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy</u></p> <p>Condition: Proliferative Diabetic Retinopathy</p> <p>Intervention:</p>
95	Recruiting	<p><u>Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)</u></p> <p>Condition: Stargardt's Macular Dystrophy</p> <p>Intervention: Biological: MA09-hRPE</p>
96	Recruiting	<p><u>Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration</u></p> <p>Condition: Age-related Macular Degeneration</p> <p>Interventions: Dietary Supplement: lutein; Dietary Supplement: Lutein; Dietary Supplement: placebo; Drug: Lutein and zeaxanthin</p>
97	Recruiting	<p><u>Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Procedure: rehabilitation of limb function; Procedure: Stem Cells Transplantation</p>
98	Recruiting	<p><u>Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</u></p>

		<p>Conditions: Retinal Degeneration,; Retinitis Pigmentosa</p> <p>Intervention: Procedure: surgical implantation of subretinal device</p>
99	Recruiting	<p><u>Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion</u></p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Procedure: Intravitreal expansile gas and ranibizumab injection</p>
100	Recruiting	<p><u>Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy</u></p> <p>Condition: Macular Edema</p> <p>Intervention: Procedure: Intravitreal injection</p>
101	Recruiting	<p><u>A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)</u></p> <p>Condition: Dry Age Related Macular Degeneration</p> <p>Intervention: Biological: MA09-hRPE</p>
102	Unknown †	<p><u>Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema</u></p> <p>Condition: Diabetic Macular Edema</p> <p>Interventions: Device: Micropulse 577 nm yellow diode laser; Device: 532 nm green diode laser</p>
103	Unknown †	<p><u>To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation</u></p> <p>Conditions: Macular Edema; Diabetic Retinopathy; Visual Field Loss</p> <p>Interventions: Procedure: PASCAL laser; Procedure: Conventional laser</p>
104	Unknown †	<p><u>Intravitreal Bevacizumab for Retinal Disorders</u></p> <p>Conditions: Wet AMD; Macular Oedema;</p>

		<p>Proliferative Diabetic Retinopathy</p> <p>Intervention: Drug: Bevacizumab (Avastin)</p>
105	Unknown †	<p><u>Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure : macular laser photocoagulation</p>

73. Retinal Detachment

Rank	Status	Study
1	Completed Has results published in journals	<u>Gas injection versus vitrectomy with gas for treating retinal detachment owing to macular hole in high myopes.</u> Condition: Retinal Detachment Interventions: Procedure: gas injection; Procedure: Vitrectomy with Gas
2	Completed no results published yet	<u>Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole</u> Condition: Retinal Detachment Interventions: Procedure: Pneumatic Retinopexy; Procedure: Vitrectomy with Gas
3	Completed no results published yet	<u>Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function</u> Condition: Rhegmatogenous Macula-off Retinal Detachment Interventions: Drug: 200 µg Brimonidine Tartrate Posterior Segment Drug Delivery system; Drug: 400 µg Brimonidine Tartrate Posterior Segment Drug Delivery system; Drug: Sham Posterior Segment Drug Delivery system
4	Completed no results published yet	<u>Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration</u> Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment Intervention: Drug: Ranibizumab
5	Completed no results published yet	<u>Macular Function After Scleral Buckle</u> Condition: Rhegmatogenous Retinal Detachment Intervention: Procedure: Scleral buckling
6	Completed no results published yet	<u>Comparison of Air and Expansile Gas in Pneumatic Retinopexy</u> Condition: Retinal Detachment Interventions: Procedure: air; Procedure: expansile gas
7	Completed no results	<u>Vitrectomy for Optic Disc Pit Maculopathy</u> Condition: Optic Disc Pit Maculopathy

	published yet	Intervention: Procedure: vitrectomy without laser or gas tamponade
8	Completed no results published yet	<u>Optical Coherence Tomography in Gas-filled Eyes</u> Condition: Macular Hole Intervention: Procedure: Vitreous surgery
9	Recruiting	<u>Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment</u> Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous body(FCVB)
10	Recruiting	<u>Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy</u> Condition: Proliferative Diabetic Retinopathy Intervention:
11	Unknown †	<u>The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body</u> Condition: Retinal Detachment Intervention: Device: foldable capsular vitreous body(FCVB)

74. Retinal Drusen

Rank	Status	Study
1	Completed no results published yet	<u>A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population</u> Conditions: Geographic Atrophy; Wet Macular Degeneration etinal Drusen Intervention: Other: Follow-up observation

75. Retinal Dystrophies

Rank	Status	Study
1	Completed no results published yet	<p><u>Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmentosa</u></p> <p style="text-align: center;">Condition: Retinitis Pigmentosa</p> <p style="text-align: center;">Intervention:</p>
2	Completed no results published yet	<p><u>The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction</u></p> <p style="text-align: center;">Conditions: Retinitis Pigmentosa; Cataract</p> <p style="text-align: center;">Intervention: Procedure: IOL surgery</p>
3	Active, not recruiting	<p><u>Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury</u></p> <p style="text-align: center;">Condition: Spinal Cord Injuries</p> <p style="text-align: center;">Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone; Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone, Lithium Carbonate</p>
4	Active, not recruiting	<p><u>Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury</u></p> <p style="text-align: center;">Condition: Spinal Cord Injury</p> <p style="text-align: center;">Interventions: Procedure: Conventional Treatment; Drug: Lithium Carbonate; Biological: Cord Blood Cell; Other: Placebo</p>
5	Active, not recruiting	<p><u>Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord</u></p> <p style="text-align: center;">Condition: Spinal Cord Injuries</p> <p style="text-align: center;">Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Drug: Methylprednisolone; Drug: Lithium</p>
6	Enrolling by invitation	<p><u>Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa</u></p> <p style="text-align: center;">Conditions: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degeneration</p> <p style="text-align: center;">Intervention: Drug: Valproic Acid</p>
7	Enrolling by	<p><u>Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal</u></p>

	invitation	<p><u>Injection in Patients With Retinitis Pigmentosa</u></p> <p>Condition: Retinitis Pigmentosa</p> <p>Intervention: Other: Intravitreal injection of bone marrow-derived mesenchymal stem cells</p>
8	Recruiting	<p><u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Device: ReJoyce Workstation; Other: Standard Care</p>
9	Recruiting	<p><u>Pilot Study of a Suprachoroidal Retinal Prosthesis</u></p> <p>Conditions: Retinitis Pigmentosa; Choroideremia</p> <p>Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis</p>
10	Recruiting	<p><u>Molecular Genetics of Retinal Degenerations</u></p> <p>Conditions: Retinal Degeneration; Retinitis Pigmentosa</p> <p>Intervention:</p>
11	Recruiting	<p><u>Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Procedure: rehabilitation of limb function; Procedure: Stem Cells Transplantation</p>
12	Recruiting	<p><u>Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</u></p> <p>Conditions: Retinal Degeneration,; Retinitis Pigmentosa</p> <p>Intervention: Procedure: surgical implantation of subretinal device</p>

76. Retinal Hemorrhage

Rank	Status	Study
1	Completed no results published yet	<u>Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy</u> Condition: Proliferative Diabetic Retinopathy Intervention:

77. Retinal Neoplasms

Rank	Status	Study
1	Completed no results published yet	<p><u>Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation</u></p> <p>Conditions: Neuroblastoma; Brain Tumor; Retinoblastoma; Wilms Tumor; Mycoses</p> <p>Intervention: Drug: itraconazole</p>
2	Completed no results published yet	<p><u>Rebectamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma</u></p> <p>Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Retinoblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific</p> <p>Intervention: Drug: becatecarin</p>
3	Completed no results published yet	<p><u>Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation</p>
4	Active, not recruiting	<p><u>Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors</u></p> <p>Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma</p> <p>Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis</p>
5	Active, not recruiting	<p><u>Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser surgery</p>
6	Active, not recruiting	<p><u>Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma</u></p>

		<p>Condition: Intraocular Retinoblastoma</p> <p>Intervention: Drug: carboplatin</p>
7	Recruiting	<p><u>Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With Newly Diagnosed Retinoblastoma in Both Eyes</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclosporine; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser therapy; Procedure: neoadjuvant therapy</p>
8	Recruiting	<p><u>Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy</p>
9	Unknown †	<p><u>Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas</u></p> <p>Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Retinoblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific</p> <p>Intervention: Drug: alvocidib</p>

78. Retinal Neovascularization

Rank	Status	Study
1	Terminated	<p data-bbox="549 322 1343 398"><u>Clinical Research on Retinal Neovascularization of Diabetic Retinopathy</u></p> <p data-bbox="772 416 1295 537">Conditions: The Mechanism of Retinal Neovascularization of Diabetic; Retinopathy.</p> <p data-bbox="759 555 1289 586">Intervention: Genetic: genetic analyzer</p>
2	Recruiting	<p data-bbox="549 604 1315 680"><u>Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration</u></p> <p data-bbox="772 698 1356 999">Conditions: Macular Degeneration; Age-related Maculopathies; Age-related Maculopathy; Maculopathies, Age-related; Maculopathy, Age-related; Retinal Degeneration; Retinal Neovascularization; Eye Diseases</p> <p data-bbox="743 1016 1353 1093">Interventions: Biological: rAAV.sFlt-1; Other: Control (ranibizumab alone)</p>

79. Retinal Perforations

Rank	Status	Study
1	Completed no results published yet	<p><u>Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole</u></p> <p style="text-align: right;">Condition: Retinal Detachment</p> <p style="text-align: right;">Interventions: Procedure: Pneumatic Retinopexy; Procedure: Vitrectomy with Gas</p>
2	Completed no results published yet	<p><u>Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery</u></p> <p style="text-align: right;">Condition: Macular Holes</p> <p style="text-align: right;">Intervention: Procedure: Vitreous surgery for macular hole</p>
3	Completed no results published yet	<p><u>Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery</u></p> <p style="text-align: right;">Condition: Macular Holes</p> <p style="text-align: right;">Intervention: Procedure: Vitrectomy</p>
4	Completed no results published yet	<p><u>Evaluation of Anatomic and Visual Outcomes of Initially Closed Macular Holes</u></p> <p style="text-align: right;">Condition: Macular Holes</p> <p style="text-align: right;">Intervention:</p>
5	Completed no results published yet	<p><u>Elongation of Foveal Tissue After Macular Hole Surgery</u></p> <p style="text-align: right;">Condition: Macular Holes</p> <p style="text-align: right;">Intervention: Procedure: pars plana vitrectomy and fluid gas exchange</p>
6	Completed no results published yet	<p><u>Macular Hole in Diabetic Retinopathy</u></p> <p style="text-align: right;">Conditions: Macular Hole; Proliferative Diabetic Retinopathy</p> <p style="text-align: right;">Intervention:</p>
7	Completed no results published yet	<p><u>Optical Coherence Tomography in Gas-filled Eyes</u></p> <p style="text-align: right;">Condition: Macular Hole</p> <p style="text-align: right;">Intervention: Procedure: Vitreous surgery</p>
8	Completed no results published yet	<p><u>Macular Hole Reopening</u></p> <p style="text-align: right;">Condition: Vitrectomy</p> <p style="text-align: right;">Intervention: Procedure: Vitrectomy</p>

9	Not yet recruiting	<p><u>Study of the Surgical Timing of Traumatic Macular Hole</u></p> <p>Condition: Traumatic Macular Hole</p> <p>Intervention: Procedure: vitrectomy surgery</p>
10	Recruiting	<p><u>Macular Hole Surgery With and Without Internal Limiting Membrane Peeling: A Systematic Review and Meta-analysis</u></p> <p>Condition: Macular Holes</p> <p>Intervention:</p>
11	Recruiting	<p><u>Early Vitrectomy for Impending Macular Hole</u></p> <p>Condition: Retinal Perforation</p> <p>Intervention: Procedure: Pars plana vitrectomy with ILM peeling</p>

80. Retinal Vein Occlusion

Rank	Status	Study
1	Completed Has Results published on website	<u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u> Condition: Retinal Vein Occlusion Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Other: Sham treatment
2	Completed Has Results published on website	<u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion</u> Conditions: Macular Edema; Retinal Vein Occlusion Interventions: Drug: Dexamethasone; Drug: Sham injection
3	Completed no results published yet	<u>Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion</u> Conditions: Macular Edema; Branch Retinal Vein Occlusion Interventions: Procedure: Arteriovenous Crossed Laser; Procedure: Intravitreal Triamcinolone Injection
4	Completed no results published yet	<u>A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion</u> Conditions: Macular Degeneration; Macular Edema; Retinal Vein Occlusion Intervention: Drug: dexamethasone
5	Completed no results published yet	<u>Vitreotomy for Branch Retinal Vein Occlusion</u> Condition: Vitrectomy Intervention: Procedure: Vitrectomy w/o ILM peeling for macular edema with BRVO
6	Completed no results published yet	<u>Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision</u> Condition: Central Retinal Vein Occlusion With 20/200 or Worse Visual Acuity Intervention: Procedure: intravitreal injection
7	Completed	<u>Major and Macular Branched Retinal Venous Occlusion</u>

	no results published yet	<p>Condition: Macular Edema</p> <p>Intervention: Procedure: intravitreal bevacizumab</p>
8	Completed no results published yet	<p><u>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)</u></p> <p>Condition: Macular Edema Secondary to Central Retinal Vein Occlusion</p> <p>Interventions: Biological: VEGF Trap-Eye 2.0mg; Drug: Sham</p>
9	Enrolling by invitation	<p><u>Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
10	Active, not recruiting	<p><u>Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion</u></p> <p>Condition: Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
11	Active, not recruiting	<p><u>Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)</u></p> <p>Conditions: Macular Edema; Retinal Vein Occlusion</p> <p>Interventions: Drug: AGN208397 intravitreal injection; Drug: dexamethasone intravitreal implant</p>
12	Recruiting	<p><u>Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting</u></p> <p>Conditions: Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion</p> <p>Intervention: Other: Ranibizumab</p>
13	Recruiting	<p><u>Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)</u></p> <p>Condition: Macular Edema</p> <p>Interventions: Drug: 700 µg Dexamethasone</p>

		; Other: Sham
14	Recruiting	<p><u>Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: Laser</p>
15	Recruiting	<p><u>Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Central Retinal Vein Occlusion</p> <p>Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection</p>
16	Recruiting	<p><u>Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)</u></p> <p>Condition: Macular Edema Following Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Betamethasone Microsphere (DE-102) Low Dose ; Drug: Betamethasone Microsphere (DE-102) High Dose; Drug: Sham</p>
17	Recruiting	<p><u>Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Procedure: intravitreal bevacizumab monotherapy; Procedure: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection</p>
18	Recruiting	<p><u>Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion</u></p>

		<p>Condition: Retinal Vascular Occlusion</p> <p>Intervention: Device: Watchpat 100</p>
19	Unknown †	<p><u>Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: macular laser photocoagulation</p>

81. Retinitis

Rank	Status	Study
1	Completed no results published yet	<p><u>Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmentosa</u></p> <p>Condition: Retinitis Pigmentosa</p> <p>Intervention:</p>
2	Completed no results published yet	<p><u>The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction</u></p> <p>Conditions: Retinitis Pigmentosa; Cataract</p> <p>Intervention: Procedure: IOL surgery</p>
3	Active, not recruiting	<p><u>Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Drug: Methylprednisolone; Drug: Lithium</p>
4	Enrolling by invitation	<p><u>Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa</u></p> <p>Conditions: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degereneration</p> <p>Intervention: Drug: Valproic Acid</p>
5	Active, not recruiting	<p><u>Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Procedure: Conventional Treatment; Drug: Lithium Carbonate; Biological: Cord Blood Cell; Other: Placebo</p>
6	Active, not recruiting	<p><u>Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Biological: Umbilical Cord Blood Mononuclear Cell, Methylprednisolone; Biological:</p>

		<p>Umbilical Cord Blood Mononuclear Cell, Methylprednisolone, Lithium Carbonate</p>
7	Enrolling by invitation	<p><u>Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa</u></p> <p>Condition: Retinitis Pigmentosa</p> <p>Intervention: Other: Intravitreal injection of bone marrow-derived mesenchymal stem cells</p>
8	Recruiting	<p><u>Pilot Study of a Suprachoroidal Retinal Prosthesis</u></p> <p>Conditions: Retinitis Pigmentosa; Choroide remia</p> <p>Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis</p>
9	Recruiting	<p><u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Device: ReJoyce Workstation; Other: Standard Care</p>
10	Recruiting	<p><u>Molecular Genetics of Retinal Degenerations</u></p> <p>Conditions: Retinal Degeneration; Retinitis Pigmentosa</p> <p>Intervention:</p>
11	Recruiting	<p><u>Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Procedure: rehabilitation of limb function; Procedure: Stem Cells Transplantation</p>
12	Recruiting	<p><u>Molecular Genetics of Retinal Degenerations</u></p> <p>Conditions: Retinal Degeneration; Retinitis Pigmentosa</p> <p>Intervention:</p>
13	Recruiting	<p><u>Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</u></p> <p>Conditions: Retinal Degeneration,; Retinitis</p>

		<p>Pigmentosa</p> <p>Intervention: Procedure: surgical implantation of subretinal device</p>
--	--	---

82. Retinitis Pigmentosa

Rank	Status	Study
1	Completed no results published yet	<p><u>The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction</u></p> <p style="text-align: right;">Conditions: Retinitis Pigmentosa; Cataract</p> <p style="text-align: right;">Intervention: Procedure: IOL surgery</p>
2	Completed no results published yet	<p><u>Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmentosa</u></p> <p style="text-align: right;">Condition: Retinitis Pigmentosa</p> <p style="text-align: right;">Intervention:</p>
3	Enrolling by invitation	<p><u>Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa</u></p> <p style="text-align: right;">Conditions: Retinitis Pigmentosa; Retinal Diseases; Eye Diseases; Eye Disease, Hereditary; Retinal Degeneration</p> <p style="text-align: right;">Intervention: Drug: Valproic Acid</p>
4	Enrolling by invitation	<p><u>Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa</u></p> <p style="text-align: right;">Condition: Retinitis Pigmentosa</p> <p style="text-align: right;">Intervention: Other: Intravitreal injection of bone marrow-derived mesenchymal stem cells</p>
5	Active, not recruiting	<p><u>Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury</u></p> <p style="text-align: right;">Condition: Spinal Cord Injuries</p> <p style="text-align: right;">Interventions: Biological: Umbilical Cord Blood Cell; Biological: Umbilical Cord Mononuclear Cell, Methylprednisolone; Biological: Cord Blood Mononuclear Cell, Methylprednisolone, Lithium Carbonate</p>
6	Active, not recruiting	<p><u>Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury</u></p> <p style="text-align: right;">Condition: Spinal Cord Injury</p> <p style="text-align: right;">Interventions: Procedure: Conventional Treatment with Lithium Carbonate; Biological: Cord Blood Cells</p>

		er: Placebo
7	Active, not recruiting	<p><u>Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord</u></p> <p>Condition: Spinal Cord Injuries</p> <p>Interventions: Biological: Umbilical Cord Blood Mononuclear Cell; Drug: Methylprednisolone; Drug: Lithium</p>
8	Recruiting	<p><u>Pilot Study of a Suprachoroidal Retinal Prosthesis</u></p> <p>Conditions: Retinitis Pigmentosa; Chorioideremia</p> <p>Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis</p>
9	Recruiting	<p><u>Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients</u></p> <p>Conditions: Retinal Degeneration,; Retinitis Pigmentosa</p> <p>Intervention: Procedure: surgical implantation of subretinal device</p>
10	Recruiting	<p><u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Device: ReJoyce Workstation; Other: Standard Care</p>
11	Recruiting	<p><u>SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury</u></p> <p>Condition: Spinal Cord Injury</p> <p>Interventions: Device: ReJoyce Workstation; Other: Standard Care</p>
12	Recruiting	<p><u>Molecular Genetics of Retinal Degenerations</u></p> <p>Conditions: Retinal Degeneration; Retinitis Pigmentosa</p> <p>Intervention:</p>
13	Recruiting	<p><u>Molecular Genetics of Retinal Degenerations</u></p> <p>Conditions: Retinal Degeneration; Retinitis Pigmentosa</p> <p>Intervention:</p>

14	Recruiting	<p data-bbox="576 208 1177 241"><u>Molecular Genetics of Retinal Degenerations</u></p> <p data-bbox="802 255 1401 331">Conditions: Retinal Degeneration; Retinitis a</p> <p data-bbox="788 351 959 385">Intervention:</p>
15	Recruiting	<p data-bbox="576 403 1378 479"><u>Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China</u></p> <p data-bbox="818 497 1243 530">Condition: Spinal Cord Injuries</p> <p data-bbox="772 548 1401 627">Interventions: Procedure: rehabilitation of limb edure: Stem Cells Transplantati</p>

83. Retinoblastoma

Rank	Status	Study
1	Completed no results published yet	<p><u>Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation</u></p> <p>Conditions: Neuroblastoma; Brain Tumor; Retinoblastoma; Wilms Tumor; Mycoses</p> <p>Intervention: Drug: itraconazole</p>
2	Completed no results published yet	<p><u>Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation</p>
3	Completed no results published yet	<p><u>Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma</u></p> <p>Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Retinoblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific</p> <p>Intervention: Drug: becatecarin</p>
4	Active, not recruiting	<p><u>Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser surgery</p>
5	Active, not recruiting	<p><u>Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors</u></p> <p>Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma</p>

		<p>ma; Sarcoma</p> <p>Interventions: Biological: cixutumumab; Other: laboratory biomarker analyses</p>
6	Active, not recruiting	<p><u>Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma</u></p> <p>Condition: Intraocular Retinoblastoma</p> <p>Intervention: Drug: carboplatin</p>
7	Recruiting	<p><u>Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With Newly Diagnosed Retinoblastoma in Both Eyes</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclosporine; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser therapy; Procedure: neoadjuvant therapy</p>
8	Recruiting	<p><u>Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma</u></p> <p>Condition: Retinoblastoma</p> <p>Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide;</p> <p>Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy</p>
9	Recruiting	<p><u>Study of Late-Occurring Complications in Childhood Cancer Survivors</u></p>

		<p>Condition: Cancer</p> <p>Interventions: Genetic: cytogenetic analysis;</p> <p>Genetic: mutation analysis; Genetic: polymorphism analysis;</p> <p>Other: questionnaire administration</p>
10	Unknown †	<p><u>Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas</u></p> <p>Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Liver Cancer; Lymphoma; Neuroblastoma; Retinoblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific</p> <p>Intervention: Drug: alvocidib</p>
11	Unknown †	<p><u>Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors</u></p> <p>Condition: Cancer</p> <p>Interventions: Biological: filgrastim; Biological: recombinant human thrombopoietin; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide</p>

84. Retinopathy of Prematurity

Rank	Status	Study
1	Completed no results published yet	<p data-bbox="539 315 1182 349"><u>Premature Infants in Need of Transfusion (PINT)</u></p> <p data-bbox="778 365 1238 398">Condition: Anemia of Prematurity</p> <p data-bbox="746 416 1353 488">Intervention: Procedure: Red blood cell transfusion</p>
2	Recruiting	<p data-bbox="539 510 1350 589"><u>Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis</u></p> <p data-bbox="762 607 1334 678">Conditions: Infant, Premature, Diseases; Bronchopulmonary Dysplasia;</p> <p data-bbox="954 741 1356 857">Retinopathy of Prematurity; Infant, Newborn, Diseases; Infant, Very Low Birth Weight</p> <p data-bbox="730 880 1356 1048">Interventions: Procedure: Higher oxygen saturation target range (91%-95%); Procedure: Lower oxygen saturation (85%-89%)</p>
3	Unknown[†]	<p data-bbox="539 1064 1302 1142"><u>Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants</u></p> <p data-bbox="762 1160 1356 1328">Conditions: Infant, Premature; Leukomalacia, Periventricular; Intraventricular Hemorrhage; Retinopathy of Prematurity</p> <p data-bbox="730 1350 1356 1458">Interventions: Drug: recombinant human erythropoietin (rhEpo); Drug: Normal saline</p>

85. Retinoschisis

Rank	Status	Study
1	Recruiting	<u>Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy</u> Condition: Proliferative Diabetic Retinopathy Intervention:

86. Scotoma

Rank	Status	Study
1	Unknown †	<p data-bbox="587 315 1353 483"><u>Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral-Domain Technology as a Diagnostic Predictor of Glaucoma.</u></p> <p data-bbox="826 499 1361 573">Condition: Primary Open Angle Glaucoma</p> <p data-bbox="799 595 970 629">Intervention:</p>
2	Unknown †	<p data-bbox="587 645 1353 768"><u>To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation</u></p> <p data-bbox="810 786 1353 902">Conditions: Macular Edema; Diabetic Retinopathy; Visual Field Loss</p> <p data-bbox="783 925 1353 1043">Interventions: Procedure: PASCAL laser; Procedure: Conventional laser</p>

87. Sjogren's Syndrome

Rank	Status	Study
1	Completed no results published yet	<p><u>Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome</u></p> <p style="text-align: right;">Conditions: Xerostomia; Sjogren's Syndrome</p> <p style="text-align: right;">Intervention: Drug: Rebamipide</p>
2	Enrolling by invitation	<p><u>Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome</u></p> <p style="text-align: right;">Condition: Primary Sjogren's Syndrome</p> <p style="text-align: right;">Intervention:</p>
3	Recruiting	<p><u>Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome</u></p> <p style="text-align: right;">Conditions: Autoimmune Diseases; Sjogren's Syndrome; Dry Eye</p> <p style="text-align: right;">Interventions: Drug: Hydroxychloroquine; Drug: Placebo</p>
4	Unknown[†]	<p><u>Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)</u></p> <p style="text-align: right;">Conditions: Sjogren's Syndrome; Mesenchymal Stem Cells</p> <p style="text-align: right;">Intervention: Biological: Allogeneic Mesenchymal Stem Cells (AlloMSC)</p>

88. Strabismus

Rank	Status	Study
1	Completed no results published yet	<u>Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin</u> Condition: Esotropia Intervention:
2	Completed no results published yet	<u>Under-correction in Refractive Accommodative Esotropia</u> Condition: Accommodative Esotropia Intervention: Device: Glasses prescription
3	Completed no results published yet	<u>Surgery and Convergence Insufficiency Intermittent Exotropia</u> Condition: Complications Interventions: Procedure: Post exercise Surgery; Procedure: Orthoptics; Procedure: Postop orthoptics; Procedure: Post exercises surgery
4	Recruiting	<u>The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery</u> Condition: Strabismus Interventions: Drug: Dexmedetomidine; Drug: placebo group
5	Recruiting	<u>A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery</u> Conditions: Child; Anesthesia Morbidity; Delirium on Emergence Interventions: Drug: Midazolam 0.03mg/kg; Drug: Midazolam 0.05mg/kg; Drug: Placebo
6	Recruiting	<u>Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus</u> Condition: Strabismus Intervention: Drug: GSK1358820
7	Recruiting	<u>Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires</u> Condition: Strabismus Intervention:

8	Recruiting	<p data-bbox="555 208 1310 286"><u>Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia</u></p> <p data-bbox="794 300 1246 333">Condition: Intermittent Exotropia</p> <p data-bbox="767 349 1337 432">Intervention: Procedure: Non surgical therapy</p>
---	------------	---

89. Supranuclear Palsy, Progressive

Rank	Status	Study
1	Active, not recruiting	<u>Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy</u> Condition: Progressive Supranuclear Palsy Interventions: Drug: Davunetide; Drug: Placebo

90. Usher Syndromes

Rank	Status	Study
1	Recruiting	<u>Molecular Genetics of Retinal Degenerations</u> Conditions: Retinal Degeneration; Retinitis Pigmentosa Intervention:

91. Uveal Diseases

Rank	Status	Study
1	Completed Has Results published in journal	<u>A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis</u> Conditions: Intermediate Uveitis; Posterior Uveitis Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection
2	Completed Has Results published on website	<u>Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)</u> Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration Interventions: Drug: dexamethasone; Biological: ranibizumab
3	Completed Has Results published on website	<u>Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)</u> Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration Interventions: Drug: dexamethasone; Biological: ranibizumab; Other: sham
4	Completed Has Results Published in journal	<u>A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis</u> Conditions: Intermediate Uveitis; Posterior Uveitis Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection
5	Completed Has Results published on website	<u>Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration</u> Condition: Macular Degeneration Intervention: Drug: pegaptanib sodium
6	Completed Has Results published in journals	<u>Multicenter Uveitis Steroid Treatment (MUST) Trial</u> Condition: Uveitis Interventions: Drug: fluocinolone acetonide intraocular implant; Drug: oral corticosteroid with immunosuppressive agents as needed
7	Terminated Has Results published on website	<u>A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration</u> Conditions: Choroid Neovascularization; Age-Related Macular Degeneration Interventions: Drug: AGN 211745; Drug: Ranibizumab

		µg
8	Completed Has Results published in journals	<p><u>Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</u></p> <p>Condition: Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)</p> <p>Intervention: Drug: Ranibizumab</p>
9	Completed Has Results published on website	<p><u>Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)</u></p> <p>Conditions: Choroidal Neovascularization; Age-Related Maculopathy</p> <p>Interventions: Drug: dexamethasone; Biological: ranibizumab; Other: sham</p>
10	Completed no results published yet	<p><u>Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients</u></p> <p>Condition: Age Related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab 0.5 mg</p>
11	Completed no results published yet	<p><u>A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD</u></p> <p>Condition: Neovascular Age-related Macular Degeneration</p> <p>Intervention: Biological: Intravitreal injection of KH902</p>
12	Completed no results published yet	<p><u>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</u></p> <p>Condition: Uveitis, Anterior</p> <p>Interventions: Drug: EGP-437 1.6 mA-min at 0.4 mA with EyeGate® II System; Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System; Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System; Drug: EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System</p>
13	Completed	<u>A Study of LX211 in Clinically Quiescent Non-infectious</u>

	no results published yet	<p><u>Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis</u></p> <p>Conditions: Uveitis, Posterior; Uveitis, Intermediate; Panuveitis</p> <p>Interventions: Drug: Placebo; Drug: LX211</p>
14	Completed no results published yet	<p><u>Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Biological: AIN457; Biological: Placebo</p>
15	Completed no results published yet	<p><u>A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis</u></p> <p>Conditions: Uveitis, Anterior; Panuveitis</p> <p>Interventions: Drug: Placebo; Drug: LX211</p>
16	Completed no results published yet	<p><u>Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).</u></p> <p>Condition: Age Related Macular Degeneration</p> <p>Interventions: Drug: 0.5 mg ranibizumab; Drug: 3 mg PF-04523655; Drug: 1 mg PF-04523655</p>
17	Completed no results published yet	<p><u>Phase III Study in Refractory Behcet's Disease</u></p> <p>Condition: Behcet Disease</p> <p>Interventions: Drug: AIN457; Drug: Placebo</p>
18	Completed no results published yet	<p><u>A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population</u></p> <p>Conditions: Geographic Atrophy; Wet Macular Degeneration; Retinal Drusen</p> <p>Intervention: Other: Follow-up observation</p>
19	Completed no results published yet	<p><u>Observation on the Treg in the Uveitis Patients</u></p> <p>Condition: Uveitis</p> <p>Intervention:</p>
20	Completed no results published yet	<p><u>Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)</u></p> <p>Condition: Wet Age-Related Macular Degeneration</p> <p>Interventions: Drug: PTK787; Drug: Placebo</p>

21	Completed no results published yet	<p><u>Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration</u></p> <p>Conditions: Choroidal Neovascularization; Retinal Pigment Epithelial Detachment</p> <p>Intervention: Drug: Ranibizumab</p>
22	Completed no results published yet	<p><u>Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</u></p> <p>Conditions: Subfoveal Choroidal Neovascularization (CNV); Secondary to Age-related Macular Degeneration (AMD)</p> <p>Intervention: Drug: ranibizumab</p>
23	Completed no results published yet	<p><u>Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)</u></p> <p>Condition: Macular Degeneration</p> <p>Intervention: Drug: pegaptanib sodium</p>
24	Completed no results published yet	<p><u>EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)</u></p> <p>Conditions: Choroidal Neovascularization; Age-Related Macular Degeneration</p> <p>Intervention: Drug: ranibizumab</p>
25	Completed no results published yet	<p><u>Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</u></p> <p>Condition: Pathological Myopia</p> <p>Interventions: Drug: 0.5 mg ranibizumab driven by disease activity; Drug: 0.5 mg ranibizumab driven by stabilization criteria; Drug: verteporfin PDT</p>
26	Completed no results published yet	<p><u>A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis</u></p> <p>Conditions: Uveitis, Posterior; Uveitis, Intermediate; Panuveitis</p> <p>Interventions: Drug: Placebo; Drug: LX211</p>

27	Enrolling by invitation	<p><u>A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis</u></p> <p>Condition: Uveitis</p> <p>Intervention: Drug: adalimumab</p>
28	Terminated	<p><u>A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration</u></p> <p>Condition: Age-Related Macular Degeneration</p> <p>Intervention: Drug: AG-013,958</p>
29	Terminated	<p><u>Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis</u></p> <p>Condition: Uveitis</p> <p>Interventions: Biological: AIN457; Drug: Placebo</p>
30	Terminated	<p><u>Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Study</u></p> <p>Condition: Non-infectious Uveitis</p> <p>Interventions: Biological: AIN457; Drug: Placebo</p>
31	Active, not recruiting	<p><u>VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)</u></p> <p>Condition: Myopia, Pathological</p> <p>Interventions: Biological: VEGF Trap-Eye (BAY86-5321); Procedure: No Drug</p>
32	Active, not recruiting	<p><u>A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease.</u></p> <p>Condition: Intestinal Behcet's Disease</p> <p>Intervention: Biological: Adalimumab</p>
33	Active, not recruiting	<p><u>Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome</u></p> <p>Condition: Cataract With Exfoliation Syndrome</p> <p>Intervention:</p>
34	Active, not recruiting	<p><u>First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial</u></p> <p>Condition: Uveitis</p> <p>Interventions: Drug: Methotrexate; Drug: Mycop henolate mofetil</p>
35	Active, not recruiting	<p><u>Natural History of IOL in Pseudo Exfoliation Syndrome</u></p> <p>Condition: Pseudo Exfoliation Syndrome</p>

		Intervention: Device: Capsular Tension Ring
36	Recruiting	<u>Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis</u> Condition: Uveitis Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo
37	Recruiting	<u>Efficacy and Safety of Adalimumab in Subjects With Active Uveitis</u> Condition: Uveitis Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo
38	Recruiting	<u>Pilot Study of a Suprachoroidal Retinal Prosthesis</u> Conditions: Retinitis Pigmentosa; Choroideremia Intervention: Device: Prototype wide view suprachoroidal retinal prosthesis
39	Recruiting	<u>Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study</u> Condition: Uveitis Intervention: Drug: Myfortic
40	Recruiting	<u>Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis</u> Condition: Anterior Uveitis Intervention:
41	Recruiting	<u>LOXL1 Polymorphism in Pseudoexfoliation Syndrome</u> Condition: Pseudoexfoliation Syndrome Intervention:
42	Recruiting	<u>A Randomized, Double-masked, Multicenter, Sham-controlled, Safty and Efficacy Study of KH902 in Patients With Wet AMD</u> Condition: Neovascular Age-related Macular Degeneration Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein
43	Recruiting	<u>Efficacy and Safety of Adalimumab in Subjects With Active Uveitis</u> Condition: Uveitis Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo
44	Recruiting	<u>Study Assessing Double-masked Uveitis Treatment</u>

		<p>Condition: Uvea; Posterior, Disorder</p> <p>Intervention: Drug: DE-109</p>
45	Recruiting	<p><u>Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions</u></p> <p>Conditions: Behcet's Disease; Behcet Syndrome; Neuro-Behcet's Disease</p> <p>Intervention: Drug: TA-650</p>
46	Recruiting	<p><u>Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis</u></p> <p>Conditions: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis</p> <p>Intervention: Drug: Ganciclovir</p>
47	Unknown †	<p><u>Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia</u></p> <p>Condition: Myopic Choroidal Neovascular Membrane</p> <p>Intervention: Drug: Intravitreal Pegaptanib</p>
48	Unknown †	<p><u>Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease</u></p> <p>Conditions: Ocular Behcet's Disease,; Non-Infectious Uveitis; Refractory Uveitis</p> <p>Intervention: Drug: flucinolone acetonide</p>

92. Uveitis

Rank	Status	Study
1	Completed Has Results Published in journal	<u>A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis</u> Conditions: Intermediate Uveitis; Posterior Uveitis Interventions: Drug: Dexamethasone; Drug: dexamethasone; Drug: Sham injection
2	Completed no results published yet	<u>Phase III Study in Refractory Behcet's Disease</u> Condition: Behcet Disease Interventions: Drug: AIN457; Drug: Placebo
3	Completed no results published yet	<u>Observation on the Treg in the Uveitis Patients</u> Condition: Uveitis Intervention:
4	Completed no results published yet	<u>A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis</u> Conditions: Uveitis, Posterior; Uveitis, Intermediate; Panuveitis Interventions: Drug: Placebo; Drug: LX211
5	Completed no results published yet	<u>A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis</u> Conditions: Uveitis, Posterior; Uveitis, Intermediate; Panuveitis Interventions: Drug: Placebo; Drug: LX211
6	Completed no results published yet	<u>Phase III Study in Refractory Behcet's Disease</u> Condition: Behcet Disease Interventions: Drug: AIN457; Drug: Placebo
7	Completed no results published yet	<u>Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis</u> Condition: Uveitis, Anterior Interventions: Drug: EGP-437 1.6 mA-min at 0.4 with EyeGate® II System; Drug: EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System; Drug: EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System; Drug:

		EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
8	Completed no results published yet	<u>A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis</u> Conditions: Uveitis, Anterior; Panuveitis Interventions: Drug: Placebo; Drug: LX211
9	Terminated	<u>Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis</u> Condition: Uveitis Interventions: Biological: AIN457; Drug: Placebo
10	Terminated	<u>Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u> Condition: Uveitis Interventions: Biological: AIN457; Biological : Placebo
11	Terminated	<u>Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis</u> Condition: Uveitis Interventions: Biological: AIN457; Biological : Placebo
12	Terminated	<u>Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis</u> Condition: Non-infectious Uveitis Interventions: Biological: AIN457; Drug: Placebo
13	Terminated	<u>Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Study</u> Condition: Non-infectious Uveitis Interventions: Biological: AIN457; Drug: Placebo
14	Enrolling by invitation	<u>A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis</u> Condition: Uveitis Intervention: Drug: adalimumab
15	Active, not recruiting	<u>A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease.</u> Condition: Intestinal Behçet's Disease

		Intervention: Biological: Adalimumab
16	Active, not recruiting	<u>First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial</u> Condition: Uveitis Interventions: Drug: Methotrexate; Drug: Mycophenolate mofetil
17	Recruiting	<u>Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis</u> Condition: Anterior Uveitis Intervention:
18	Recruiting	<u>Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study</u> Condition: Uveitis Intervention: Drug: Myfortic
19	Recruiting	<u>Study Assessing Double-masked Uveitis Treatment</u> Condition: Uvea; Posterior, Disorder Intervention: Drug: DE-109
20	Recruiting	<u>Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis</u> Conditions: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis Intervention: Drug: Ganciclovir
21	Recruiting	<u>Efficacy and Safety of Adalimumab in Subjects With Active Uveitis</u> Condition: Uveitis Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo
22	Recruiting	<u>Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions</u> Conditions: Behcet's Disease; Behcet Syndrome; Neuro-Behcet's Disease Intervention: Drug: TA-650
23	Recruiting	<u>Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis</u> Condition: Uveitis

		<p>Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo</p>
24	Unknown †	<p><u>Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease</u></p> <p>Conditions: Ocular Behcet's Disease,; Non-Infectious Uveitis; Refractory Uveitis</p> <p>Intervention: Drug: flucinolone acetonide</p>

93. Vision Disorders

Rank	Status	Study
1	Completed Has Results published on website	<u>Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema</u> Condition: Diabetic Macular Edema Interventions: Drug: Ranibizumab; Procedure: Laser photocoagulation; Drug: Sham ranibizumab; Procedure: Sham laser photocoagulation
2	Completed Has Results Published in journals	<u>Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh</u> Conditions: Vitamin A Deficiency; Maternal Mortality; Infant Mortality Intervention: Dietary Supplement: Vitamin A or Beta-Carotene Supplements
3	Completed no results published yet	<u>Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema</u> Conditions: Diabetic Macular Edema; Vision Disorders Intervention: Drug: Dexamethasone Drug delivery system (Ozurdex)
4	Completed no results published yet	<u>Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia</u> Condition: Pathological Myopia Interventions: Drug: 0.5 mg ranibizumab driven by disease activity; Drug: 0.5 mg ranibizumab driven by stabilization criteria; Drug: verteporfin PDT
5	Completed no results published yet	<u>Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan</u> Condition: Vitamin A Deficiency

		<p>Interventions: Dietary Supplement: Vitamin A; Dietary Supplement: Placebo</p>
6	Completed no results published yet	<p><u>An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand</u></p> <p>Conditions: Vitamin A Deficiency; Iron Deficiency; Zinc Deficiency</p> <p>Intervention: Dietary Supplement: fortified extruded rice</p>
7	Completed no results published yet	<p><u>Efficacy of Vitamin A in Fortified Extruded Rice in School Children</u></p> <p>Condition: Vitamin A Deficiency</p> <p>Intervention: Dietary Supplement: Triple fortified extruded rice (Fe, Zn and vitamin A)</p>
8	Completed no results published yet	<p><u>Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema</u></p> <p>Conditions: Diabetic Macular Edema; Macular Edema, Cystoid; Vision Disorders; Clinically Significant Macular Edema</p> <p>Intervention: Drug: long acting intravitreal dexamethasone implant</p>
9	Completed no results published yet	<p><u>The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial</u></p> <p>Condition: Obesity</p> <p>Intervention: Drug: the extract of green tea</p>
10	Completed no results published yet	<p><u>Dietary Vitamin A Requirement in Chinese Children and the New Technology of Dietary Assessment</u></p> <p>Condition: Vitamin A Deficiency</p> <p>Intervention:</p>
11	Completed no results	<p><u>Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status</u></p>

	published yet	<p>Condition: Vitamin A Deficiency</p> <p>Interventions: Other: 0 mg retinol activity equivalents; Other: 12 mg of BC; Other: 6 mg of CX; Other: 1.0 mg RAE</p>
12	Completed no results published yet	<p><u>Thickness of Retinal Layers in Amblyopia</u></p> <p>Condition: Amblyopia</p> <p>Intervention: Other: Optical coherence tomography</p>
13	Completed no results published yet	<p><u>Retina Projection System Trials for Low Vision People</u></p> <p>Condition: Vision, Low</p> <p>Intervention:</p>
14	Terminated	<p><u>Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh</u></p> <p>Conditions: Infant Mortality; Vitamin A Deficiency</p> <p>Intervention: Drug: vitamin A supplementation (50,000 IU)</p>
15	Active, not recruiting	<p><u>Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion</u></p> <p>Condition: Retinal Vein Occlusion</p> <p>Intervention: Drug: ranibizumab</p>
16	Active, not recruiting	<p><u>An Open-label Extension Study to Evaluate the Safety of Ranibizumab as Symptomatic Treatment for Visual Impairment Due to Diabetic Macular Edema in Patients</u></p> <p>Conditions: Diabetic Macular Edema; Visual Impairment</p> <p>Intervention: Drug: ranibizumab</p>
17	Recruiting	<p><u>Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion</u></p> <p>Condition: Branch Retinal Vein Occlusion</p> <p>Interventions: Drug: Ranibizumab; Procedure: Laser</p>
18	Recruiting	<p><u>Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion</u></p> <p>Conditions: Macular Edema; Central</p>

		<p>Retinal Vein Occlusion</p> <p>Intervention: Drug: Ranibizumab 0.5 mg/0.05 ml, intravitreal injection</p>
19	Recruiting	<p><u>Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function</u></p> <p>Condition: Vitamin A Deficiency</p> <p>Interventions: Dietary Supplement: retinyl palmitate; Dietary Supplement: Placebo</p>
20	Recruiting	<p><u>Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema</u></p> <p>Conditions: Macular Edema, Cystoid; Vision Disorders; Diabetic Macular Edema; Cystoid Macular Edema Following Cataract Surgery; Cataract</p> <p>Interventions: Drug: Dexamethasone Drug delivery system (Ozurdex); Procedure: Cataract surgery</p>
21	Recruiting	<p><u>Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial</u></p> <p>Conditions: Fractures; Enophthalmos; Diplopia</p> <p>Interventions: Device: Polycaprolactone / Tri-Calcium Phosphate; Device: Titanium Mesh</p>
22	Unknown †	<p><u>To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation</u></p> <p>Conditions: Macular Edema; Diabetic Retinopathy; Visual Field Loss</p> <p>Interventions: Procedure: PASCAL laser;</p>

		Procedure: Conventional laser
23	Unknown †	<p><u>RCT of an Intervention to Improve the Health of Adolescents With Intellectual Disability</u></p> <p>Conditions: Vision Impairment; Hearing Impairment; Obesity</p> <p>Intervention: Behavioral: Health Intervention Package</p>

94. Vitreous Detachment

Rank	Status	Study
1	Completed no results published yet	<p data-bbox="515 320 1082 353"><u>Vitreotomy for Optic Disc Pit Maculopathy</u></p> <p data-bbox="759 369 1273 403">Condition: Optic Disc Pit Maculopathy</p> <p data-bbox="730 421 1310 495">Intervention: Procedure: vitrectomy without laser or gas tamponade</p>
1	Recruiting	<p data-bbox="515 517 1302 591"><u>Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion</u></p> <p data-bbox="579 607 1350 640">Condition: Neovascular Age-related Macular Degeneration</p> <p data-bbox="547 658 1270 732">Intervention: Procedure: Intravitreal expansile gas and ranibizumab injection</p>
1	Unknown †	<p data-bbox="515 757 1158 831"><u>A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects</u></p> <p data-bbox="759 846 1198 880">Condition: Diabetic Retinopathy</p> <p data-bbox="730 898 1150 931">Intervention: Drug: Vitreosolve</p>

95. Vitreous Hemorrhage

Rank	Status	Study
1	Completed no results published yet	<u>Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy</u> Condition: Proliferative Diabetic Retinopathy Intervention:
2	Completed no results published yet	<u>Bevacizumab and Long Acting Gas in Diabetic Vitrectomy</u> Condition: Proliferative Diabetic Retinopathy Intervention: Drug: Bevacizumab
3	Completed no results published yet	<u>Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage</u> Conditions: Vitreous Hemorrhage; Diabetic Retinopathy Intervention: Drug: Vitrase (ovine hyaluronidase)
4	Completed no results published yet	<u>Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy</u> Conditions: Proliferative Diabetic Retinopathy; Vitrectomy Intervention: Drug: Bevacizumab
5	Recruiting	<u>Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy</u> Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy Intervention: Drug: intravitreal injection of bevacizumab
6	Unknown †	<u>Efficacy and Safety of Intravitreal Triamcinolone Acetonide in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage</u> Conditions: Post Vitrectomy State; Recurrent Diabetic Vitreous Hemorrhage Interventions: Procedure: Intravitreal triamcinolone injection; Procedure: Air-fluid exchange
7	Unknown †	<u>Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy</u>

		<p>Conditions: Diabetes Mellitus; Diabetic Retinopathy; Vitreous Hemorrhage</p> <p>Intervention: Procedure: Intravitreal long acting gas</p>
--	--	--

96. Xerophthalmia

Rank	Status	Study
1	Completed Has Results published on website	<u>Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes</u> Conditions: Xerophthalmia; Blepharitis Interventions: Drug: Systane Ultra eyedrops; Drug: Refresh eye drops
2	Completed no results published yet	<u>Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye</u> Condition: Xerophthalmia Intervention: Drug: Autologous serum eyedrops